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QUILL ON SCALPEL
This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Ileoanal Anastomosis: Improving Functional Results
The surgeon’s armamentarium for treat
ing chronic ulcerative colitis has broad
ened with resurgence of the concept of
restorative proctocolectomy. For over 30
years the standard operation of panproc
tocolectom y and ileostom y has
saved many lives, but it leaves the patient
with a permanent stoma, which may be
as disabling as chronic diarrhea. The early
attempts by Ravitch1 in 1948 to achieve
continence with direct anastomosis of the
distal ileum to the anal canal maintained
the normal route of defecation, but stool
frequency and perianal soreness were
often unacceptable. In 1955, Valienteand
Bacon2 described a technique in dogs in
which a reservoir was constructed as a
storage organ with three loops of distal
ileum and sutured to the anal canal. Con
tinence was preserved but septic compli
cations prevented widespread acceptance
of the method at that time. Then, in 1969,
Kock developed an intra-abdominal reser
voir ileostomy and showed promising
results with continence of the stoma. His
patients tolerated the reservoir well and
he found no serious nutritional abnorma
lities 10 years la te r.3 Parks and
colleagues4 and Fonkalsrud5 revived the
concept of an S-shaped reservoir anasto
mosed to the anal canal following colec
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tomy and mucosal protectomy for
ulcerative colitis. Utsunomiya and
associates6 used a J-loop pouch anasto
mosed end to side in the anal canal and
reported favourable results. Nicholls and
associates7 studied patients with reser
voirs functioning for more than 6 months
and correlated leakage of mucus from
the anus with lowered sphincter pressures;
none had biochemical or absorptive
abnormalities.
In the March 1983 issue of this Jour
nal (pages 132 to 134), Heppell and col
leagues described the use of anorectal
manometry to help predict the functional
outcome of patients with ileoanal anas
tomosis. The resting anal pressure reflects
the tone of the sphincters and is one of
the determinants of continence along with
anorectal angulation, consistency of
stools and sensory perception in the area.
Ileoanal anastomosis, performed by bring
ing a segment of small bowel through a
muscular tube of rectum denuded of
mucosa, may be thought to have adverse
effects on sphincter control. In fact, most
patients maintain fecal continence, and
frequency of defecation appears to be a
function of compliance of the neorectum.
The authors did not identify which
patients had reservoirs and which did not,
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but one may expect that patients with
reservoirs constructed proximal to the
anastomosis had increased compliance
and better functional results. Heppell and
colleagues formulated an index, using the
resting pressure of the anal sphincter and
neorectal compliance, to identify patients
who experienced a poor clinical result.
It appears that a reservoir must be
constructed proximal to the ileoanal anas
tomosis to achieve a good functional
result more rapidly than waiting for a sin
gle distal ileal segment to dilate proximal
to the anastomosis. The best type of reser
voir remains controversial. Parks favours
an S-shaped reservoir, using three loops
of ileum each measuring 15 cm sutured
together after opening their antimesenteric borders but leaving a distal efferent
limb o f 5 cm to be anastomosed to the
dentate line of the anal canal. One third
to half his patients must intubate them 
selves for evacuation but all are continent
and have fewer than four bowel move
ments a day on average. Heppell and col
leagues used a J-shaped reservoir with two
15-cm limbs and the most dependent part
was anastomosed to the anal canal. Their
patients had slightly more frequent eva
cuation but rarely needed intubation. A
theoretical disadvantage of this type of
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reservoir is the effect of distension on the
proximal anal canal by the volume of the
reservoir producing reflex relaxation of
the sphincter muscles analogous to a rectosphincteric inhibitory reflex. The Parks
reservoir sits outside the anal canal; it
rests on the levator ani muscles in the hol
low of the sacrum and uses the anorectal
angle to advantage.
Detailed study of this new procedure
is certainly warranted as many young pa
tients with chronic ulcerative colitis or
familial polyposis are being offered this
as an alternative to permanent ileostomy.
The long-term effects of any procedure
must be monitored closely by interested
groups to make sure we are not just ex
changing one disease state for another.
Patients with Crohn’s disease and those
with sphincters severely damaged by
fistulas and their treatment are not
su itab le candidates for ileoanal

anastomosis. The quality of life is
definitely improved when construction of
a permanent stoma is avoided. Overall,
the few who find it necessary to intubate
the reservoir are not inconvenienced by
this maneuver as they can determine the
timing of evacuation; often they can delay
emptying for 10 to 12 hours quite easily.
Ileoanal anastomosis is a tedious opera
tion and carries a significant risk of mor
bidity; hence, it should be performed only
by a few surgeons who can obtain more
experience and follow their patients close
ly. Anal manometry appears to be a good
predictor of functional outcome.
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The Difficulty in Assessing the Rate of Recurrence
after Proximal Gastric Vagotomy
Since the first clinical reports in 1970 by
Johnston and Wilkinson1 and Amdrup
and Jensen,2 proximal gastric vagotomy
without drainage has become popular
among surgeons treating peptic ulcer. The
slow initial acceptance of this operation
has been replaced by almost universally
accepted use. The operation is now per
formed for all types of peptic ulceration
in any situation, elective or emergency,
with or without stenosis. The early reports
on this procedure were all cautious
because of the short follow-up. Now we
have reports of 15-year follow-up and the
patients have been well studied, some
even prospectively. In this issue (page 220)
Macmillan and associates present a 7-year
review of this procedure.
Proximal gastric vagotomy is the most
physiologic operation for peptic ulcer,
with the least morbidity and mortality.
The surgeon’s view of himself as a
physiologist is certainly more satisfied
with this operation than with subtotal
gastrectomy with or without truncal or
selective vagotomy.
Hundreds of clinical reports have been
published and they have one common
denominator: the exact rate of recurrence
has been difficult to assess. In 1974,
Johnston3 reported that after 350 highly
selective vagotomies there were no recur
202

rent duodenal ulcers up to 5 years after
operation. On the other hand, Liedberg
and Oscarson4 reported a 20% recur
rence rate within 1 year of operation.
Many explanations have been advanced
for such discrepancies including the
definition of recurrence, the length of the
follow-up, the type of peptic ulcer
operated on, the importance of the
technique used and the surgeon’s
experience.
In the definition of a recurrence, one
should differentiate between recurrent
ulcer symptoms and proven recurrent
ulcer.
After proximal gastric vagotomy, the
short-term recurrence rate is acceptable.
In the majority of reports it ranges from
6% to 14% at 5 years. The suspected rate
of ulcer and the symptoms of recurrent
ulcer are higher. With long-term follow
up (ranging from 5 to 15 years), the recur
rence rates are less acceptable. Nilsell5
reported a 19% recurrence, and Madsen
and Kronborg6 26%. These rates are not
unique to proximal gastric vagotomy.
After truncal vagotomy, Nobles7 found
a recurrence rate of 6% after 5 years,
15% after 10 years and 28% after 15 years.
Recently, Jensen and colleagues,8 using
actuarial methods, calculated the risk of
recurrence after parietal cell vagotomy:

7% after 2'A years, 13% after 5 years,
21% after 8 years and 23% after 10 years.
They found that the rate at which recur
rences occurred remained constant
throughout the 11 years of the study.
Their analysis indicated a constant mon
thly recurrence risk of 0.23% and an an
nual risk of 2.78%. They found no dif
ference between duodenal, pyloric or
prepyloric ulcers. However, others9 have
found that the rate of recurrence varied
between proximal gastric vagotomy done
for duodenal, pyloric, prepyloric or
gastric ulcer.
Hollinshead and associates9 showed a
recurrence rate of 5.8% after surgery for
duodenal ulcer and a recurrence rate of
44% when the operation was performed
for prepyloric and combined duodenal
and gastric ulcer. A few reports have
given recurrence rates ranging from 22%
to 50% after proximal gastric vagotomy
for gastric ulcer. Thus, the efficacy of this
operation for pyloric, prepyloric and
gastric ulcer is not proven.
The importance of technique has been
stressed by Jaffe10 and others. In par
ticular, the removal of all vagal fibres in
the terminal 6 cm of the esophagus is
most important.
Another important point is the ex
perience of the vagotomist. Poppen and
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Delin'1 reported a prospective study of
170 consecutive, unselected patients who
underwent elective parietal cell vagotomy
for duodenal ulcer. They found a
decrease in the rate of proven recurrence
from 24% to 3% between the beginning
and end of their study. In patients with
pyloric ulcer, the incidence decreased
from 48% to 19%. They concluded that
these decreases reflected their increased
experience with the operation.
It is worth pointing out that there is no
proven predictive value of either
preoperative (acid output) or peroperative
tests (e.g., Grassi’s test) in relation to the
rate of recurrence.
In conclusion, proxim al gastric
vagotomy is an acceptable operation for
duodenal ulcer; the risk of recurrence in

creases with time. The operation should
be avoided for pyloric, prepyloric and
gastric ulcers.
Marcel J. R heault, md , m sc , frcs[c ],
facs

Member,
Editorial Board
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Acute Necrosis of the Gastrointestinal Tract:
a Unified View
A recent article by Bounous1 provided
an interesting overview of a syndrome
characterized by acute necrosis of the
gastrointestinal mucosa without apparent
vascular occlusion. Starting in the early
19th century this syndrome has been
reported in association with burns, car
diac failure, perinatal hypotension or
hypoxemia, or both, hemorrhage, sepsis
and postoperative hypotension.1 The
common pathway for these etiologic
events appears to be insufficient oxygen
delivery, which inhibits the high
metabolic activity of the surface mucosal
epithelium. The specific susceptibility of
the intestinal mucosa to low-flow states
is evidenced by the patchy or diffuse areas
of necrosis in the mucosa of the small and
large intestine. These are often associated
with focal erosions in the gastroduodenal
mucosa known as “ stress ulcers” .
Whereas the advent of peroral and col
onic endoscopy has increasingly focused
attention upon lesions in the upper and
lower gastrointestinal tract, a thorough
examination of the entire intestine
naturally takes place only at autopsy and
usually only when specific aspects of the
clinical picture attract the pathologist’s at
tention to the gastrointestinal tract.
Intestinal lesions may exist without sug
gestive signs and symptoms. The review
by Bounous, based on a survey of de
tailed autopsy reports from the medical
literature, reveals an interesting fact:

when the entire gastrointestinal tract is ex
amined, mucosal lesions are not limited
to the gastroduodenal area but are also
seen in the small bowel and colon. In
deed, with the possible exception of the
burn series,1 the small intestine appears
to be the most frequent site of mucosal
necrosis. Thus, enteric lesions in man
display the same anatomic distribution as
those found at postmortem examination
of laboratory animals following ex
perimentally induced shock. Gastroin
testinal complications of severe hypoten
sion should then be reviewed as a general
syndrome that may, at some stages of
various conditions, involve the entire
gastrointestinal tract.
The many synonyms used in the
English literature to describe the intestinal
syndrome indicate how much confusion
there is concerning this clinical entity. The
term enterocolitis, suggesting inflamma
tion, is inappropriate, because when in
flammation occurs it is purely secondary
to hemorrhagic necrosis. Terms derived
from specific anatomicopathologic fea
tures, such as pseudomembranous, ul
cerative and hemorrhagic, are equally
misleading. While the lesions may vary
from scattered patches of superficial
necrosis to pseudomembrane formation
and even perforation, the occurrence of
all varieties in the same individual in
dicates that they represent a single disease
process at different stages rather than

separate clinical entities. The adjective
nonocclusive is limited to a negative
aspect, namely the absence of occlusion.
Indeed, the unifying concept in this syn
drome appears to rely more on its
pathogenesis than its cause or specific
anatomic features. In 1964 Bounous and
associates2 discovered that pancreatic
proteases play a crucial role in the patho
genesis of the small-bowel lesion obser
ved in dogs following hemorrhagic hypo
tension. Hemorrhagic necrosis of the
mucosa was minimized by previous inhi
bition of trypsin and chymotrypsin in the
lumen or by previous ligation of the pan
creatic ducts.
Evidence obtained experimentally in
different laboratories and in various
animal species such as dogs, rabbits, rats
and cats subsequently confirmed these
findings.1 It is reasonable to assume that
a similar mechanism applies to man. The
explanation for this peculiar susceptibility
of the gut’s mucosa to ischemia resulting
from anoxia is to be found, according to
Bounous, in the “ physiologic” make-up
of the intestinal milieu: in the initial phase
o f ischemia intraluminal factors such as
pancreatic elastase and bile contribute
substantially to the accelerated loss of
b ru sh -b o rd e r pro tein s. M oreover,
ischemia likely renders the brush border
even more vulnerable to these luminal
factors. In the advanced phase of
ischemia, the brush border is lost, as is
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the protection provided by its trypsinresistant glycoproteins; hence, the
underlying structures are accessible to the
digestive action of pancreatic endopeptidases present in the intestinal lumen.
Although other factors such as in
creased capillary permeability may ag
gravate the problem, the loss of the brush
border followed by the digestion of the
surface epithelium apparently represents
the initial phase of acute necrosis of the
intestinal wall. The luminal factors that
render the mucosa more susceptible to
low-flow states in the absence of vascular
obstruction are the same ones that con
tribute to rapid mucosa! infarction dur
ing vascular occlusion. Pancreatic pro
teases have been found to play a similar
role in the pathogenesis of intestinal
mucosal necrosis produced by such
unrelated injuries as ra d ia tio n ,3'5
antimetabolites6 and uremia.7 Indeed,
the intestinal lesion that results from
various types of injury seems to find a
common mechanism in the physiologic
action of pancreatic proteases. Moreover,
the recent discovery that hydrolases from
human colonic microflora degrade mucin
and render the polypeptide core of mucin
more susceptible to pancreatic proteases
could explain the colonic lesion on a
similar pathogenetic basis.
Neglected necrosis of the small-bowel
mucosa during hypoxemia and in lowflow states can also play a prominent role
in the pathogenesis of gastric lesions. Re

cent experimental evidence indicates that
duodenal chyme refluxing during shock
brings into the stomach hydrolytic en
zymes derived from necrosing intestinal
mucosa in addition to its own proteases.1
Clinical and laboratory data suggest that
regurgitation of intestinal content could
be a factor in the genesis of gastritis and
focal mucosal erosions.1
The frequent association between the
intestinal syndrome and circulatory shock
has prompted speculation on the possi
ble cause and effect relation of the two
phenomena. While Bounous quotes most
ly autopsy data, clinical and experimen
tal evidence suggests that this intestinal
syndrome is not just a terminal event
without practical importance. In 1957
Lillehei8 proposed the concept of an “ in
testinal factor in shock” when he showed
that a dog subjected to hemorrhage could
survive if its bowel was perfused via the
superior mesenteric artery at normal
pressure. In contrast, maintenance of nor
mal flow to the brain, liver or kidney did
not protect the animals against irreversi
ble shock. Thus, the prevention of hemor
rhagic necrosis in the gut mucosa was
crucial to survival. Systemic protection
was also obtained by enterectomy im
mediately before intravenous injection of
endotoxin.9 The ischemic intestinal
mucosa appears to release substances to
which an important role has been given
in the shock cycle.
Surgeons, internists and pediatricians

alike should be more aware of the
dramatic effect of severe hypotension on
the entire gastrointestinal mucosa, with
potential serious effects on the entire
body. Such awareness can only lead to
better prevention, detection and treat
ment of these potentially lethal lesions.
Bernard J. P erey , m d ,

facs , frcs [c ]

Professor and chairman,
Department of surgery,
Dalhousie University,
Halifax, NS
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A Registry for Surgery of Hepatic Metastases
This issue (page 215) contains a report of
what may be the first relatively large
Canadian experience of hepatic resection
for metastatic disease. This procedure is
gaining popularity across Canada as well
as in the United States. Undoubtedly,
there will be further reports. Since most
Canadian experiences will be relatively
small numerically, it would be valuable
for all surgeons performing these opera
tions to document their cases (including
data recorded by all other surgeons in the
country). This information could then be
compiled on a national basis to give a
more comprehensive idea of indications,
contraindications and benefits of this
kind of therapy.
I suggest that, as a basic minimum in
addition to age, sex, racial origin and site
of the primary tumour, the following
items should be noted:
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1. Site, stage and grade of primary
cancer.
2. Site, size and number of liver
metastases.
3. Liver metastases found syn
chronously or metachronously.
4. Interval between diagnosis of the
primary tumour and of liver metastasis.
5. Interval between resection of
primary tumour and of liver metastasis.
6. Any other sites of metastases.
7. Any other chronic or important
diseases.
8. Duration of life following resection
of the primary tumour.
9. Duration of life following resection
of the metastases.
10. Level of carcinoembryonic anti
gen before resection of the primary
tumour, before resection of metastases and
1 year following resection of metastases.

It would also be important to note the
applicable items of the above list in pa
tients who were judged suitable for opera
tion, but who refused to undergo hepatic
resection.
If all of us, nation wide, who are do
ing this kind of operation were to com
pile these data, then in 5 years’ time it
would be simple to forward the informa
tion without names to a person willing to
compile and analyse the data. In this
regard I urge those wishing to participate
to send their case summaries, drawn up
along the lines I have suggested, to me at
the Department of surgery, Rm. GF419,
Health Sciences Centre, 700 William
Ave., Winnipeg, Man. R3E 0Z3.
R.J. Blanchard ,
Member,
Editorial Board

m d , frcs [c ], facs
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Is TPN obsolete?

No, not really.
There will always be
some patients who
require TPN.
However, for the majority
of patients, those with
a functioning gut, there
is a preferred alternative.
Vivonex® HN, total
enteral nutrition, is that
preferred alternative.

Vivonex HN is as effective,
and is safer, easier to handle
and is less expensive, g
Equally effective
“ It is probable that the nitrogen and body
weight preservation provided by enteral
hyperalimentation equals or exceeds that
demonstrated for total parenteral nutrition
in postoperative patients.”1
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Vivonex HN reduces the risk of catheter
sepsis or embolism.

Easier to handle
With Vivonex HN, aseptic handling is
not as stringent as in TPN. This reduces
physician and staff time needed for
nutritional care.

Substantially less expensive
The cost of Vivonex HN is less than half
that of TPN.

For more information on indications and
precautions of Vivonex HN, please contact
your Norwich Eaton representative or write:
NORWICH EATON
PARIS, ONTARIO N3L 3T8

Division of Norwich Eaton Pharmaceuticals, Inc.,
the registered trademark® owner
PAAB
CCPP
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CORRESPONDENCE

Contributions to the Correspondence section are welcomed.
They should be typewritten and double spaced.

Abortion in the Second Trimester
To the editors.—1 congratulate Dr. R.J.
Blanchard of your Editorial Board for his
comments (Can JSurg 1982; 25: 599-600)
on the article “ Mid-trimester abortions:
a decade in review” by Martin and Gelfand (Can J Surg 1982; 25: 641-3). It is
difficult to understand why such an arti
cle should be included in a scientific jour
nal. The destruction of human life for
sociologic reasons does not appear to be
a surgical procedure. Dr. Blanchard states
that “ the ethical climate blows with many
winds” . Let us hope that these winds do
not completely blow away our traditional
values that show respect for life.
C.L. O ’Connell , md , frcs[c ]
509 Park St.,
Kitchener, Ont.

suggestions to Dr. Gagic’s operative
description. First, a flexible, mercury
loaded dilator (no. 44 French) should be
passed into the esophagus by the
anesthetist under the finger direction of
the surgeon. This gives an unyielding,
relatively immobile surface against which
the muscle can be more easily divided. Se
cond, the presence of the dilator when
closing the esophagus after diverticulectomy makes certain that stenosis is
avoided postoperatively. Incidentally,
closure is quickly and simply achieved
with a 30-mm stapler. Finally, I re
commend the use of 2.5 magnification
loops to allow a really clear view of mus
cle layers and the point of change to the
oblique inferior constrictor fibres. I also
use loops for performing muscle section
in Heller myotomy at the lower end of the
esophagus; here again the transition from
esophageal to gastric musculature is much
more easily seen. I believe it was Deaver
who said that to do well you have to see
well!

Cricopharyngeal Myotomy
J ulius L. Stoller , mb, frcs, frcs[c ]
To the editors.—In his interesting paper
on cricopharyngeal myotomy in the
January 1983 issue (pages 47 to 49), Dr.
Gagic notes that responsible investigators
have reported different findings in study
ing abnormalities of esophageal motility
in this field. This remains a puzzle, but
fortunately the divergence may be irrele
vant. When no diverticulum is present, it
is my experience, over the last 20 years,
that the results of myotomy are equivocal,
unless the roentgenogram obtained after
a swallow of contrast medium demon
strates an obvious abnormality. When
there is no relaxation (with or without a
hypertrophic muscle bar) myotomy
works. Motility studies are unreliable in
predicting the results of operation and I
now use only the cine esophagogram in
making a decision to perform myotomy.
On the other hand, when a diverticulum
is present, it is not unreasonable and pro
bably harmless to perform myotomy with
excision or diverticulopexy. However, the
case for muscle section cannot be con
sidered proved.
I would also like to add three technical

Department of surgery,
Vancouver General Hospital,
Vancouver, BC
V5Z 1M9

The "D ark Ages" of Neurosurgery
To the editors.— I read with considerable
interest the article on head injuries in
multiple trauma in the January 1983 issue
(pages 23 to 26) by Schwartz and the com
mentary by Ford. I would take issue with
the comment that the Glasgow coma scale
and that intracranial pressure monitoring
have brought neurosurgery out of the
“ dark ages” . Jennett’s own article,1 sum
marizing the experience of three countries,
stated there was no difference in the mor
tality between those who were monitored
with pressure screws and those who were
not. I believe he also stated that, although
there was no statistical proof, his impres
sion was that those who received inten
sive care (i.e, those who were paralysed,
intubated and so on) as a group did not

do as well as expected. Until someone has
proof that there is a better survival rate
and a better quality of survival with any
given form of treatment, we should not
call the efforts of neurosurgery up to date
the “ dark ages” . Indeed, if we train our
residents to watch a monitor rather than
the patient we may slip into some “ dark
ages” . Your article is very timely and con
tains a lot of worthwhile observations and
suggestions for the profession as a whole.
D wight P arkinson , md , facs, frcs [c ]
Professor of neurosurgery,
University of Manitoba,
Health Sciences Centre,
Winnipeg, Man.
R3E 0Z3
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To the editors.—In response to Dr.
Parkinson’s letter, although the phrase
“ dark ages” was used by Dr. Ford in the
discussion of my paper, I find myself on
Dr. Ford’s side of the argument.
I agree with Dr. Parkinson that physi
cians should watch the patient’s clinical
performance. The Glasgow coma scale,
which forces the observer to systematical
ly and consistently evaluate certain
elements of clinical behaviour, is an ad
junct to this. Monitoring intracranial
pressure by means of measuring devices
is indeed best reserved for those who are
so severely injured that their neurologic
function is greatly reduced or for those
whose behaviour, for other reasons, is not
an accurate guide to treatment and
evaluation of its effect.
Monitoring, in addition to serving as
a guide to treatment and a measure of its
effectiveness, has ushered in “ an age of
enlightenment” that has brought us bet
ter understanding of the significance of
intracranial hypertension in severe head
injury.1
Becker and colleagues,2 reporting on
the outcome of severe head injury with
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From cells
to organ systems...

Solu-Medrol
protects against
the inroads of
shock and improves
the patient’s
chance for survival*

Inadequate tissue perfusion, which
occurs during shock, changes the
metabolic function of vital organs,
leading to multiple organ failure.
® Particularly insidious is the effect
on the lung. Polysaccharides
released in shock cause chaotic
activation of complement. This
affects granulocytes, which
migrate to the lung, plug the
pulmonary microvasculature, and
trigger the release of toxic oxygen
radicals that damage the
epithelium and permit capillary
leakage. The result is the acute
adult respiratory distress
syndrome (ARDS).

» Pharmacologic doses of SoluMedrol Sterile Powder (methylprednisolone sodium succinate)
given early in the course of the
illness can be lifesaving.
• In the lungs of patients with sep
tic and hemorrhagic shock, such "
doses have reduced the perme
ability defect and increased sur
vival rates.1-4
* Solu-Medrol inhibits complementinduced granulocyte aggregation
and formation of leukostatic
plugs, decreases arteriovenous
shunting, and increases oxygen
consumption.56
*adjunctively with standard methods of
combating shock

(See page 00 for prescribing information)
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Dosage
• In early or impending shock, a
pharmacologic dose of 30 mg/kg
Solu-Medrol intravenously over
a period of 10 to 20 minutes
• Additional doses at four-hour
intervals until patient’s condition
has stabilized (up to 48-72 hours)

Timing
Immediate stabilization of the pa
tient with respiratory support,
fluids and vasoactive drugs is of
primary concern. Solu-Medrol
may tip the balance toward
survival.78
• Early treatment with steroid
appeared to be “ a critically
important prerequisite for
successful recovery” of animals
subjected to experimental
shock.910
• Large doses of Solu-Medrol did
not depress phagocytic activity
or delay time of recovery in
dogs or baboons.
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Solu-Medrol

early diagnosis and intensive manage
ment, had better results on average for
their patients than did Jennett and
colleagues3 in the “ three countries”
report that Dr. Parkinson cites.
It is one o f the claims o f those who use
the Glasgow coma scale that it permits
valid comparisons o f patients in one cen
tre with those in another. If such com
parisons are valid (and they may very well
not be) there is some evidence that inten
sive treatment can improve the outcome
for patients after severe head injury.

protects the chain
o f organ systems in shock
Sterile

Solu-Medrol
(methylprednisolone sodium succinate)
Action:

Solu-Medrol, like other corticosteroids, exerts its action by its
anti-inflammatory effect.
Indications and Clinical Uses:

Intravenous administration of Solu-Medrol is indicated in situa
tions in which a rapid and intense hormonal effect is required.
Shock:

In severe shock adjunctive use of intravenous methylpredni
solone sodium succinate (Solu-Medrol) may aid in achieving
hemodynamic restoration. Corticoid therapy should not replace
standard methods o f combating shock, but present evidence
indicates that concurrent use of large doses of corticoids with
other measures may improve survival rates. In particular, large
pharmacological doses of Solu-Medrol have been proven useful
in bacteremic or endotoxin shock, hemorrhagic shock, traumatic
shock, and cardiogenic shock.

protein intake. In patients with diabetes mellitus, Solu-Medrol
may increase insulin requirements during the period of adminis
tration. Ecchymotic manifestations, while noted only rarely
during the clinical evaluation of Medrol may occur. Excessive
loss of potassium is not likely to be induced by effective mainte
nance doses of Medrol. If such reactions are serious or distres
sing to the patient, reduction in dosage or discontinuance of
corticoid therapy may be indicated. While a retardant effect on
wound healing is seldom encountered, except in high doses, it
should be a matter of consideration when Solu-Medrol is ad
ministered in conjunction with surgery.

M

Single large doses of Solu-Medrol do not have any apparent
toxic effect and require no specific therapy. Continuous over
dosage would require careful gradual reduction of dosage in
order to prevent the occurrence of acute adrenal insufficiency.

Except when used for short-term or emergency therapy as in
acute sensitivity reactions, Solu-Medrol is contraindicated in
patients with arrested tuberculosis, herpes simplex keratitis,
acute psychoses, Cushing’s syndrome, peptic ulcer, vaccina and
varicella.

In treating severe shock there is a tendency in current medical
practice to use massive (pharmacological) doses of corticoste
roids. The following are Solu-Medrol doses suggested by various
authors:
A uthor

Dose

Repeal

Precautions:

Oaks
Weil
Melby
Cavanagh
Dietzman

100 mg
200 mg
250 mg
15 mg /kg
30 mg /kg

Every 2-6 hours
100 mg every 4-6 hours
Every 4-6 hours
Every 24 hours
In 4 hours if needed

Adverse reactions are not likely to result from short-term intra
venous administration of Solu-Medrol, but may be anticipated if
continued therapy with oral or intra-muscular corticosteroid
preparations is to follow. Medrol has less tendency than pred
nisolone to induce retention of sodium and water, and in some
cases has been observed to produce diuresis and an increased
excretion o f sodium. Likewise, therapy with Medrol appears to
produce less nervousness and psychic stimulation than that
produced by prednisolone. While epigastric distress has not been
totally lacking in patients receiving Medrol, the incidence and se
verity o f this side reaction to date suggest that although Medrol
has an enhanced anti-inflammatory potency when compared
with prednisolone on a weight basis, the so-called ulcerogenic
potential o f this corticosteroid is no greater, and may even be
less, than that o f prednisolone.
With the exception o f the differences noted in the preceding
paragraph, Medrol is similar to hydrocortisone and prednisolone
in regard to the kinds of adverse reactions and metabolic altera
tions to be anticipated when treatment is intensive or prolonged.
Negative nitrogen balance is usually counteracted by a high
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Dosage and Administration:

Adverse Reactions:

Sc h w a r t z ,

Symptoms and Treatment of Overdosage:

Contraindications:

Existence of diabetes, osteoporosis, chronic psychoses, active
tuberculosis, renal insufficiency or predisposition to throm bo
phlebitis requires that Solu-Medrol be administered with
extreme caution. In the presence of infection, the causative
organism must be brought under control with appropriate anti
bacterials, or therapy with Solu-Medrol should be discontinued.
While therapy with corticoids does not appear to be contraindi
cated in pregnancy, caution is recommended, particularly during
the first trimester. Also, newborn infants of mothers who
received such therapy during pregnancy should be observed for
signs o f hypoadrenalism and appropriate measures instituted if
such signs are present. Since Medrol, like prednisolone, suppres
ses endogenous adrenocortical activity, it is highly important
that the patient receiving Solu-Medrol be under careful observa
tion, not only during the course of treatment but for some time
after treatment is terminated. Adequate adrenocortical suppor
tive therapy including ACTH, must be employed promptly if the
patient is subjected to any unusual stress such as surgery,
traum a, or severe infection. Patients should be advised to
inform subsequent physicians of the prior use of Solu-Medrol.
There have been a few reports of cardiovascular collapse asso
ciated with the rapid intravenous administration of large doses
of Solu-Medrol (greater than 0.5 grams) in organ transplant reci
pients. The cause and relation to other medications (i.e.,
diuretics) is not known at this time, but physicians should be
alert to this possibility.

ic h a e l

Therapy is initiated by administering Solu-Medrol intravenously
over a period of at least 10 minutes. In general high dose corti
costeroid therapy should be continued only until the patient’s
condition has stabilized, usually not beyond 48 to 72 hours.
Although adverse effects associated with high dose short term
corticoid therapy are uncommon, peptic ulceration may occur.
In other indications initial dosage will vary from 10 to 500 mg
depending on the clinical problem being treated. The larger
doses may be required for short-term management o f severe,
acute conditions. The initial dose usually should be given intra
venously over a period of at least 10 minutes. Subsequent doses
may be given intravenously or intramuscularly at intervals dic
tated by the patient’s response and clinical condition.
Solu-Medrol may be given by intravenous infusion using as the
infusion solution either 5% dextrose in water, isotonic saline
solution or 5% dextrose in isotonic saline solution. Solu-Medrol
is also compatible with most other commonly used infusion
solutions and plasma or whole blood.
Availability:

Solu-Medrol Mix-O-Vial, 40 mg (1 ml)
Solu-Medrol Mix-O-Vial, 125 mg (2 ml)
Solu-Medrol, 500 mg:
Reconstitute with 7.8 ml Bacteriostatic Water for Injection
U.S.P. (benzyl alcohol as preservative)
Solu-Medrol, 1 gram:
Reconstitute with 15.6 ml Bacteriostatic Water for Injection
U.S.P. (benzyl alcohol as preservative)
Product monograph available on request,

ce
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Wound Measurement
To the editors.— I was interested to read
the letter of Drs. Sutherland and Cruse
in the July 1982 issue o f the Canadian
Journal o f Surgery (page 364) concern
ing yvound measurement. Silastic foam
dressing (Dow Corning) is readily
available and is very useful for making
serial measurements o f wound volume in
this way. Moreover, it is itself an ideal
dressing for such wounds, being cheap,
comfortable and effective.1 It is now
used extensively in Britain and in many
other countries, but not, as far as I am
aware, in North America. Its use has
simplified the management o f most
granulating wounds and it allows many
patients to be treated at home who would
otherwise have to be hospitalized.
L.E. H u g h e s ,

m b, d s, fr c s, fra cs

Professor of surgery,
Welsh National School of Medicine,
Cardiff, Wales
CF4 4XN
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[Editor’s note.—See also Gledhill T, Water
fall WE: Silastic Foam: a new material for
dressing wounds. Can Med Assoc J 1983; 128:
685,]
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REVIEW ARTICLE
Norman S. T rack,

ph d

Regulatory Peptides of the Gut and Brain
The concept of the gut-brain axis has
emerged from the recent demonstration,
mainly by radioimmunoassay and immunohistochemistry, that many peptides
are common to both gut and brain cells.
The general term regulatory peptide is at
present the most appropriate for these
peptides until more is known about their
precise hormonal, neurotransmitter and
neuromodulator activities. Consideration
of possible local endocrine (paracrine)
and neuroendocrine secretion
necessitates re-evaluation of the impor
tance of peripheral regulatory peptide
concentrations. Central and peripheral
administration of these peptides is a
useful way to establish their potential
regulatory roles in endocrine and nervous
pathways. The concept of the gut-brain
axis demonstrates the intimate relations
between endocrinology and neuroendo
crinology.
Le concept d'un axe intestin-cerveau est
ne d'une observation recente au moyen
de radioimmunoessai et immunohistochimie temoignant de la presence de pep
tides communs a I'intestin et au cerveau.
Le nom general de peptides regulatoires
semble le plus approprie jusqu'a plus
ample connaissance de leurs activites
hormonales, neurotransmitteurs et neuromodulateurs. Si une secretion locale
(paracrine) et neuroendocrine est consideree possible, il devient necessaire de
re-evaluer I'importance de la concentra
tion peripherique des peptides regulatoi
res. L'administration au niveau central et
peripherique est un moyen utile pour etablir leur possible role regulateur dans les
systemes endocriniens et nerveux. Le
concept d'un axe intestin-cerveau
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demontre la relation intime entre I'endocrinologie et la neuroendocrinologie.

Advances in protein chemistry have made
it easier to isolate and characterize many
polypeptides from different areas of the
gut and brain that have a wide spectrum
of biologic activities. These peptides have
been located in specific gut and brain cells
by radioim m unoassay and immunohistochemistry. The recent findings
of gut peptides in brain and nerve cells
and brain peptides in gut cells and nerves
created the concept of the gut-brain
axis.1-3 For example, gastrin/cholecystokinin (CCK), motilin, bombesin,
vasoactive intestinal polypeptide, pan
creatic polypeptide, insulin and glucagon,
found originally in the gut, have been
detected in certain cells of the brain;
similarly, somatostatin, neurotensin,
adrenocorticotropic hormone, enkephalin
and substance P, found originally in the
brain, have been detected in certain cells
of the gut. The wide, overlapping
distribution of these peptides has led to
a major rethinking of their potential
regulatory roles and the mechanisms in
volved in performing them. It is inap
propriate to refer to these peptides solely
as hormones, neurotransmitters or
neuromodulators because of their diverse
potential functions; until more is known
about their precise functions, they are
best described as regulatory peptides.
Modes of Cellular Communication

When regulatory peptides were found
exclusively in endocrine cells, then bloodborne messages, classic endocrine secre
tion, were considered to be the major
communication network. This type of
secretion involved the production and
release of a regulator from an endocrine
cell that was carried by the blood to a dis
tant organ to regulate its cellular
metabolism. Endocrine messages can be
measured in the peripheral circulation; a
change in circulating regulator concentra
tion in response to a physiologic stimulus

has been a measure of the physiologic
status of a regulatory peptide (hormone).
Recent studies by radioimmunoassay
and immunohistochemistry have confirm
ed earlier suggestions that there is a type
of local endocrine communication called
paracrine secretion.4 Release of a
regulatory peptide from an endocrine cell
influencing neighbouring cells is describ
ed as paracrine secretion. This type of
secretion cannot be detected in the
peripheral circulation. Therefore, old
definitions and criteria for regulatory
peptides (hormones) are inadequate to
classify paracrine regulators. Other types
of cellular communication are neurocrine
and neuroendocrine. The first involves
the release of a regulatory peptide from
a nerve ending that functions as a
neurotransmitter or neuromodulator. The
second involves the release of a regulatory
peptide from a nerve ending into the cir
culation. Widespread localization of
regulatory peptides in both gut and brain
nerve cells enhances the importance of
these two
routes of cellular
communication.
Isolation, Characterization and
Measurement of Regulatory Peptides

The classic preparation of peptides
from both gut and brain employed
bioassays initially to search for and subse
quently to follow the biologically active
fractions through the extraction and
purification steps. By the classic method,
structurally similar but biologically inac
tive peptides (with respect to the bioac
tivity being followed), either larger or
smaller than the most active fraction,
were not characterized. Enormous quan
tities of tissue, time and labour were in
vested to establish the amino-acid se
quences of a number of peptides from gut
and brain tissue. The introduction and
application o f radioim m unoassay
methods provided a new approach to
study gut-brain peptides. With antisera
to these peptides it has been possible to
measure minute quantities of peptides and
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also to stain cells containing the peptides
by immunohistochemical methods. With
the new radioimmunoassay technique,
structurally related peptides have been
detected and characterized. At present
their biologic activities are unknown. This
new approach has revealed the similarities
in peptides produced both in the gut and
in the brain, thereby raising new
questions.
The first and probably most important
question is what criteria must be satisfied
to establish the existence of peptides com
mon to both gut and brain. Classic studies
relied upon biologic activity to character
ize peptides; most contemporary studies
rely mainly upon immunohistochemical
techniques to localize peptides and
radioimmunoassay to quantify and
characterize them. These techniques rely
on recognition of a specific region of the
peptide by the antisera used; they are
structural assays and do not, in most
cases, reflect biologic activity. Further,
single, positive radioim m unoassay
measurements or immunohistochemical
staining of peptides cannot be taken as
absolute evidence of the presence of a
peptide. Measurements and staining must
be repeated with different antisera to
reduce the risk of artefacts (false
positives). The ultimate proof is to purify
the peptide from the tissue source and
demonstrate biologic activity. What is the
appropriate and relevant bioassay for
newly purified peptides? It is now
necessary to develop new bioassays for
these peptides, since assessing a
neurotransmitter as a hormone means
nothing.
Regulatory peptides extracted from the
porcine upper small intestine were assum
ed to originate in the endocrine cells of
the mucosal layer. There is evidence of
immunoreactive motilin in both mucosal
and muscularis layers of the small
intestine5 and immunoreactive vasoactive
intestinal polypeptide in both mucosal
and muscularis layers of the large
intestin e.6 From Sephadex G-50
chromatography of these four extracts,
both immunoreactive motilin and vasoac
tive intestinal polypeptide eluted as single

peaks. From CM-Sephadex chromato
graphy, the Sephadex G-50 muscularis
peak of immunoreactive vasoactive
intestinal polypeptide eluted again as
a single peak, while the muscosal peak
separated into three immunoreactive
components. Since both mucosal and
muscularis extracts were prepared by a
similar technique, it seems unlikely that
the mucosal heterogeneity was generated
by the chemical extraction. The real test
for all cases of peptide heterogeneity is
to assess the biologic activity of each
component.
Cholecystokinin is extracted routinely
with acetic acid from the porcine upper
small intestine; CCK33 and the CCKvariant CCK39 are the two major com
ponents detected.7 Ryder and associates8
demonstrated that alkaline extracts of rat
brain contain two to four times more
CCK than neutral or acid extracts.8 The
extraction pFl, while affecting recovery,
did not influence the distribution of the
CCK component. In contrast, recovery of
enkephalin was similar with both alkaline
and acid extracts.8 Another study of rat
brain detected less CCK33 with aqueous
than with acid extracts.9 The CCK an
tisera used in these two studies probably
had different recognition characteristics.
Antisera can be directed against different
parts of the peptide sequence. The part
that they recognize may possess no
biologic activity. This is why it is very im
portant to have well-characterized an
tisera especially with heterogeneity, as dif
ferent molecular sizes may be recognized
to varying extent by each antiserum.
Classically, before a peptide could be
considered a real hormone, a change,
usually an increase, in its circulating con
centration was an important criterion to
be fulfilled. Recent findings10 necessitate
re-evaluation of the relevance,
physiologically, of peripheral regulatory
peptide measurements. Circulating basal
and stimulated regulatory peptide concen
trations have been used as guidelines for
physiologic levels for infusion studies.10
How accurately do peripheral regulatory
peptide measurements reflect local release
and concentrations? An experimental ap
proach to this question has been to infuse

Table 1-Local and Peripheral Plasma Motilin Concentrations
after Bolus Arterial Infusions of Increasing
Quantities of Synthetic Porcine Motilin
Plasma motilin concentration,
ng/l
Bolus infusion
Duodenal vein,
Femoral vein,
of motilin into
min
min
duodenal artery,
ng/100 pi
2
5
2
5
0.1
146
278
176
176
346
1.0
281
266
255
837
172
10.0
273
192
2720
458
179
100.0
204
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peptides into the duodenal artery and col
lect samples from both the duodenal and
femoral veins.10 Arterial bolus infusions
of increasing doses of motilin have
resulted in a concomitant increase in
plasma motilin concentrations in the
duodenal vein but not in the femoral vein
(Table I), demonstrating that enormous
changes in regulatory peptide concentra
tions can occur locally with no detectable
change at the periphery.
Function of Regulatory Peptides

Regulatory peptides function as in
tercellular messengers in the endocrine
and nervous systems. Both gut and brain
regulatory peptides have been shown to
have specific effect upon cellular
metabolism. They may possess similar
functions in different locations or entirely
different ones. One molecular size may
be active in one location and a different
molecular size in another. Studies of cen
tral and peripheral administration of
these peptides may shed some light upon
the actions.
Beta endorphin and bombesin are
found in both the gut and the brain. Beta
endorphin when administered centrally
was found to decrease both basal pan
creatic and gastric secretions;11 in
travenous administration was without ef
fect. Bombesin administered centrally
also decreased basal gastric secretion12
while intravenous administration had no
effect. These central effects seem to be
mediated by neural pathways. Brain
bombesin may act primarily by regulating
gastric
secretion12
and
body
temperature13 while gastric bombesin
(gastrin-releasing peptide) may act
primarily by regulating the release of a
num ber of g astro en teropancreatic
regulatory peptides.14
Motilin is another example of a gutbrain regulatory peptide that may have
different activities in the two locations.
Im m unoreactive m otilin has been
detected in all gut and brain samples
assayed to date starting with the primitive
Atlantic hagfish (Table II). Fresh

Table II—Detection of Immunoreactive
Motilin in Different Species
Species
Brain
Gut
+
Atlantic hagfish
NSA
+
Scorpion
NSA
+
+
Quail
+
Lizard
NSA
+
Frog
NSA
Goldfish
+
NSA
+
+
Hamster
+
+
Opossum
+
+
Dog
+
+
Man
+ - detectable, NSA - no sample available.
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gastrointestinal and brain tissues were ex
tracted in 0.2M acetic acid; the extracts
were boiled and centrifuged. The motilin
content of the supernatants was determin
ed by radioimmunoassay. In the gut,
motilin has been detected in both mucosa
and muscularis layers,5 presumably act
ing as a hormone and neurotransmitter
to regulate motility. In the brain, motilin
has been used as a marker for Purkinje
cells and may be a factor in cerebellar
development.15
Evidence to date suggests that the
balance between two brain regulatory
peptides may contribute to satiety con
trol. Beta endorphin stimulated food in
take in satiated ra ts .16 Pituitary
13-endorphin concentrations were elevated
in o vereating, genetically obese
animals.17 On the other hand, CCK sup
pressed food intake in a number of
species.18'20 Significantly reduced
cerebral concentrations of CCK were
found in obese mice compared with their
lean littermates and normal mice.21 Since
these two regulatory peptides have oppos
ing effects upon satiety, it is important
that both stimulatory and inhibitory fac
tors be considered when assessing an
overall metabolic effect.
Regulatory peptides bind with specific
cell membrane receptors to initiate
biologic activity. From studies with

glucagon,22 it was generally believed that
each peptide’s bioactivity involved a se
cond messenger. No clear second
messenger has been found for other pep
tides (e.g., insulin, growth hormone,
various growth factors). It now seems that
“ internalization” of the peptide-receptor
complex into the cell is a necessary com
ponent of the peptide’s bioactivity.23
This raises the possibility that the role of
the peptide is to facilitate the internaliza
tion of the receptor which really possesses
the biologic activity. Further studies are
necessary to delineate peptide-receptor
interactions and activities within target
cells.
The receptor is an important factor to
be considered in the modulation of
regulatory peptide bioactivities. Vasoac
tive intestinal polypeptide receptors of
brain possess different characteristics
from those of gut. Deschodt-Lanckman
and associates24 found that vasoactive
intestinal polypeptide receptors of brain
were very specific and brain adenyl
cyclase, which is sensitive to vasoactive
intestinal polypeptide, was not affected
by secretin or by guanyl triphosphate
nucleotides. The presence of distinct
receptors in the gut and the brain provides
the differential for bioactivities of a com
mon regulatory peptide. One must con
sider modulation of regulatory peptide ac

tivity by changing peptide or receptor
concentration, or both. Such changes
may occur during the a n im a l’s
development.25
The discovery of the brain-gut axis has
necessitated a re-examination of the basic
concepts of endocrinology and indicates
th a t en d o crin o lo g y and n e u ro e n 
docrinology are more closely related than
was originally thought.
The motilin studies described in the text were
supported in part by the Harold Tanenbaum
department of research, Mount Sinai Hospital,
and the Medical Research Council of Canada
(PG-8) and were performed in collaboration
with Drs. J.E.T. Fox, E.E. Daniel (McMaster
University) and S. Falkmer (University of
Lund, Sweden).
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Role of Resection in the Management of Metastases to the Liver
The results of 22 hepatic resections for
metastatic disease are reviewed. There
were no operative deaths and survival
was encouraging. Life-table analysis of
ail 22 patients predicted a 5-year sur
vival of 56.4% , and if 16 patients who
had primary colorectal tumours are con
sidered separately, the expected
42-month survival was 42 .2% . Patients
with a single metastasis generally lived
longer, and there was no difference in
survival between hepatic metastases
resected synchronously or metachronously. The authors recommend an
aggressive approach to the treatment of
hepatic metastases.
Les resultats de 22 resections hepatiques pour des metastases cancereuses
sont passes en revue. Aucun deces operatoire n'est survenu et la survie est
encourageante. L’analyse de la survie de
22 patients par la methode actuarielle a
projete un taux a 5 ans de 56.4% ; si
I'on considere separement les 16
patients qui avaient des tumeurs primaires du colon ou du rectum, le taux de
survie prevu a 42 mois etait de 42.2% .
Les patients porteurs d'une metastase
unique vivaient generalement plus longtemps, et il n'y avait pas de difference
de survie pour les resections synchrones
ou asynchrones de metastases hepatiques. Les auteurs recommandent d'adopter une attitude agressive face au traitement des metastases hepatiques.

When cancer at any site metastasizes to
the liver, the likelihood of cure becomes
remote and treatment is usually aimed at
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palliation. Data from a number of
reviews1-4 indicate that the mean survival
after discovery of hepatic metastases
ranges from 6 to 9 months. Radiotherapy,
hepatic artery ligation, system ic
chem o th erapy and in tra-arterial
chemotherapy have not resulted in
substantial gains in the quality or quan
tity of life and have produced no cures
in this group of patients.5' 11
Hepatic resection for metastatic disease
was first reported in 1888.12 In the
1950s, when hepatic anatomy was better
understood and techniques of lobar resec
tion were developed, operations on the
liver became possible with acceptably low
risk, and resection became a reasonable
option for treating selected patients with
hepatic secondary tumours.13 Several
studies reported an operative mortality
below 10% and 5-year survival of more
than 25% .14'20 Based on these reports,
our approach to hepatic metastases has
become more aggressive and since 1974
we have carried out hepatic resection in
22 patients with secondary liver deposits
from various primary sites.
Patients and Methods
Hepatic resection was carried out in 22
patients (13 women, 9 men), who ranged
in age from 26 to 75 years (mean 56
years). The most common site of primary
disease (Table I) was the colorectum (10
women, 6 men, mean age 56 years). Ten
of the 22 hepatectomies were carried out
for secondary disease found synchronous
ly before or at operation for the primary
disease, and 12 were performed for
metastases found later, from 11 months
to 15 years (mean 39 months) after
removal of the primary tumour.
If liver involvement was discovered
unexpectedly at laparotomy, bimanual
examination was used to determine, along
with general factors, whether syn
chronous liver resection was advisable. In
3 of the 10 patients with synchronous
disease, wedge resections were perform
ed at the same time as excision of the
primary lesion. Six other patients under
went resection of the primary tumour

and, after further investigation to rule out
widespread disease, had liver resection 1
to 7 months later. One patient with car
cinoid syndrome had his hepatic secon
dary tum our resected first, followed in 3
weeks by resection of the primary tumour
in the terminal ileum.
The 12 patients with metachronous
liver metastases had all been followed up
regularly. Liver involvement was sug
gested by the symptoms, physical signs,
or increase in serum carcinoembryonic
antigen or alkaline phosphatase values. It
was confirmed by radionuclide scanning.
Further assessment, with computerized
tomography, bone scanning and lung
tomography, was then carried out. If
these investigations confirm ed the
presence of secondary liver involvement
with no other metastatic disease, and the
lesions were thought to be amenable to
surgery, arterial and venous angiograms
of the liver were obtained to determine
if the lesion was technically resectable. A
single lobar metastasis or multiple lesions
confined to one lobe were considered
resectable.
The extent o f resection is noted in
Table II. Wedge resections were performTable 1—Site of Primary Tumour
No. of
patients
Site
16
Colorectum
2
Adrenal gland
1
Terminal ileum (carcinoid)
1
Thyroid
1
Pancreas (islet cell tumour)
1
Abdominal wall (leiomyosarcoma)

Table II—Extent of Liver Resection
No. of
Procedure
patients
Extended right lobectomy
(trisegmentectomy)
3
Formal right lobectomy
8
Formal left lobectomy
2
1
Left lateral segmentectomy
Wedge resections
8
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ed in 8 of the 22 patients and various
types of formal lobar resection in 14.
Conventional anesthetic and surgical
techniques were used with particular at
tention to hemostasis. Postoperatively,
patients were closely monitored in the in
tensive care unit. After discharge from
hospital, they were followed up closely.
A dditional treatm ent consisted of
chem otherapy (six p a tie n ts), im 
munotherapy (one patient) or a combina
tions of these two (eight patients). Seven
patients were simply observed.
Results

Complications
There were no operative deaths.
Operative morbidity consisted of tran
sient bile fistula (one patient), subphrenic
abscess (one) and transient jaundice and
encephalopathy (one).
Survival
Survival data are shown in Table III.
The expected 5-year survival for the whole
group, by life-table analysis, was 56.4%
(Fig. 1).
The predicted 42-month survival for
the 16 patients who had hepatic resection
for metastatic colorectal cancer was
42.2% (Fig. 1); the longest surviving pa
tient in this group available for study was
alive 44 months after resection.
The group of six patients who had
primary tumours at sites other than the
colorectum was heterogeneous. The two

patients with primaries in the adrenal
gland were alive 81 and 88 months after
resection and the patient with carcinoid
syndrome from a primary in the terminal
ileum was alive with disease at 46 months.
The three patients who had a primary
thyroid tumour, leiomyosarcoma in the
abdominal wall and pancreatic islet cell
tumour, respectively, only recently under
went resection.
Single versus multiple metastases.—
The predicted 5-year survival rate by the
life-table method for the 17 patients with
a single metastasis (Fig. 2) was 61.7%.
The small number of patients having
resection of multiple lesions does not
allow statistical analysis. The 13
patients with primary lesions in the col
orectum who had removal of a single
metastasis were examined separately; 10
were alive at follow-up from 1 to 44
months and 3 died 14, 22 and 31 months
postresection respectively. Life-table
analysis of these patients with a single and
multiple colorectal secondary lesions is
shown in Fig. 3. The predicted 42-month
survival for patients with a single resected
metastasis was 55.6% (longest survivor in
this group was alive at 44 months). The
three patients in the colorectal group with
excision of multiple metastases died at 11,
11 and 20 months after resection.
Synchronous versus metachronous.—
At present, there is no difference between
survival of patients who underwent liver
resection at the same time as removal of
the primary tumour and those who had
resection at a later date (Fig. 4). The
predicted survival at 42 months after syn

chronous resection in 10 patients was
56.3% (longest survivor alive at 46
months), and 5 years after metachronous
resection in 12 patients was 59.3%.
Similarly, if the colorectal group is con
sidered separately, there was no signifi
cant difference between the synchronous
and metachronous groups (Fig. 5).
Discussion

The presence of liver metastases accom
panying any primary malignant tumour
is an ominous sign. Bengtsson and
associates4 followed the natural history
of untreated hepatic metastases in 155 pa3
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FIG. 2—Life-table analysis of survival (all
patients) after hepatic resection; single versus
multiple metastases.

FIG. 5—Life-table analysis of survival (pa
tients with colorectal primary tumour) after
hepatic resection; synchronous versus
metachronous lesions.
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tients, and reported a median survival
time of 4.5 months from diagnosis.
Attempts to treat multiple hepatic
secondary tum ours by nonsurgical
methods have been frustrating. Long
term infusion of 5-fluorouraciI (5-FU) in
to the hepatic artery resulted in subjec
tive and objective remission in 70% of pa
tients in Reed’s series,7 but the median
overall survival was still only 10 months,
13 months in “ responders” . Comparison
of the intra-arterial and intravenous
routes of 5-FU administration by the Cen
tral Oncology G roup8 did not
demonstrate any differences in quantity
or quality of life for patients with primary
disease in the colon and hepatic involve
ment. Addition of other agents, such as
Corynebacterium parvum, to 5-FU in the
intra-arterial infusion has also been us
ed, without substantial benefit.9 Con
tinuous percutaneous intrahepatic infu
sion with 5-FU was evaluated by Oberfield and associates.10 On average the pa
tients survived approximately 6 months,
and serious arterial complications were
common.
Hepatic artery ligation, an alternative
method that can be replaced now by
arteriographic embolization, has been us
ed sporadically without marked success.5
Even whole liver irradiation has been us
ed in combination with intrahepatic ad
ministration of Adriamycin, leading to a
55% response rate in the study of Fried
man and associates,11 median survival
being less than 4 months.
Few series have studied the approach
to potentially resectable hepatic lesions
(i.e., single or multiple unilobular hepatic
involvement). Patients with a single
metastasis treated by nonsurgical methods
may fare somewhat better than those with
multiple metastases, as suggested by the
data of Wanebo and associates.16 In
their study, the mean survival of 18 pa
tients with a single hepatic metastasis,
unresected, was 19 months, whereas 149
patients with multiple lesions survived on
ly 9Vi months.
The results of resection of varying
amounts of liver in selected patients with
secondary hepatic involvement are en
couraging. Foster and Berman’s liver
tumour survey20 reported a 5-year sur
vival of 24% in 164 patients with a varie
ty of primary tumours and of 22% in 109
with colorectal primary lesions. Wanebo
and colleagues16 and Wilson and
Adson17 reported similar survival, both
with 5-year rates of 28%. Wilson and
Adson compared their 60 patients who
underwent liver resection for secondary
disease with 60 historical control patients
with similar hepatic lesions that were
found at laparotomy and not resected.
They reported a substantial improvement
in survival in the resected group as a
whole, as well as when single and multi

ple metastases were evaluated separately.
Risk of hepatic resection has been a
major deterrent to definitive treatment in
the past. However, Wilson and Adson
performed 60 resections with a 1.7%
operative mortality,17 and Foster and
Berm an,20 Flanagan and F oster,21
Wanebo and colleagues16 and others
reported acceptable rates of less than
10%. There were no operative deaths in
our 22 cases. Our early survival statistics
suggest, both overall and in those with
primary tumour of the colorectum, that
results will be comparable to published
studies.
Although Foster and Berman,20 in
their liver tumour review, reported no dif
ference in survival between those with
single and with multiple metastases,
others suggest that patients with a single
metastasis survive longer. Although in
our series the number of resections in pa
tients with multiple metastases was small,
all three patients in the colorectal primary
group died within 20 months. We cannot
tell whether hepatic resection in these pa
tients prolonged or improved life.
Foster and Berman20 did not show im
proved survival in patients who under
went liver resection for metastases after
the primary resection compared to those
operated upon synchronously. However,
others16’17 found that the length of
ultimate survival varied directly with the
interval between resection of the primary
and secondary lesions. To this point, our
results show no significant difference be
tween metachronous and synchronous
resection; both are associated with en
couraging survival rates.
Candidates for hepatic resection of
metastatic disease must be meticulously
selected. Approximately 10% to 15% of
patients presenting with a primary tumour
in the colorectum also have secondary
deposits in the liver. Only about 20% of
these will be suitable for hepatic resection,
that is those with unilobar disease or easi
ly resectable multiple lesions unaccom
panied by extrahepatic disease.
Therefore, overall, the likelihood of find
ing resectable hepatic metastases in pa
tients with colorectal carcinoma is ap
proximately 2% to 5%. However, if pa
tients are properly selected, 5-year sur
vival can be expected to be in the 25% to
30% range. Currently, we use the serum
carcinoembryonic antigen and alkaline
phosphatase values as part of the
p reoperative
assessm ent
and
postoperative follow-up of patients with
colorectal carcinoma. The patients in
whom abnormalities appear to suggest
hepatic metastatic disease then have com
plete assessment including liver scan,
search for o ther m etastases and
preoperative hepatic angiography.
At present, we recommend an ag
gressive surgical approach to hepatic

secondary lesions in selected cases,
whether the tumour is found at the same
time as the primary or later. The question
of resection of multiple metastases,
especially from colorectal prim ary
tumours, remains controversial. Hepatic
resection can be carried out relatively
safely and there is a real chance of cure
in selected cases.
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PIPRACIL

An Extended Spectrum of Activity

Pipracil is an effective advanced agent for
gram negative,gram positive and
anaerobic infections.
ipracil* (piperacillin sodium) is a major advance
in first-line antibiotic mono and combination therapy.
Pipracil’s* spectrum of bactericidal activity is broader
than other antibiotics, such as the aminoglycosides,
cephalosporins, penicillins and clindamycin.
Yet Pipracil* has an excellent clinical safety profile,
having a low sodium content and causing no
nephrotoxicity, ototoxicity or pseudomembranous
colitis. In addition, Pipracil* achieves excellent
concentrations in body tissues and fluids.
if

By providing a high degree of efficacy in a wide
range of mixed infections, Pipracil* is a logical ther
apeutic alternative for first-line therapy in surgery,
urology and gynecology, as well as for the com
promised patient.
'PIPRACIL'The Spectrum of
a Combination in One Advanced Agent
Cyanamid Canada Inc.
Toronto
‘Pipracil is a trade mark of Lederle Piperacillin, Inc.
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PIPRACIL

k piperacillin sodium

Parenteral Antibiotic for Intravenous and Intramuscular Use
INDICATIONS AND CLINICAL USES: Treatment of serious infections caused by susceptible strains of the designated
organisms in the conditions listed below.
Intra-abdominal Infections including hepatobiliary and surgical infections caused by Escherichia coli, Pseudo
monas aeruginosa, enterococci. Clostridium sp., anaerobic cocci, and Bacteroides sp., including B. fragilis.
Urinary Tract Infections (complicated and uncomplicated) caused by Escherichia coli, Klebsiella sp., Pseudomonas
aeruginosa, Proteus mirabilis and enterococci. Also uncomplicated urethritis caused by Neisseria gonorrhoeae.
Gynecological Infections including endometritis and pelvic inflammatory disease caused by Bacteroides sp.,
including B. fragilis, anaerobic cocci, Neisseria gonorrhoeae, and enterococci (Streptococcus faecalis).
Septicemia caused by Escherichia coli, Klebsiella sp., Serratia sp., Proteus mirabilis, S. pneumoniae, enterococci,
Pseudomonas aeruginosa, Bacteroides sp., and anaerobic cocci.
Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella sp., Enterobacter sp., Pseudomonas
aeruginosa, Serratia sp., Haemophilus influenzae, Bacteroides species and anaerobic cocci. Although improvement
has been noted in patients with cystic fibrosis, lasting bacterial eradication may not be achieved.
Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella sp., Serratia sp., Acinetobacter sp.,
Enterobacter sp., Pseudomonas aeruginosa, indole-positive Proteus sp., Proteus mirabilis, Bacteroides sp., including
B. fragilis, anaerobic cocci and enterococci.
Bone and Joint Infections caused by Pseudomonas aeruginosa, enterococci, Bacteroides sp„ and anaerobic cocci.
PIPRACIL* is useful for the treatment of mixed infections and presumptive therapy prior to the identification
of the causative organisms; infections produced by organisms resistant to other penicillins, some aminoglycosides
and cephalosporins; and infections at various sites caused by streptococcus species including Group A beta-hemoy lytic Streptococcus and Streptococcus pneumoniae.
PIPRACIL* may be administered as single drug therapy in some situations where normally two antibiotics
might be employed. In vitro synergism has been shown between Piperacillin and some aminoglycosides in some
bacterial strains. PIPRACIL* has been used clinically with aminoglycosides, especially in patients with impaired host
defences. Both drugs were used in full therapeutic doses.
PIPRACIL* can be used safely in combination with a penicillinase-resistant penicillin, e.g. oxacillin, in mixed
infections when beta-lactamase-positive Staphyloccus aureus is isolated along with piperacillin-susceptible
organisms. It may be administered concomitantly with a cephalosporin, provided that an additive or synergistic
antibacterial action of the two antibiotics is ascertained through in vitro tests. Based on in vitro data, cefoxitin should
not be given with piperacillin when Pseudomonas infections are suspected or confirmed.
Because PIPRACIL* is excreted not only renally, but also by the biliary route, it can be used in patients with
v hepatobiliary infections, or severely restricted kidney function, and in patients who have had nephrotoxic reactions
to other drugs, with appropriate adjustment of dosage (See DOSAGE).
Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted,
if appropriate, once the results are known.
CONTRAINDICATIONS: A history of allergic reactions to any of the penicillins and/or cephalosporins.
WARNINGS: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients
receiving therapy with pencillins. These reactions are more apt to occur in persons with a history of sensitivity to
multiple allergens.
Cross-sensitivity of patients to penicillins and cephalosporins has been reported. Before initiating therapy with
PIPRACILT careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalospo
rins and other allergens.
r
If an allergic reaction occurs, the antibiotic should be discontinued.
SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE.
OXYGEN, INTRAVENOUS STEROIDS. AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISx TERED AS NECESSARY.
PRECAUTIONS: Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics including
piperacillin.These reactions have sometimes been associated with abnormalities of coagulation tests such as
clotting time, platelet aggregation and prothrombin time and are more likely to occur in patients with renal failure.
If bleeding manifestations or significant leukopenia occur, PIPRACIL* should be discontinued and appropriate
therapy instituted.
The possibility of the emergence of resistant organisms and the development of superinfections should be
kept in mind, particularly during prolonged treatment.
^
As with other penicillins, patients may experience neuromuscular excitability or convulsions if higher than
recommended doses are given intravenously.
Dosage adjustment should be made in renal insufficiency.
^
PIPRACIL* is a monosodium compound containing 1.98 milliequivalents (45.5 mg) of Na -fper gram based on
vial content which includes the U.S.P. allowed average. The calculated value, based on molecular weight is 1.85
mEq/g (42.55 mg.). Periodic electrolyte determinations should be made in patients with low potassium reserves
and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium
reserves, receiving cytotoxic therapy or diuretics. Electrolyte and cardiac status should also be monitored during
prolonged-treatment in patients with impaired cardiac function.
Prior to treatment, patients with gonorrhea should also be evaluated for syphilis. Specimens for darkfield
examination should be obtained from patients with any suspected primary lesions, and serologic tests should be
vperformed.ln all cases where concomitant syphilis is suspected, monthly serological tests should be made for a
minimum of 4 months.
The use of some penicillins (ampicillin, amoxicillin) has been associated with morbilliform rashes in some
cases of infectious mononucleosis. PIPRACIL* should be used with caution in the treatment of patients with infec* tious mononucleosis.
Drug Interactions: The mixing of PIPRACIL* with an aminoglycoside in vitro can result in substantial inactivation of the
aminoglycosides.
Usage During Pregancy or Lactation: Safety of PIPRACIL* use in pregnant women has not been determined. Because
animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy
only if clearly needed. It has been found to cross the placenta in rats. Caution should be exercised when PIPRACIL*
is administered to nursing mothers. It is excreted in low concentrations in milk.
Pediatric Use: Dosages for children under the age of 12 have not been established.
►ADVERSE REACTIONS: PIPRACIL* is generally well tolerated. The most common adverse reactions have been local in
nature, following intravenous or intramuscular injection. The following adverse reactions may occur:
Local Reactions - In clinical trials thrombophlebitis was noted in 3.8% of patients. Pain, erythema, and/or indura- tion at the injection site in 1.9% of patients. Less frequent reactions: ecchymosis, deep vein thrombosis and
hematomas.
Hypersensitivity Reactions-Rash was noted in 1.9% of patients. Drug fever 2.1%. Less frequent findings; pruitis,
vesicular eruptions, positive Coombs tests.
Gastrointestinal - Diarrhea and loose stools were noted in 2.8% of patients. Less frequent reactions: vomiting,
nausea, bloody diarrhea.
Hepatic - Increases in liver enzymes (LDH, SGOT, SGPT), hyperbilirubinemia. Rarely, cholestatic hepatitis
Renal-Elevations of creatinine or BU'N.
Central Nervous System - Headache, dizziness, fatigue.
*
Hemic and Lymphatic - Reversible leukopenia, neutropenia, thrombocytopenia and/or eosinophilia, bleeding and
decreases in prothrombin time have been reported. Reversible leukopenia (neutropenia) is more apt to occur in
patients receiving prolonged therapy at high dosages or in association with drugs known to cause this reaction.
Serum Electrolytes - Individuals with liver disease or individuals receiving cytotoxic therapy or diuretics, were
reported rarely to demonstrate a decrease in serum potassium concentrations with high doses of PIPRACIL*
Musculo-Skeletal - Rarely, prolonged muscle relaxation.
Other-Superinfection, including candidiasis.
DOSAGE AND ADMINISTRATION: PIPRACIL* may be administered by the intramuscular route or intravenously by injec
tion or infusion. Dosage and route of administration should be determined by the severity of the infection and
condition of the patient. The usual dosage for serious infections is 3 to 4 grams given every 4 to 6 hours as a 20 to 30
minute infusion administered intravenously.
The maximum daily dose usually administered to adults is 24 g/day, although higher doses have been used.

DOSAGE
Type of Infection
Serious infections such as septicemia, nosocomial pneumonia, intraabdominal infections, aerobic and anaerobic gynecologic infections,
and skin soft-tissue infections.
Complicated urinary tract infections.
Uncomplicated urinary tract infections and most community-acquired
pneumonia.
Uncomplicated gonococcal urethritis.

Usual Total
Daily Dosage
12-18 gl.V.
(200-300 mg/kg)

Frequency of
Administration

8-16 gl.V.
(125-200 mg/kg)
6-8 g I.M. or I.V.
(100-125 mg/kg)
2 g I.M*

Every 6 to
8 hours
Every 6 to
12 hours
Single dose

*One gram of probenecid given orally 1/2 hour prior to injection.
Dosage In Renal Impairment
Urinary Tract
Urinary Tract
Creatinine
Infection
Infection
Clearance
(complicated)
mL/min.
(uncomplicated)

Every 4 to
6 hours

Serious Systemic
Infection

>40

No dosage adjustment necessary

20-40

No dosage adjustment necessary

9 g/day 3 g every 8 hrs.

12 g/day 4 g every 8 hrs.

<20

6 g/day 3 g every 12 hrs.

6 g/day 3 g every 12hrs.

8 g/day 4 g every 12 hrs.

•Hemodialysis removes 30-50% of piperacillin in 4 hours;
6 g/day 2 g every 8 hrs.
Patients on
Hemodialysis* 1 g additional dose should be administered following each dialysis period.
For patients with renal failure and hepatic insufficiency, measurement of serum levels of PIPRACIL* will provide
additional guidance for adjusting dosage.
Infants and Children - Dosages in infants and children under 12 years of age have not been established.
The average duration of PIPRACIL* treatment is from 7 to 10 days, except for gynecologic infections, in which
it is from 3 to 10 days; the duration should be guided by the patient’s clinical and bacteriological progress. For most
acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asympto
matic. Therapy for Group A beta-hemolytic streptococcal infections should be maintained for at least 10 days to
reduce the risk of rheumatic fever of glomerulonephritis.
ADMINISTRATION
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular administration of 6 to 8 g. daily
of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for m ainte
nance therapy after clinical and bacteriologic improvement has been obtained with intravenous piperacillin sodium
treatment. Administration should not exceed 2 g. per injection at any one site. This route has been used primarily in
the treatment of patients with uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12Years of Age: The reconstituted solution is given by deep intramuscular injection.The
preferred site of injection is the upper outer quadrant of the buttock (i.e. gluteus maximus). Also may be given in the
mid-lateral muscles of the thigh. The deltoid area should be used only if well developed, and then only with caution
to avoid radial nerve injury. Intramuscular injection should not be made into the lower or mid-third of the upper arm.
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted with 5 mL of suitable diluent listed below
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation.
Intravenous Infusion: A dilution of at least 15 mL per gram is recommended to reduce potential for vein irritation.
The reconstituted and diluted solution may be administered by intermittent or continuous drip. Intermittent infusion
should be administered over a period of about 30 minutes. During intermittent infusion it is desirable to discontinue
the primary intravenous solution. Any unused portion must be discarded. For continuous infusion the solution may
be administered over a longer period of time.
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for Injection, or if required
•Bacteriostatic Water for Injection.
**Lidocaine HC1 0.5 or 1% (without epinephrine)- For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required,
•Bacteriostatic Water for Injection.
•Either parabens or benzyl alcohol.
**Lidocaine HC1 is contraindicated in patients with a known history of hypersensitivity to local anesthetics of
the amide type.
RECONSTITUTION TABLE
Product
Size

VOLUME OF
Diluent to be added

Approximate
Available Volume

Approximate
Average Concentration

1 g/2.5 mL
4.0 mL
5.0 mL
1 g/2.5 mL
6.0 mL
7.5 mL
39
10.0 mL
1 g/2.5 mL
7.8 mL
4g
Infusion Bottles
17 mL
15 mL
3g
23 mL
20 mL
4g
The prepared solution may be further diluted to the desired volume with any of the solutions for intravenous
infusion listed below.
The contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram.
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag containing
any of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion:
Intravenous Admixtures:
Intravenous Solutions:
Normal Saline (-H<CL 40 mEq).
5% Dextrose in Water [D5W]
5% Dextrose/Water [D 5W] (+KCL 40 mEq).
0.9% Sodium Chloride (Normal Saline) [NS],
5% Dextrose/Normal Saline [D 5 NS] (+KCL 40 mEq).
Dextrose 5% and 0.9% Sodium Chloride [D 5 NS].
Ringer's Injection, U.S.P. (+KCL 40 mEq).
Lactated Ringer's Injection, U.S.P.
Lactated Ringer's Injection, U.S.P. (+KCL 40 mEq).
Dextran 6 % in 0.9% Sodium Chloride.
STABILITY OF SOLUTIONS: PIPRACIL* is stable in both glass and plastic containers when reconstituted with recom
mended diluents and further diluted with the indicated intravenous solution and intravenous admixtures.
Stability studies have demonstrated chemical stability (pH, potency and clarity) through 24 hours at room
temperature and up to 72 hours refrigerated. Appropriate consideration of aseptic technique, however, recom
mends discarding unused portions after storage for 24 hours at room temperature or 48 hours refrigerated. If used
as a multi-dose container, the vials must be reconstituted only with the bacteriostatic diluents noted above.
INCOMPATIBILITY: Because of chemical instability, PIPRACIL* should not be used for intravenous administration with
solutions containing sodium bicarbonate
PIPRACIL* should not be added to blood products, protein hydrolysates or amino acids.
When PIPRACIL* is given concurrently with aminoglycosides, it is recommended that both drugs be used in full
therapeutic doses, but administered separately. PIPRACIL* should not be mixed with an aminoglycoside in a
syringe or infusion bottle, since this can result in inactivation of the aminoglycoside.
DOSAGE FORMS: PIPRACIL* (sterile, lyophilized piperacillin sodium) is available in vials containing amounts of pipera
cillin sodium equivalent to 2,3 and 4 grams of piperacillin. Available in boxes of 12 vials.
Product Numbers: 2 g /v ia l- 3879-48 3 g/vial- 3882-49 4 g /via l- 3880-50
Available in 100 mL size infusion ("piggyback'') bottles, containing sterile, freeze-dried piperacillin sodium
powder equivalent to 3 and 4 grams of piperacillin. Boxes of 12 infusion bottles.
Product Numbers: 3 g /b o ttle s-3882-41 4 g /b o ttle s-3880-42
Piperacillin Sensitivity Discs impregnated with 100 ug of piperacillin are also available.
Storage:
PIPRACIL* vials and infusion bottles should be stored at controlled room temperatures of 15-30°C (59-86°F).
Piperacillin Sensitivity Discs should be refrigerated upon receipt. Product Monograph available on request.

Vials 2 g

‘ PIPRACIL is a trade mark of Lederle Piperacillin, Inc.
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Toronto
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Proximal Gastric Vagotomy: a 7-Year Review
The records of 31 patients (25 men, 6
women) who had a proximal gastric
vagotomy for duodenal ulcer between
1975 and 1981 were reviewed. The
mean follow-up was 48 months (range
from 9 to 86 months). The mean dura
tion of symptoms was 9 years. Nine patients
were treated for bleeding and one had
had perforation. In nine patients, con
comitant fundoplication was performed
and three patients had dilatation of the
pylorus.
In the postoperative period,
nasogastric suction was used for 1 day,
full diet was given after 3 days and the
hospital stay was 6 days on average.
Two patients (6.5% ) probably had
recurrence, but only one underwent in
vestigation. Postoperative symptoms
were generally mild and transient. Two
patients described late dumping and four
had early satiety. None thought these
symptoms were very important. Diarrhea
and weight loss were not problems.
By a modified Visick grading system,
91% had a result that was satisfactory
or better.
This study supports the use of prox
imal gastric vagotomy as the operation
of choice for the elective surgical treat
ment of duodenal ulcer.
On a etudie les dossiers de 31 patients
(25 hommes et 6 femmes) qui ont subi
une vagotomie gastrique proximale pour
un ulcere du duodenum entre 1975 et
1981. La duree moyenne de surveillance
des suites therapeutiques etait de 48
mois (allant de 9 a 86 mois). La duree
moyenne des symptdmes etait de 9 ans.
Neuf patients avaient ete traites pour des
saignements et un avait eu une perfora
tion. Chez neuf patients, un fundoplica-
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tion concomitante fur pratiquee et trois
patients subirent une dilatation du
pylore.
Dans la periode postoperatoire, on pratiqua une aspiration gastrique par voie
nasale durant 1 journee et un regime alimentaire complet fut donne apres 3
jours. Le sejour hospitalier moyen fut de
6 jours.
Deux patients (6.5% ) ont probablement eu une recidive mais seulement un
d'entre eux a subi une investigation. Les
symptomes postoperatoires furent generalement benins et transitoires. Deux
patients decrivent un syndrome de
"dumping" tardif et quatre autres rapporterent un phenomene de satiete
immediate. Aucun ne jugea ces sympto
mes importants. La diarrhee et la perte
de poids ne presentment pas de
probleme.
D'apres une echelle de Visick modifiee,
91% des resultats etaient au moins
satisfaisants.
Cette etude va a I'appui de la vagoto
mie gastrique proximale comme opera
tion de premier choix dans le traitement
chirurgical non urgent de I'ulcere
duodenal.

The form ation o f gastric acid is
stimulated by gastrin, histamine and
acetylcholine. Sectioning of the vagus
nerves as a means of interrupting the
acetylcholine-mediated release of acid
dates back to the use of transthoracic
vagotomy by Dragstedt and Owens in
1943.1 Gastric stasis after this operation
led to the introduction of abdominal
vagotomy combined with drainage of the
stomach by pyloroplasty or gastro
enterostomy. In an attempt to avoid the
denervation of viscera other than the
stomach, selective vagotomy was in
troduced, but it did not appear to yield
a clinical advantage. In 1967, Holle and
H art2 introduced proximal gastric
vagotomy, which was modified by Amdrup and Jensen3 and by Johnston and
Wilkinson4 to eliminate the drainage
procedure thought to be responsible for
many of the side-effects of ulcer opera
tions; this operation was to become in
creasingly popular.

In choosing an ulcer procedure, we
must consider mortality, recurrence rate
and postoperative morbidity.
Proximal gastric vagotomy has a recur
rence rate of about 6°7o, similar to that
of vagotomy with pyloroplasty but higher
than vagotom y with antrectom y.
However, the mortality is 0.3% and the
incidence of side-effects is much lower
than for vagotomy with either pyloroplas
ty or antrectomy.
Considering the differences in the three
types of operation, we prefer to perform
proximal gastric vagotomy when feasible.
Initially used only for uncomplicated
duodenal ulcer, it is now being carried out
in patients with obstruction, acute
bleeding or perforation.
Our operative procedure is of standard
type; we divide the anterior and posterior
vagal branches down to the “ crow’s
foot” , and pay particular attention to
denervation of the distal 5 cm of the
esophagus. The importance of this por
tion of the operation has been stressed by
most authorities. The length of denervated distal esophagus seems to be much
more important than the length of inner
vated antrum.
We conducted a retrospective review of
proximal gastric vagotomy performed for
duodenal ulcer over a 7-year period.

Patients
Between 1975 and 1981, 35 patients
underwent proximal gastric vagotomy for
duodenal ulcer; 31 (88%) were available
for follow-up the remainder could not be
located.
The 31 patients (25 men, 6 women)
ranged in age from 22 to 65 years (mean
44 years). All had duodenal ulcer disease,
which had been present for a mean period
of 9 years.
Presenting symptoms and preoperative
complications are shown in Table I. Nine
patients had bled from their ulcers, but
none underwent emergency operation to
control bleeding.
The operating time varied from 1.5 to
3.0 hours (mean 2.25 hours). Six patients
had concomitant Nissen fundoplication
and three had dilatation of the pylorus.
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One patient required splenectomy; this
was the only peroperative complication.
The mean follow-up was 48 months
(range 9 to 86 months).
We used a modified Visick grading
system to evaluate the operative results as
follows: grade 1 — excellent, no symp
toms; grade 2 — satisfactory, mild symp
toms, easily controlled; grade 3 — poor,
persistent symptoms, recurrence of ulcer.
Findings

Postoperative recovery was rapid. Thir
teen patients did not need a nasogastric
tube and another 13 required a tube for
1 day only. The longest period of
nasogastric suction was 4 days (one
patient).
Mean time required for patients to pro
gress to a full diet was 3 days, the longest
time being 8 days. The hospital stay
ranged from 3 to 15 days (mean 6 days).
Postoperative complications were un
common and minor (Table II). There
were no deaths.

T a b le 1 - S y m p t o m s a n d P r e o p e r a t iv e
C o m p lic a t io n s (n -

31)
No. of

S y m p t o m lc o m p lic a t io n

p a t ie n t s

S y m p to m s
P a in

29
6

B e lc h in g
F la t u le n c e

7

H e a r tb u r n

8

F u lln e s s

A number of patients complained of
symptoms at follow-up (Table III) but
most of these were transient, lasting 2 to
4 weeks. Three patients had pain that sug
gested recurrent disease; one had
undergone endoscopic examination but
no abnormality was found, and of the
other two, only one sought attention. He
had proven ulcer recurrence and was the
only patient who underwent further
surgery for ulcer. The possible recurrence
rate was, therefore, 6.5% (2 of 31). The
symptoms in all three of these patients
were noted less than 12 m onths
postoperatively. Heartburn was present
occasionally in two patients (neither of
whom had heartburn preoperatively).
Four patients had heartburn more often
and three of these suffered from it
preoperatively.
Table IV notes the side-effects of
gastric surgery. Both patients with persis
tent late dumping described the symptoms
as mild and rare. The four patients with
early satiety felt full with less food than
they had preoperatively, but this did not
interfere with their life-style. There were
no instances of persistent diarrhea and
weight loss. One patient had anemia that
was investigated but not explained and
was not recurrent; it was not iron defi
ciency in type and did not seem to be
related to the operation.
One patient had dysphagia 6 months
postoperatively which responded to a
single esophageal dilatation. This patient

had
com plained
of
h e a rtb u rn
preoperatively but had not undergone a
fundoplication.
Excellent (20 patients) or satisfactory
(8 patients) results by the modified Visick
grading were obtained in 91% of patients.
Only three had a poor result. Twenty-five
of 31 stated that they would undergo the
operation again but, surprisingly, 3 with
good results said they would not.
Discussion

There are many advantages to proximal
gastric vagotomy.
1. An innervated pyloroantrum is
maintained, so emptying is unaffected.
2. The pylorus remains intact, thus
preventing reflux.
3. Duodenal innervation is preserved,
permitting normal release of duodenal
hormones.
4. The inhibition of acid secretion may
be preserved by intact extragastric and an
tral branches o f the vagus nerve.
Potential disadvantages of the opera
tion that led to early caution in its use are:
1. Gastric stasis.
2. Continued gastrin secretion by the
innervated antrum, causing increased acid
output.
3. Denervation of too much or too lit
tle stomach, producing stasis or inade
quate acid reduction.
4. An unknown, possibly high, recur
rence rate.
There are two complications particular
ly associated with this operation. First,
because of the amount of hiatal dissec
tion required, there is a 5% incidence of
injury to the spleen, requiring splenec
tomy. Second, necrosis of the lesser cur
vature of the stomach, of undetermined
cause, occurs in 0.15% of cases.
The findings o f our study are consis
tent with those o f other reports showing
low morbidity and mortality for this pro
cedure (Table V5'9). With respect to mor
bidity, we included all patients who com-

10

N ausea

11

V o m it in g

10

T a b le IV — S id e - E f f e c t s o f
P r o x im a l G a s t r ic V a g o t o m y (n = 3 1 )

C o m p lic a t io n s
B le e d in g

9

P e r f o r a t io n

1

O b s t r u c t io n

1

T a b le II— P o s t o p e r a t iv e C o m p lic a t io n s
N o . of
C o m p lic a t io n

p a t ie n t s

U r in a r y in f e c t io n

1

A t e le c t a s is

4

P n e u m o n ia

1

S p le n e c t o m y

1

No. of
p a t ie n t s

S id e - e f f e c t
D u m p in g
E a r ly

5

L a te *

6*

D ia r r h e a

2

E a r ly s a t ie t y

4

D ie t r e s t r ic t io n

2

A n e m ia (u n e x p la in e d )

1

’ P e r s is t e n t (b u t in f r e q u e n t ) in 2 .

T a b le V - S t u d i e s o f P r o x im a l G a s t r i c V a g o t o m y
M o r b id it y , %
M o r t a lit y ,
S tu d y

T a b le I l l - P o s t o p e r a t i v e S y m p t o m s

a s s o c ia t e s , 1 9 7 7 s

N o . of
S y m p to m

%

R e c u rre n c e

D u m p in g

D ia r r h e a

S a t ie t y

S a w y e rs and

p a t ie n t s

P a in

9

H e a r tb u r n

6

F u lln e s s

5

B e lc h in g

5

0 .5

3 .5

1 .2

1 .2

8 .1

0

4

0

1

0

0

1 2 .7

1 .3

2 .2

0

5

1 .5

1 .5

0 .3

4 .3

5

3

0

6 .5

6 .5

0

M a rce a u and
a s s o c ia t e s , 1 9 7 9 6
A d am i and
a s s o c ia t e s ,

19807

v a n H e e rd e n a n d
a s s o c ia t e s , 1 9 8 0 ®

26

_

R o s s i and B ra a sc h ,

F la t u le n c e

4

N a u s e a / v o m it in g

7

O b s t r u c t io n

1

P re s e n t s tu d y

D y s p h a g ia

1

-

19809

-

13

n o t n o te d .
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plained of dumping or early satiety, even
though these were minor problems.
Early reports gave recurrence rates as
high as 22% for proximal gastric
vagotomy.7'10*11 In many studies, the
most important variable in recurrence rate
was the surgeon.8 The denervation of 5
cm of esophagus produced a marked
lowering of recurrence rates.5’8’12' 16 This
points out the importance of precise
surgical technique. It is estimated that the
long-term recurrence rate with proximal
gastric vagotomy will be 10%.9 Rossi
and Braasch9 suggested a higher recur
rence rate if the maximal acid output ex
ceeds 35 m m o l/h . Blackett and
Johnston12 found no difference based on
either maximal or basal acid production.
There can be no doubt that the sideeffects of proximal gastric vagotomy are
much less frequent than those of vago
tomy with pyloroplasty or vagotomy with
antrectomy.5’8'1‘’I4-16 The best results for
ulcer surgery are produced by vagotomy
with antrectomy, but so too are the most
bothersome side-effects. Ninety-one per
cent of our patients were happy with the
results of their operation. Side-effects,
when they occurred, were transient or
minimal. In this setting we are prepared
to accept a recurrence rate of 6.5%.
Patients with pyloric ulcer seem to have
a higher rate of recurrence than those with
duodenal ulcer, although there is no
demonstrable difference between the two
in terms of either acid secretion or
microscopic appearance.17
Pyloric dilatation through a gastrotomy at the time of proximal gastric
vagotomy now appears safe and effective.
Of our three patients having this pro
cedure, one required subsequent
gastroenterostomy for recurrent obstruc
tion. Other reports of larger numbers of
patients are more encouraging. Dunn and
associates13 reported 15 patients, 6 with
complete obstruction, all treated by this
method without recurrent obstruction. In
their series, two pyloric perforations oc
curred and were repaired without com
plication by su tu re. Rossi and
associates18 had no recurrent obstruc
tions in 19 patients, although almost half
had transient mildly delayed gastric
emptying.
Marceau and associates5 reported
three patients treated by proximal gastric
vagotomy at the time of acute perfora
tion, all without complication.
Many recent reports have documented
the physiologic effects of proximal gastric
vagotomy. Gastrin levels are elevated
after all three types of vagotomy, but are
no higher in proximal gastric vagotomy
than in the other types, suggesting that
vagal release of gastrin is not important.
Serial studies of acid secretion show lit
tle difference among the three types of
vagotomy; much greater variation results
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from different surgeons than from dif
ferent operations. Parietal cells have been
shown to be morphologically normal
after 2 to 3 years, but have diminished
secretory capacity.19 In the absence of a
drainage procedure, bile reflux is almost
nonexistent. As expected, receptive relax
ation of the stomach is lost after proximal
gastric vagotomy,20 and the amplitude of
gastric contractions is reduced but
radiologic emptying is normal in 81% of
patients.14 Dilatation of the gallbladder
and development of stones are common
after vagotomy with pyloroplasty but
proximal gastric vagotomy produces no
change in gallbladder size or function.21
Pancreatic response to hypoglycemia and
to glucose, blunted by vagotomy with
drainage, is normal after proximal gastric
vagotom y.14 Fecal fat excretion is
normal.
Early reports suggested an increase in
the incidence of reflux esophagitis after
proximal gastric vagotomy, but studies of
the lower esophageal sphincter discovered
no change in length or pressure.22-23
Reflux occurring after this operation,
therefore, must be fortuitous.
Proximal gastric vagotomy seems to
provide good control o f the ulcer
diathesis, while at the same time main
taining near-normal physiologic function
of the gastrointestinal tract, except for the
parietal cell mass, and producing minimal
side-effects. We believe this operation
represents the current “ state of the art”
for a first surgical attack on duodenal
ulcer, and agree with others5'24 that it is
the procedure of choice.
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O n decrit un m odele perm ettant la perfu
sion in vivo du foie isole de rat avec soit
des agents cytotoxique s, soit du solute
physiologique hypertherm ique adm inistres par I'artere hepatique ou par la veine
porte. Les rats ont pu survivre a la perfu
sion par ce s deux v o ie s de d o se s allant
ju sq u 'a 0 . 2 5 g/kg de 5 fluorouracile et
de 2 .0 a 2 .5 mg/kg de m itom ycine-C. La
perfusion regionale du foie a I'aide d 'u n e
solution hypertherm ique a produit des
effets hepatotoxiques en fonction de la
temperature et du te m p s de perfusion.
U ne elevation m arquee m ais reversible
des transam inases glutam ique oxaloacetique et glutam ique pyruvique seriq u e s a ete observee 2 4 heures apres la
perfusion. L'activite de I'a m in opyrine Ndem ethylase d a n s le foie de rat intact
normal ou en voie de regeneration n 'a
p a s ete affectee; cependant, l'activite
d a n s le foie intact norm al a ete nettement supprim ee par la perfusion hyper
thermique a 4 3 ° C seulem ent. L'incorporation de thym idine tritiee d a n s I'acide
desoxyribonucleique hepatique 2 4 heures
apres une hepatectom ie partielle a ete
fortement inhibee par une perfusion
hepatique prealable, soit de m edicam ents
cytotoxiques, soit d 'u n e solution hyper
thermique. Cette technique de perfusion
in vivo d 'u n organe isole pourrait etre
utilisee pour evaluer les effets de la
therm o-chim iotherapie sur la croissance
des tum eurs hepatiques.

chemotherapy. However, hepatotoxic ef
fects have been found at therapeutic levels
of hyperthermia.10,11 Boddie and
associates12 demonstrated such effects of
regional hepatic hyperthermia by in-vivo
isolation and regional perfusion in the
dog.
Ryan and associates13 perfused the rat
liver in vivo with chemotherapeutic agents
through the portal vein. We have reported
previously14 the effects on hepatic
biochemical function of hyperthermochemotherapeutic perfusion of the in-vivo
isolated rat liver through the portal vein.
However, because primary as well as
secondary liver tumours receive their
main blood supply from the hepatic
artery,15,16 it is also important to study
liver function after hepatic arterial per
fusion of the in-vivo isolated liver.
This report describes our methods of
providing thermochemotherapy by invivo isolated perfusion of the rat liver
through the portal vein or hepatic artery.
We determined the maximum dose of
cytotoxic agents and the maximum
temperature and duration of regional
hyperthermia tolerated, and assessed the
effects of high doses of cytotoxic drugs
on liver function, hepatic aminopyrine
metabolism and hepatic regeneration
after partial hepatectomy. These
parameters are compared in a model of
in-vivo isolated perfusion of the rat liver
through either the portal vein or the
hepatic artery.

By perfusing isolated organs, much higher
concentrations of chemotherapeutic
agents can be delivered with less general Materials and Methods
toxicity than when these drugs are ad
ministered systemically. Several attempts Animals
have been made to isolate and perfuse
Male rats of the Fischer strain (Charles
organs and regions of the body involved River,
NY), weighing 300 to
with cancer, most commonly the 350 g, Kingston,
were
fed
laboratory chow and
extremities1,2 and the liver.3,4
water
ad
libitum.
Fortner and associates5 applied a
technique of isolated liver perfusion with Operative Technique fo r In-vivo
large doses of cytotoxic agents to treat ex Isolated Liver Perfusion
tensive liver cancers5 and to provide ad
All operative procedures were carried
juvant therapy before resection of
metastatic liver cancers.6 Recently, out for 30 to 40 minutes under ether
several investigators7'9 have reported that anesthesia and were clean but not sterile.
hepatic tumours respond to hyperthermia The method for in-vivo isolated perfusion
alone or in combination with regional of the rat liver through the portal vein was
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a modification (Fig. la) of that de
scribed by Ryan and colleagues.13 The
abdomen was opened by a midline
incision. An inflow catheter (inner
diameter 0.28 mm, outer diameter 0.61
mm) was introduced into the portal vein
through a pyloric branch and an outflow
catheter (inner diameter 0.50 mm, outer
diameter, 0.88 mm) was placed in the in
ferior vena cava in the vicinity of the
hepatic veins through the infrahepatic
suprarenal branch. All catheters were
prefilled with heparinized saline (50
IU/ml). After clamping the portal vein,
we infused 3 ml of 0.9% sodium chloride
solution, through the liver via the portal
vein, into the systemic circulation. The
suprahepatic inferior vena cava was
clamped and 10 ml of the 0.9% sodium
chloride solution, containing different
doses of 5-fluorouracil (5-FU) (HoffmanLaRoche Ltd., Vaudreuil, PQ),
mitomycin-C (Mit-C) (Bristol Myers
Canada Inc., Toronto, Ont.) or heated
saline for regional hyperthermia, were
perfused through the inflow catheter by
a Harvard infusion pump. Perfusion
flows were adjusted at 2 ml/min for
cytotoxic drugs and at 1 and 2 ml/min for
regional hyperthermia. The efflux was
collected through the inferior vena caval
catheter into a heparinized container.
Following this, 2.5 ml of the 0.9% NaCl
solution was perfused through the liver
to remove any traces of drug remaining.
The suprahepatic inferior vena caval
clamp was then removed followed by the
portal vein clamp. The volume of cir
culating blood volume lost was estimated
by determining the volume of fluid col
lected through the inferior vena caval
catheter and correcting appropriately.
The catheter was withdrawn, the incision
was closed with 7-0 silk on an 8-mm
atraumatic needle (K803; Ethicon
Sutures, Ltd., Peterborough, Ont.) and
the inferior vena caval clamp removed.
The portal venous catheter was
withdrawn and the pyloric branch of the

portal vein ligated. The abdomen was
closed. The hepatic artery was not occlud
ed at any time during the operation.
For perfusion of the liver through the
hepatic artery (Fig. lb), an inflow
catheter was inserted into the common
hepatic artery and the gastroduodenal
branch ligated. The portal vein was
clamped during the perfusion. By this
method, we achieved total isolation and
regional perfusion of the liver. After per
fusion, the inflow catheter was withdrawn
and the common hepatic artery ligated.

Regional Hyperthermia
The infusion of saline warmed to a
temperature of 5° to 10°C higher than
that desired in the liver produced a
hepatic temperature of 37°, 41° or 43°C
selectively and maintained it for the dura
tion of study by controlling the flow rate
of perfusate. A flexible temperature pro
be consisting of 30-gauge copper/constantan thermocouple wire attached to a
calibrated 150 AR microvoltammeter
(Keithley Instruments Inc., Cleveland,
Ohio) was inserted into a hepatic
lobe to monitor liver temperature. To
prevent an undesirable reduction of liver
temperature during laparotomy, an
externally focused infrared lamp was
used during the perfusion. Systemic
temperature was monitored by a rectal
temperature probe. After the per
fusion of heated saline, the liver was
rapidly returned to normal temperature
by perfusing with chilled saline.

Aminopyrine Metabolism
Aminopyrine N-demethylase activity
was measured by monitoring the forma
tion of formaldehyde according to the
method of Matsubara and associates.17
The formaldehyde formed was quantified
by conversion to a chromogen in the
Hantszch reaction.18 The standard reac
tion was performed in a total volume of
2.0 ml; the reaction mixture contained
nicotinamide adenine dinucleotide
phosphate (0.7 ^mol), glucose-6-phosphate (8 /imol), glucose-6-phosphate
dehydrogenase (1.0 unit), magnesium
chloride (20.0 mol) and potassium
phosphate buffer (80 /tmol, pH 7.4).
Aminopyrine concentration was 2 mM,
and the homogenate (9000 x g superna
tant), prepared from 0.2 g of liver in
1.14% potassium chloride, was added to
an Erlenmeyer flask to start the reaction.
The mixture was incubated at 37°C for
15 minutes and the reaction terminated
by 20% trichloroacetic acid (1.0 ml).
After centrifugation, a 2-ml aliquot was
treated with 1 ml of Nash reagent and the
solution incubated at 37°C for 40
minutes. The absorbance was measured
at 412 nm; the standard curve was ob
tained by adding the known amount of
formaldehyde instead of aminopyrine.
Hepatic specimens were sampled 24 hours
after hepatic perfusion and 24 hours after
partial hepatectomy following hepatic
perfusion and stored at —70°C until the
appropriate assay was performed.
Hepatic Regeneration Studies

We studied the effect on hepatic
regeneration after partial hepatectomy of
cytotoxic drugs and regional hyperther
Serum glutamic oxaloacetic trans mia after in-vivo isolated hepatic perfu
aminase (SGOT) and glutamic pyruvic sion. Partial hepatectomy (68%) was per
transaminase
(SGPT),
alkaline formed 48 hours after perfusion through
phosphatase and total bilirubin levels either the portal vein or hepatic artery.
were measured at 1,3,7, 14 and 21 days The incorporation of tritiated thymidine
after operation by autoanalyser.
(3H-TdR) into hepatic deoxyribonucleic
acid (DNA) 24 hours after partial
hepatectomy was used as an index of
hepatic cell regeneration. All rats were
killed 90 minutes after being given a single
intraperitoneal injection of 100 ;cCi of
3H-TdR (New England Nuclear, Boston,
Mass.). Their livers were excised and
stored at -7 0 °C for subsequent DNA
determination. The DNA was isolated
and radioactivity was measured as
previously described.19 The results are
expressed as disintegrations per minute
divided by optical density of DNA at 260
nm (dpm/OD260).
Hepatic Biochemical Estimations

Statistical Analysis
FIG. 1— In-vivo perfusion of isolated rat liver through (a) portal vein and (b) hepatic artery.
PV = portal vein, HA = hepatic artery, RV = renal vein, IVC = inferior vena cava.

Significant differences between means
were determined by Student’s /-test and
the x2 test was applied for survival
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figures. A p value of 0.05 was considered
statistically significant.

Results
Survival following Hepatic Perfusion
After perfusion with 0 to 1.5 g/kg of
5-FU through the portal vein or the
hepatic artery, animals were followed up
for 21 days. No deaths occurred after
hepatic perfusion of less than 0.125 g/kg
5-FU through either the portal vein or the
hepatic artery (Table I). Following per
fusion with 0.25 g/kg of 5-FU by both
routes, 75% of rats survived compared
with a 75% mortality when this dose was
administered systemically (data not
shown). No significant differences were
apparent in the survival of animals per
fused by the two routes at any doses
tested.
A similar evaluation was carried out for
Mit-C (0 to 2.5 mg/kg) (Table II). Rats
were able to survive after perfusion of up
to 1.5 mg/kg of Mit-C by either route.
Survival of rats perfused with 2.5 mg/kg
of Mit-C was 0% in four animals perfus
ed through the portal vein and 80% in
five animals perfused through the hepatic
artery (p < 0.05).

perfused with normal saline alone. Values
all returned to normal by postoperative
day 5. No significant differences of
SGOT and SGPT values between portal
vein and hepatic artery perfusions were
found. There were no abnormal alkaline
phosphatase and total bilirubin values
(data not shown).
Aminopyrine N-Demethylase Activity
Fig. 2 demonstrates the aminopyrine Ndemethylase activity of liver microsomes
after either hepatic perfusion with 5-FU

Table 1-Survival at 21 Days after In-vivo
Isolated Hepatic Perfusion through Portal Vein
and Hepatic Artery with 5-fluorouracil
Survival, no./total no.
Portal
vein Hepatic artery
Dose, glkg
8/8
10/10
0
4/4
8/8
0.125
3/4
6/8
0.25
1/4
2/5
0.5
0/4
0/4
1.0
0/4
0/4
1.5

Survival following Regional
Hyperthermia

Table II—Survival at 21 Days after In-vivo
Isolated Hepatic Perfusion through Portal Vein
and Hepatic Artery with Mitomycin-C
Survival, no./total no.
Dose, mg,/kg
Portal vein Hepatic artery
0
10/10
8/8
1.0
4/4
5/5
1.5
4/4
4/4
2.0
3/4
4/5
2.5
0/4 *
4/5*
*p < 0.05.

Table Ill-Survival 21 Days after In-vivo Isolated Hepatic
Hyperthermic Perfusion through Portal Vein and Hepatic Artery

Survival after hyperthermic perfusion
at various temperatures and two different
perfusion times (5 and 10 minutes) was
studied (Table III). Regional hyperther
mia of the liver by the method described
here produced toxic effects that were both
time- and temperature-dependent. No
deaths followed hyperthermic perfusion
for 5 minutes through the hepatic artery
at any temperature tested (37° to 43°C).
In contrast, 6 of 11 animals died after per
fusion through the portal vein at 43°C for
5 minutes. Hyperthermic perfusion of the
liver at 41°C for 10 minutes resulted in
0% survival when the portal vein was
used and 50% survival when the hepatic
artery was used (p < 0.05). The
hepatotoxic effect in terms of mortality,
of hyperthermic perfusion of the in-vivo
isolated liver, was more severe when the
portal vein was used than the hepatic
artery.
Hepatic Biochemical Estimations
Table IV shows the biochemical
parameters of hepatic function following
perfusion with saline, 5-FU, Mit-C and
regional hyperthermia through the por
tal vein and hepatic artery. Following all
the different treatments studied, a mark
ed elevation in SGOT and SGPT levels
was noted 1 day after perfusion.
However, the hepatocellular injury was
more severe in groups perfused with
5-FU, Mit-C and hyperthermia than those
226

or partial hepatectomy following perfu
sion. The activity was not affected by per
fusion with both saline and 250 mg/kg of
5-FU. However, the activity was
significantly (p < 0.001) depressed after
partial hepatectomy even without perfu
sion. Hepatic perfusion with saline or
5-FU before partial hepatectomy did not
fu rth er decrease am inopyrine Ndemethylase activity. The effect of hyper
thermic perfusion on aminopyrine Ndemethylase is shown in Fig. 3. As can
be seen, the activity was significantly (p
< 0.05) inhibited by hyperthermic per-

Survival, no./total no.
Portal vein
°C
24
37
41
43
*p < 0.05.

5 min
10/10
8/8
10/10
6/11

Hepatic artery
10 min
4/4
2/4
0/7*
-

5 min
8/8
4/4
4/4
4/4

10 min
4/4
4/4
2/4*
1/4

Table IV-Serum Glutamic Oxaloacetic and Pyruvic Transaminase
Values following In-vivo Isolated Hepatic Perfusion*
SGOT, lU/ml
SGPT, lU/ml
Hepatic
Hepatic
Portal vein
artery
Portal vein
artery
370 ± 102
310 ± 11
270 ± 20
170 ± 55

Hepatic
perfusion with
Saline
5-FU, g/kg
0.125
1100 ± 201
438 ± 80
490 ± 116
0.25
1101 ± 134
800 ± 89
480 ± 78
0.5
1180 ± 89
920 ± 201
540 ± 243
1.0
1148 ± 212
975 ± 136
670 ± 148
1.5
1240 ± 251
1350 ± 451
690 ± 88
Mit-C, mg/kg
1.0
613 ± 37
530 ± 30
346 ± 212
1.5
665 ± 49
720 ± 142
352 ± 64
2.0
860 ± 104
760 ± 200
408 ± 111
-t
2.5
1250 ± 440
-t
Hyperthermia, “C
37
900 ± 281
1348 ± 549
469 ± 124
41
2025 ± 323
3105 ± 928
1156 ± 163
43
5025 ± 1229
4435 ± 891
2856 ± 768
'Serum sampled 24 h after operation. Results are mean ± standard error.
tNo survivors.

± 87
± 81
± 80

175
312
325
318
701

± 170
± 350

297
295
370
752

±
±
±
±

58
39
20
227

676 ± 334
1242 ± 511
2140 ± 190
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fusion at 43°C. Although the activity was
severely suppressed by partial hepatectomy (p < 0.001), pretreatment with
hyperthermic perfusion (37° to 43°C) did
not affect the activity as much. In this
study, hepatic perfusion was performed
through the portal vein.
Hepatic Regeneration
With hepatic perfusion of 5-FU
through the portal vein, 3H-TdR incor
poration into h epatic DNA was
significantly inhibited with saline, 5-FU
0.125 g/kg (p < 0.05) and 5-FU 0.25
g/kg (p < 0.01) compared with that
observed following sham hepatic perfu
sion plus partial hepatectomy (Fig. 4).
However, there were no significant dif
ferences among the doses tested. Follow
ing perfusion through the hepatic artery,
3H-TdR incorporation into hepatic DNA
was significantly (p < 0.05) inhibited with
5-FU 0.25 g/kg but not with saline and
5-FU 0.125 g/kg.

5.00

Perfusion

Perfusion prior to partial
hepatectomy

FIG. 2—Effect of hepatic perfusion with
5-fluorouracil (5-FU) on hourly aminopyrine
N-demethylase activity of norm al and
regenerating liver. * p < 0.001 (differences
determined by comparison with no-perfusion
group of intact liver). Results are mean ± stan
dard error of mean. Each group contained at
least four animals.

No 24°C 37°C 4l°C 43°C
Perfusion

No

H ypertherm ic hepatic perfusion
through the portal vein inhibited the in
corporation of 3H-TdR into hepatic
DNA at 37°C (p < 0.01), 41 °C and 43°C
(p < 0.001) compared with the control
group with sham perfusion and partial
hepatectomy (Fig. 5). Hyperthermic per
fusion through the hepatic artery marked
ly inhibited the 3H-TdR incorporation
into hepatic DNA at 37°C (p < 0.001),
41 °C and 43°C (p < 0.001). A significant
difference between perfusion via the por
tal vein and the hepatic artery was observ
ed only at 41 °C (p < 0.001).
Discussion
This report describes a technique for invivo hyperthermochemotherapeutic per
fusion of the isolated rat liver through the
portal vein and the hepatic artery. Ryan
and associates13 reported a similar
method for in-vivo perfusion of the
isolated rat liver through the portal vein.
We were able to attain regional hyperther
mia of the liver at a defined temperature
and for a defined period of time using this
technique. Furtherm ore, this model
allowed the delivery of cytotoxic drugs to
the liver in much higher doses than would
be tolerated if administered systemically.
A model for in-vivo perfusion of the
isolated liver through the hepatic artery
is also described and compared to the por
tal route. Since primary as well as secon
dary liver tumours receive their main
blood supply from the hepatic artery,14'15
it will be important to assess and compare
the effect of hyperthermochemotherapy
on tumour growth in the liver with
isolated perfusion by both routes of ad
ministration. The perfusion techniques
described here are useful for studying and

com paring the effect o f v ario u s
therapeutic agents and modalities on liver
pathophysiology.
The systemic administration of high
doses of cytotoxic drugs has been pro
hibited previously by the concomitant
systemic toxicity. Therefore, isolationperfusion techniques are valuable for a
specific organ only. In this study, rats
were able to survive following the hepatic
perfusion of doses up to 0.25 g/kg of
5-FU by both routes, a dose that pro
duced 75% mortality when administered
systemically. Hepatic tissue was able to
tolerate doses of up to 2.0 mg/kg of MitC via the portal vein and up to 2.5 mg/kg
via the hepatic artery which, when ad
ministered systemically, would result in
100% mortality. Hepatic perfusion with
sublethal doses of cytotoxic drugs produc
ed acute hepatocellular damage, as
evidenced by the disturbed biochemical
values. However, this damage was rever
sible and liver function became normal
within 5 days after perfusion.
Aminopyrine N-demethylase activity,
which serves as an index o f the
biochemical viability of the hepatocyte,
was not inhibited by in-vivo perfusion of
the isolated liver with 5-FU or hyperther
mia up to 43°C; furthermore, the decreas
ed enzyme activity of regenerating liver
was not affected by earlier hepatic per
fusion. The incorporation of 3H-TdR in
to hepatic DNA after hepatectomy was
significantly inhibited by previous hepatic
perfusion, especially through the portal
vein. It is important to note that most of
this inhibition in the present model could
be attributed to the procedure itself and
not to the cytotoxic agent. This suggests

24°C 37°C 41°C 43°C

Perfusion prior to partial
hepatectomy

FIG. 3—Effect of hyperthermic hepatic per
fusion on hourly aminopyrine N-demethylase
activity of normal and regenerating liver. * p
< 0.05, + P < 0.001 (differences determined
by comparison with no-perfusion group of in
tact liver). Results are mean ± SEM. Each
group contained at least four animals.

Portal vein

Hepatic artery

F IG. 4—Hepatic regeneration following per
fusion with 5-FU. * p < 0.05, + p < 0.01 (dif
ferences determined by comparison with group
of sham hepatic perfusion followed by partial
hepatectomy). Results are mean ± SEM, n =
4, + = with partial hepatectomy, - =
without partial hepatectomy.

FIG. 5—Hepatic regeneration following
hyperthermic hepatic perfusion at temperatures
ranging from 24° to 43°C. * p < 0.01, + p <
0.001 (differences determined by comparison
with group of sham hepatic perfusion follow
ed by partial hepatectomy).
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that in-vivo isolated hepatic perfusion
with cytotoxic agents as adjuvant therapy
before liver resection, as suggested by
Fortner and colleagues,5 might lead to
impairment of the normal hepatic
regenerative response after resection.
Specific temperatures for a defined period
were attained using the present in-vivo
isolated perfusion technique. Regional
hyperthermia as achieved by the techni
ques described produced severe
hepatotoxic effects by both routes. We
observed massive hepatic necrosis in rats
that died after hyperthermic perfusion
(41° to 43°C) through both the portal
vein14 and hepatic artery. Boddie and
colleagues12 also reported that regional
hyperthermia with isolated liver perfusion
in the dog had direct toxic effects. This
toxicity is probably related to a combina
tion of the increased temperature and a
relative state of hypoxia of the liver dur
ing isolated in-vivo perfusion, since the
human liver can tolerate temperatures up
to 45°C induced by external radiofre
quency hyperthermia.20
In this study, hepatic perfusion with
cytotoxic drugs and regional hyperther
mia through the hepatic artery resulted in
somewhat less severe toxic effects than
that through the portal vein, as
demonstrated by the hepatic tissue
tolerance to cytotoxic drugs and by inhibi
tion of regeneration. This difference
could be due to the differential blood
distribution in the liver, in that 75% of
the circulation to normal hepatic tissue
comes from the portal vein while 25%
comes from the hepatic artery.21
The present isolated perfusion tech
niques, by either portal vein or hepatic
artery, offer a novel approach to study
the response of the liver to deliberate
therapeutic insult. Thus, the effect of
hyperthermochemotherapy on tumour
growth in the liver can be assessed. Of
even greater clinical importance is that
these models will allow the development
of methods of treatment that protect
against hepatotoxicity or that reverse the
inhibitory effect on liver regeneration in
duced
by various
therapeutic
modalities.22,23 These studies are under
way in our laboratory.
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Finally,
anti-herpes therapy
that’s effective
and selective

HERPES SIMPLEX
Finally, effective
anti-herpes therapy for:
□ Sufferers o f initial
herpes genitalis
□ Immunocompromised
patients with
nonlife-threatening
cutaneous herpes
simplex infections
In a number of double-blind, placebocontrolled studies,' ZO VIRAX has demonstrated
an unprecedented efficacy, selectivity and safety
profile. ZO VIRAX provided normal patients with
initial herpes genitalis and immunocompromised
patients with herpes genitalis or herpes labialis
with prompt, effective relief from the common
symptoms of herpes infections.

ZOVIRAX-treated patients heal faster
ZO VIRAX speeds the healing of herpes
lesions, especially if therapy is started at the
earliest possible moment. In normal women with
initial herpes genitalis treated 6x per day, 86% of
ZO VIRAX patients were healed by day 12 (only
25% of placebo patients were healed within this
timeframe). And in the immunocompromised
group, ZOVIRAX-treated patients were 100%
healed by day 23, whereas only 75% of the
placebo group had similar clinical results.

ZOVIRAX-treated patients become
pain-free faster
ZO V IR A X can significantly reduce the pain
caused by the blister-like sores associated with
herpes infections. (For example, in clinical
studies involving male patients with initial herpes
genitalis, 8 8 % of ZOVIRAX-treated patients, as
compared to 45 % for the placebo group, were
pain-free by day 7.)
Similarly, impressive results were reported
with immunocompromised patients— 100% of
ZOVIRAX-treated patients were pain-free by day
23, whereas only 70% of the placebo group were
pain-free within the same period.

ZOVIRAX-treated patients become
virus-free faster
ZO V IR A X helps stop viral shedding (the
active, infectious state of the virus) by effectively
blocking the replication mechanism of the virus.
This is a particularly important point since
blocking viral replication is the first step in the
healing process.

ZOVIRALX-treated patients experience
few compromising side effects
In extensive controlled clinical studies,
ZO VIRAX therapy proved highly efficacious
without causing any significant side effects. More
placebo patients experienced transient adverse
reactions of mild pain, including burning or
stinging, than ZO V IR A X patients (31.1 % for
placebo; 2 8 .3 % for ZOVIRAX).

WELLCOME MEDICAL DIVISION
BURROUGHS WELLCOME INC.
KIRKLAND, QUE.

ZOVIRAX is highly effective.. .because
it’s highly selective
The way ZO VIRAX works is the reason it
works so well.
Z O V IR A X is highly active in infected cells
and virtually inactive in healthy cells. In fact,
this unique selectivity of ZO VIRAX is most
dramatically evidenced by in vitro data which
show ZO VIRAX to be 3,000 times more active in
the herpes-infected cell than in the normal cell.
Once it is preferentially taken up and
selectively converted to its active form by the
infected cell, ZO VIRAX interferes with the
reproductive process of the virus, effectively
stopping replication and ending the contagion
period so that the process of healing can begin.
Reference:
1. Data o n file. BURROUGHS WELLCOME INC

ZOVIRAX

ACYCLOVIR OINTMENT 5%

ANTIVIRAL AGENT
ACTIONS: ZOVIRAX (acyclovir), an acyclic nucleoside analog, is a substrate specific

for herpesvirus-specified thymidine kinase. It inhibits replication of these viruses.
Normal cellular thymidine kinase does not effectively utilize acyclovir as a substrate.
Herpesvirus-specified thymidine kinase transforms acyclovir to its monophosphate
which is then transformed by cellular enzymes to acyclovir diphosphate and acyclovir
triphosphate. Acyclovir triphosphate is both an inhibitor of, and a substrate for,
herpesvirus-specified DNA polymerase. Although the cellular a-DN A polymerase in
infected cells may also be inhibited by acyclovir triphosphate, this occurs only at
concentrations of acyclovir triphosphate which are higher than those which inhibit
the herpesvirus-specified DNA polymerase. Acyclovir is preferentially taken up and
selectively converted to its active form by herpesvirus-infected cells. Thus, acyclovir
has a very much lower toxic potential for normal uninfected cells because: 1) less is
taken up-, 2) less is converted to the active form; 3) cellular a-D N A polymerase has a
lower affinity for the active form of the drug.
INDICATIONS AND CLINICAL USE: ZOVIRAX Ointment 5% is indicated for the
management of initial episodes of genital herpes simplex infections. It is also indicated
in the management of nonlife-threatening cutaneous herpes simplex virus infections in
immunocompromised patients. The prophylactic use of this preparation has not been
established.
In genital herpes, appropriate examinations should be performed to rule out other
sexually transmitted diseases.
These indications are based on the results of a number of double-blind, placebocontrolled studies which examined changes in virus excretion, healing of lesions and
relief of pain. Because of the wide biological variations inherent in herpes simplex
infections, the following summary is presented merely to illustrate the spectrum of
responses observed to date. As in the treatment of any infectious disease, the best
response may be expected when therapy is begun at the earliest possible moment.
In immunocompromised patients. 93% were virus negative after 5 days of topical
ZOVIRAX therapy, whereas only 35% of placebo recipients were virus negative at the

same time. In patients with herpes labialis, there was a significantly greater decrease in
the amount of virus excreted after one day of therapy in those receiving ZOVIRAX within
8 hours of the onset of cold sores when compared to identically treated placebo
recipients.
Because complete re-epithelialization of herpes-disrupted integument necessitates
recruitment of several complex repair mechanisms, the physician should be aware that
the disappearance of visible lesions is somewhat variable and will occur later than the
cessation of virus shedding. A ll immunocompromised patients who received topical
ZOVIRAX had healed their lesions 23 days after the initiation of a 10-day course of
therapy; 75% of placebo patients had healed lesions at that point. Some placebo
patients continued to have visible lesions for more than 30 days.
Pain associated with herpes infections is highly variable in frequency and intensity.
One hundred percent of the ZOVIRAX-treated immunocompromised patients were painfree by day 23 versus 70% of placebo-treated patients.
Whereas cutaneous lesions associated with herpes simplex infections are often
pathognomonic, Tzanck smears prepared from lesion exudate or scrapings may assist in
the diagnosis. 1Positive cultures for herpes simplex virus offer the only absolute means
for confirmation of the diagnosis. 1
CONTRAINDICATIONS: ZOVIRAX Ointment 5% is contraindicated for patients who
develop hypersensitivity or chemical intolerance to any of the components of the
formulation, such as polyethylene glycol.
WARNINGS: ZOVIRAX Ointment 5% is intended for topical use only and should not
be used in the eye or on mucous membranes.
PRECAUTIONS: The recommended dosage, frequency of application and duration of
treatment of ZOVIRAX Ointment 5% should not be exceeded (see DOSAGE AND
ADMINISTRATION).
It is not known whether acyclovir is excreted in human milk. Because many drugs
are excreted in human milk, caution should be exercised when ZOVIRAX is
administered to a nursing mother.
All animal studies carried out to date on reproduction and teratology have been
negative. However, since animal reproduction studies are not always predictive of
human response, ZOVIRAX Ointment 5% should be used during pregnancy only if the
physician feels the benefit will outweigh the possible harm to the fetus.
Safety of use of ZOVIRAX Ointment 5% in children has not been established.
There exist no data, at this time, which demonstrate that the use of ZOVIRAX
Ointment 5% will prevent transmission of infection to other persons.
Since most cutaneous herpes simplex virus infections result from reactivation of
latent virus, it is unlikely that ZOVIRAX Ointment 5% will prevent recurrence of
infections when applied in the absence of signs and symptoms. ZOVIRAX Ointment
5% should not be applied in an attempt to prevent recurrences; application should
commence only at the earliest prodromal sign of disease onset.
Although clinically significant viral resistance associated with the use of ZOVIRAX
Ointment 5% has not been observed, this possibility exists.
ADVERSE REACTIONS: Because ulcerated genital lesions are characteristically
tender and sensitive to any contact or manipulation, patients may experience
discomfort upon application of ointment. In the controlled clinical trials, mild pain
(including transient burning and stinging) was reported by 103 (28.3%) of 364
patients treated with ZOVIRAX Ointment 5% and by 115 (31.1%) of 370 patients
treated with placebo; treatment was discontinued in 2 of these patients. Other local
reactions among acyclovir-treated patients included pruritus in 15 (4.1%), rash in 1
(0.3%) and vulvitis in 1 (0.3%). Among the placebo-treated patients, pruritus was
reported by 17 (4.6% ) and rash by 1 (0.3% ).
In all studies, there was no significant difference between the drug and placebo
group in the rate or type of reported adverse reactions.
SYMPTOMS AND TREATMENT OF OVERDOSAGE: Overdosage by topical application
of ZOVIRAX Ointment 5% is unlikely because of limited transcutaneous absorption.
DOSAGE AND ADMINISTRATION: Apply ZOVIRAX Ointment 5% liberally to the
affected area 4 to 6 times daily for up to 10 days. A sufficient quantity of ointment
should be applied to adequately cover all lesions. A finger cot or rubber glove should
be used while applying ZOVIRAX in order to prevent: (1) autoinoculation of other
body sites or (2) transmission of infection to other persons. Therapy should be
initiated as early as possible following onset of signs and symptoms.
AVAILABILITY: ZOVIRAX Ointment 5% is available in tubes of 15 g. Each gram
contains 50 mg acyclovir in a polyethylene glycol base. ZOVIRAX Ointment 5% is for
topical administration.
Product Monograph available on request.
REFERENCE: 1. NaibZM, Nahmias AJ, Josey WE: Relation of cytohistopathology of

genital herpesvirus infection to cervical anaplasia. Cancer Res 33:1452-63, 1973.
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TOPICAL OINTMENT

For sufferers of
herpes simplex infections
WELLCOME MEDICAL DIVISION
BURROUGHS WELLCOME INC.
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Circulatory Support after Coronary Artery Surgery
An important change in the pattern of
pharmacologic and mechanical cir
culatory support following coronary
artery surgery has been noted in
Newfoundland. The authors studied two
groups of patients: group 1 , 1 1 9 pa
tients who underwent coronary artery
bypass procedures from 1975 to 1978
and group 2, 344 similar patients studied
from 1979 to 1982. Both groups of pa
tients had similar left ventricular function
and similar numbers of grafts per patient
were inserted (group 1, 2.6; group 2,
2.8). There was a great reduction in the
need for perioperative circulatory support
(group 1, 34%; group 2, 6% ),
associated with a notable reduction in
the rate of myocardial infarction
perioperatively (group 1, 24% ; group 2,
4.9% ). This improvement resulted from
the routine use of invasive hemodynamic
monitoring and cold blood cardioplegia in
group 2 patients.

(groupe 1, 34% ; groupe 2, 6% ) associee
a une diminution marquee du taux d'infarctus du myocarde en peri-operatoire
(groupe 1, 24% ; groupe 2, 4.9 % ). Cette
amelioration est attribuable a I'utilisation
systematique d’une surveillance hemodynamique avec effraction tissulaire et de
la cardioplegie avec refroidissement du
sang chez les patients du groupe 2.

before invasive hemodynamic monitoring
and cold blood cardioplegia were in
troduced (group 1) and 344 who under
went operation from 1979 onwards
(group 2).
Until 1979, perioperative myocardial
infarction was diagnosed by the ap
pearance of new Q waves on the resting
electrocardiogram. Then an assay for
cardiac-specific enzymes and
pyrophosphate cardiac scanning became
available. Using the latter techniques, we
adopted the criteria of Righetti and
associates7 to diagnose perioperative in
farction in group 2 patients. Their criteria
are: (a) new persistent Q waves on the
resting electrocardiogram and either an
area of elevated MB isoenzyme of
creatine phosphokinase (MB-CPK) or
positive findings on pyrophosphate scan
ning; (b) ischemic changes in the ST-T
waves and both an elevated area of MBCPK and positive findings on cardiac
scanning.

Patients who undergo coronary artery
bypass procedures may need circulatory
support perioperatively.1'6 We noted an
important reduction in our use of such
pharmacologic and mechanical cir
culatory support in the 7 years from 1975
to 1982. This corresponds to a fall in the
rate of myocardial infarction perioper
atively that we attributed to better pro
tection of the myocardium by invasive
hemodynamic monitoring techniques and
introduction of cold blood cardioplegia.
We believe that the need for circulatory
assistance following coronary artery
Un changement important des moyens
surgery is suggestive of perioperative
pharmacologiques et mecaniques d'assismyocardial injury.
tance circulatoire a ete observe a TerreTechniques
Neuve. Les auteurs ont etudie deux grouThe anesthetic and surgical techniques
pes de patients: le groupe 1 constitue de
are briefly outlined. Anesthesia was in
Patients and Methods
119 patients qui ont subi une operation
duced with fentanyl citrate, diazepam and
de pontage aorto-coronarien entre 1975
All 463 patients who underwent coro pancuronium bromide, and was main
et 1978, et le groupe 2 forme de 344
nary artery procedures from the inception tained with repeated doses of fentanyl
patients semblables operes de 1979 a
of the cardiac surgery program in citrate and diazepam, plus nitrous oxide
1982. Les deux groupes de patients
Newfoundland (1975) until Jan. 1, 1982 and enflurane. For group 2 patients the
etaient comparables pour la fonction
were studied. This review was “ remotely pulse rate and arterial and pulmonary
ventriculaire gauche et le nombre de
retrospective” from 1975 until July 1, capillary wedge pressures were continual
vaisseaux greffes (groupe 1, 2.6; groupe
1978 and was “immediately retrospec ly monitored, and the heart rate-blood
2, 2.8). On a note une reduction importive” thereafter. It covered the pressure product was maintained at or
tante des besoins d'assistance circula
hospitalization period only.
below 12 000. Nitroglycerin or
toire dans la periode peri-operatoire
Data were collected on the following: nitroprusside were used routinely to pre
age, sex, cardiac catheterization, severi vent hypertension and to reduce left ven
From the *division o f cardiac surgery and
ty
of coronary artery disease and the tricular afterload. Catecholamines were
^department o f anesthesia, faculty o f
operation,
including number of vessels withheld and were used only if the patient
medicine, Memorial University o f
bypassed
and
the need for inotropic or could not be weaned from car
Newfoundland, St. John’s, Nfld.
mechanical circulatory assistance in the diopulmonary bypass.
Presented at the 86th annual meeting o f the perioperative period. In particular, left
For patients in group 1 in whom
Canadian Association o f Clinical Surgeons, ventricular function, assessed by hemodynamic
monitoring consisted most
eastern division, Ottawa, Ont., May 14,
angiography, was recorded (grade 1, nor often of only arterial and central venous
1982
mal; grade 2, mild impairment; grade 3, pressure lines, less attention was paid to
Accepted for publication Feb. 4, 1983
moderate impairment; grade 4, severe im hemodynamic status and vasodilators
pairment or left ventricular aneurysm). were rarely used. It was in this group that
Reprint requests to: Dr. T.E. Theman,
The patients were divided into two inotropic agents were frequently needed
Clinical assistant professor, Division o f car
groups: 119 who underwent coronary to wean the patient from car
diac surgery, Health Sciences Centre, St.
John's, Nfld. A IB 3V6
bypass operation between 1975 and 1978, diopulmonary bypass.
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The coronary bypass operation was
performed with the aid of a bubble oxy
genator and systemic hypothermia to
28°C if the cardiopulmonary bypass time
was expected to exceed 1 hour. In group
1 patients, the heart was fibrillated before
the distal coronary anastomoses were
done, and both systemic and topical
hypothermia were used to protect the
myocardium. In all group 2 patients, cold
card io p leg ic solution (containing
potassium 30 mmol/1, sodium 170
mmol/1, chloride 120 mmol/1, bicar
bonate 44.6 mmol/1, citrate-phosphatedextrose 20 ml/1 at pH 7.80) was infused
into the aortic root immediately after aor
tic cross-clamping. A 500-ml bolus was
given initially, followed by 250 ml every
20 minutes to maintain electrical and
mechanical cardiac arrest. Topical cardiac
cooling with iced Ringer’s lactate solution
was routinely used.
The distal coronary anastomoses were
all performed during one period of aor
tic cross-clamping. After the aortic cross
clam p was removed, the proximal
anastomoses were completed.
Once the operation was complete, the
p atie n t was weaned from c a r
diopulmonary bypass and then moved to
the intensive care unit for a variable
period (12 to 48 hours).

perioperative myocardial infarction from
24% to 4.9% over the study period.
Total perioperative mortality and the
subgroup of deaths from perioperative in
farction were not significantly different
(Fig. 3).
Certain patients received circulatory
support yet did not suffer a myocardial
infarction perioperatively (Fig. 4). This
was partly explained by the prophylactic
use of mechanical support for patients in
extremely unstable condition, and by the
use of pharmacologic support for patients
who suffered cardiac tamponade, stroke,
allergic reactions and pulmonary em
bolism. It was also likely that several pa
tients in group 1 did suffer myocardial
damage perioperatively but it was not
detected electrocardiographically, and
they fell into this listing by default.7 We
therefore surmise that the incidence of
perioperative myocardial infarction in
group 1 patients may have exceeded 24%.

and afterload reduction. In these cases,
the surgeon and the anesthesiologist
choose jointly whether to use the intra
aortic balloon pump or inotropic agents.
The need for circulatory support in our
patients has fallen notably since 1978 even
though our patient groups were com
parable in terms of left ventricular func
tion and number of grafts performed.
During the study period, personnel in
both surgery and anesthesia departments
changed, but we are convinced that the
improved results were not due to staff
changes but to better myocardial protec
tion in the perioperative period. This pro
tection was afforded by invasive
hemodynamic monitoring procedures and
by the use of cold blood cardioplegia.

Discussion
To minimize myocardial oxygen con
sumption following coronary artery
surgery, we have withheld catechol
amines8 unless the patient could not be
weaned from cardiopulmonary bypass
after a trial of optimal volume-loading
FIG. 3—Thirty-day perioperative mortality
is not significantly different for groups I and 2.

Statistical Analysis
Differences between the two groups
were analysed by the unpaired two-tailed
Student’s f-test. The probability values
were corrected (pcorr) to compensate for
the dependent tests; pcorr < 0.05 was
considered significant.
Results
The two groups studied were com
parable in terms of their left ventricular
functional status (group 1: average grade
1.84/4; group 2: average grade 2.2/4), as
well as in terms of the number of cor
onary bypass grafts (group 1: 2.6 per pa
tient; group 2: 2.8 per patient). There was
no difference in age (mean 56 years) or
sex (male to female ratio 4:1) between the
two groups.
A significantly smaller proportion of
group 2 patients needed circulatory sup
port perioperatively compared with group
1 (Fig. 1). Very few patients in both
groups (1.7% and 1.3% respectively for
groups 1 and 2) required circulatory sup
port before operation, and those who did
received intra-aortic balloon pump sup
port for unstable angina or stenosis of the
left main coronary artery.
Various methods of circulatory support
were provided (Fig. 2).
The changing pattern of circulatory
assistance corresponded to a significant
(p < 0.05) fall in the incidence of
234

FIG. 1—Need for circulatory support in
group I patients was significantly (p < 0.05)
higher than in group 2 patients who routinely
received cardioplegia.

FIG. 4—Circulatory support for those in
whom perioperative infarction was not proven.

FIG. 2—Types of circulatory support. IABP
= intra-aortic balloon pump assistance,
hatched bars = group 1, white bars = group 2.

FIG. 5—Differences in need for circulatory
support (hatched bars) and incidence of
perioperative myocardial infarction (white
bars) in groups 1 and 2 are significant (p <
0.05). Black bars = deaths.
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Although the criteria for diagnosing
perioperative myocardial infarction
changed in 1979, there still appears to be
a strong association between the declin
ing incidence of perioperative myocardial
infarction and the reduced need for cir
culatory assistance (either pharmacologic
or mechanical) after coronary artery
bypass procedures. Although the death
rates for our two groups were not
significantly different, the trend was
definitely towards improved survival
when careful attention was paid to
myocardial protection (Fig. 5).
In spite of firm policies of invasive
monitoring and cold blood cardioplegia,
6% of the group 2 patients did require cir
culatory support posto p erativ ely ,
although the indication in only half of
these appeared to be myocardial ischemia.
In the ideal situation (i.e., no myocardial
damage perioperatively), about 3% of pa
tients might still need some form of cir
culatory support either for prophylaxis or
for treatment of associated disorders.
The 3% incidence of perioperative in
farction in our group 2 patients raises a
question that is not answered by this
study: Why is the myocardial protection
not completely effective? A close ex
amination of the group 2 patients who did
suffer myocardial damage revealed that
they all had unstable angina, and that

they had four or more coronary artery le
sions and poor left ventricular function
(average left ventricular “ grade” in this
group was 3.5/4). We believe that there
may have been maldistribution of car
dioplegia in these patients to account for
their
perioperative
m yocardial
infarction.9’10
Our policy to withhold circulatory
assistance appears comparable to that
reported by Sandberg and associates;11
only 3.4% of their patients needed intra
aortic balloon pump support after cor
onary artery operation. Furthermore, the
incidence of perioperative myocardial in
farction following coronary artery bypass
grafting at the Cleveland Clinic is
remarkably low at 1.8% .11
The ro utine use of invasive
hemodynamic monitoring has made us
more critical of our indications for using
various circulatory aids, and it is con
ceivable that the restricted use of
catecholamines alone may have con
tributed to a decrease in the rate of
perioperative myocardial infarction. We
conclude that the routine use of inotropic
support following coronary artery opera
tion is unnecessary and may even be
harmful. Indeed, should any form of cir
culatory assistance become necessary
after operation, one should suspect
myocardial injury.

References
1. Steen p a . T inker j h , p i .uth JR, Barn horst DA,
T arh an S: Efficacy o f dopamine, dobutamine, and
epinephrine during emergence from cardiopulmonary
bypass in man. Circulation 1978; 57: 378-84
2. Merin G, Bitran d , U ret / ky G, S uperstin e E,
COTEV S, Borm an JB: The hemodynamic effects of
dopamine following cardiopulmonary bypass. Ann
Thorac Surg 1977; 23: 361-3
3. Sakam oto T, Yam ada T: Hemodynamic effects of
dobutamine in patients following open heart surgery. Cir
culation 1977; 55: 525-33
4. KlRSH MM, BOVE E, DETMER W, HILL A, KNIGHT P:
The use of levarterenol and phentolamine in patients with
low cardiac output following open-heart surgery. Ann
Thorac Surg 1980; 29: 26-3?
5. F ilner B, Karliner JS, D aily PO: Favorable in
fluence of dopamine on left ventricular performance in
patients refractory to discontinuation o f cardiopulmonary
bypass. Circ Shock 1977; 4: 223-30
6. ROSENBLLM R, F rieden J: Intravenous dopamine in the
treatment o f myocardial dysfunction after open-heart
surgery. A m Heart J 1972; 83: 743-8
7. RlGHETTI A, CRAWFORD MH, O ’ROURKE RA, H ARDARSON T, SCHELBERT H, DAILY PO, DELUCA M,
ASHBURN W, ROSS J JR: Detection o f perioperative
myocardial damage after coronary artery bypass graft
surgery. Circulation 1977; 55: 173-8
8. L azar HL, Fog lia RP, M a n gan aro AJ, Buckberg
GD: Detrimental effects of premature use o f inotropic
drugs to discontinue cardiopulmonary bypass. Surg
Forum 1978; 29: 276
9. H ilton CJ, T eubl w , ac k er M, L evinson HJ,
M illard RW, R iddle R, Mc E nany MT: Inadequate
cardioplegic protection with obstructed coronary arteries.
Ann Thorac Surg 1979; 28: 323-34
10. Becker H, Vinten -J oh a n sen J, Buckberg GD,
Foll.ETTE DM, Robertson JM: Critical importance of
ensuring cardioplegic delivery with coronary stenoses. J
Thorac Cardiovasc Surg 1981; 81: 507-15
11. Sandberg g w , l o o p FD, E stefan ous FG, S heldon
WC: Myocardial revascularization in The Cleveland
Clinic Foundation — 1979. Cleve Clin Q 1980; 47: 255-60
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A PERSONAL PERSPECTIVE
F or most physicians, time constraints make it imperative th at continuing medical education be
accomplished efficiently. This requires careful planning.
F or surgeons, there is no better way of pinpointing and correcting areas of educational need— of
planning for CME—than SESAP IV. This Surgical Education and Self-Assessment Program offers:
• comprehensive coverage of 16 areas of surgery
• authoritative m aterial, constructed and presented by 49 nationally recognized surgeons
• optional, confidential computer-scoring so that you can compare your standing with th a t of
your peers
• feedback to aid self-study: preferred answers, critical evaluations, and selected references
SESAP IV. Comprehensive, authoritative, continuing education in surgery, offering up to 75
hours of Category 1 CME credit. Send for full information today.

SESAP I V. . .Surgical Education and Self-Assessment
Program No. 4 from the American College of Surgeons
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A new approach
to the endocrine management
of m etastatic breast cancer.
CYTADREN is indicated for
postmenopausal oroophorectomized
patients with metastatic breast car
cinoma. The following groups are likely
to derive the most immediate benefit:
□ patients with estrogen receptor (ER)
positive tumors requiring palliative
therapy.

CYTADREN offers the patient an
additional period of reasonably normal
ambulatory life.
□ CYTADREN can prolong life for
responding patients with metastatic
breast cancer.

□ patients with painful bone metastases.3

□ CYTADREN patients more frequently
experience regression of bone metas
tases and pain relief.6

□ patients suitable for endocrine therapy
yet primarily unresponsive to other treat
ments, e.g. tamoxifen.4

□ CYTADREN provides an alternative,
until now unavailable, for patients not
responding to tamoxifen.

□ patients who initially responded to
other endocrine treatment, e.g. tamoxifen,
but relapsed.4

□ CYTADREN preserves quality of life
with relatively few side effects.

□ patients under consideration for major
ablative endocrine surgery.1

CYTADREN is
aminoglutethimide.
An adrenal suppressant
and reversible inhibitor
of peripheral
estrogen synthesis.

CYTADREN blocks estrogen pro
duction in the peripheral tissues.

1 Adrenocorticotrophic
hormone (ACTH)
is released by
the pituitary gland.

□ CYTADREN blocks the conversion of
cholesterol to pregnenolone, the
steroid which gives rise to pro
4 Cytadren suppresses
gesterone, androgens, the
the conversioo ot
androgens to estrogens
mineralocorticoids (aldo
and in turn diminishes
the effect of
sterone etc.) and the glu
estrogens on
breast tumor
cocorticoids (cortisol etc.)
growth.

□ CYTADREN blocks the formation
of steroids from cholesterol in
3 Estrogen stimulates the
growth of ER positive
the adrenals. At the same
breast
carcinoma
time it inhibits aromatase
tissue.
in the peripheral tissues,
thereby lowering plasma
estrogen to the same
extent as surgical adren
alectomy.1CYTADREN
maintains androgen levels
by not inhibiting the
formation of testosterone
2 ACTH stimulates steroidogenesis in the
and dehydrotestosterone.2

adrenals. Androgens produced are converted
into estrogens in the peripheral tissues.

□ Steroids escaping this
block are converted
directly to androgens,
which in turn are convert
ed to estrogens by the
aromatase enzyme in the
peripheral tissues. CYTADREN
inhibits this step as well.

The Cytadren efficacy profile.
CYTADREN provides a new option before initiating chemotherapy.

CYTADREN in patients previously treated with tamoxifen.
Patients re sista n t to tam oxifen
# o f patients
evaluated

Investigator

O bje ctive
re sp o n se

R e la p se d ta m o xife n re s p o n d e rs
# of p a tie n ts
e valuated

O b je c tiv e
re s p o n s e

SMITH, I.E., e ta l.

29

6

(21%)

20

8

(40%)

MURRAY, R.M.L., e ta l.

50

20

(40%)

41

25

(61%)

KAYE, S.B. e ta l.

20

7

(35%)

21

13

(62%)

HARVEY, H A , e ta l.

14

3

(21%)

18

9

(50%)

RAG AZ, J., et al.

15

5

(33%)

-

-

46

26

(56%)

-

-

35

7

(20%)

128

41

BUZDAR, A.U., et al.
INGLE, J.N., e ta l.
TOTAL

Cytadren in patients with
painful bone metastases.
CYTADREN im p ro ve s re g re ssio n of b o n e m e ta sta se s
a c c o m p a n ie d by b o n e h e a lin g and relief o f b o n e pain.
S tudy

C yta d re n
Num ber
evaluable

Tam oxifen

Number
responding

Num ber
evaluable

Num ber
responding

S m ith e ta l.

31

11

(35%)

29

5

(17%)

Lipton et al.

13

7

(54%)

18

4

(22%)

Total

44

18 (40.9%)

47

9 (19.1%)

(32%)

181

-

-

8 8 (48.6% )
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Safety & tolerability
□ CYTADREN is generally well tolerated at
recommended doses.
□ Transient drowsiness and lethargy, which
abate over a 6-8 week period, are the most
frequent side effects.
□ An itchy rash may appear. This normally
diminishes within 7-10 days without interrupting
therapy.

Cytadren respects the life it prolongs.
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To the Medical Profession:

BCytadren™(aminoglutethimide)
Adrenal suppressant
Reversible inhibitor of peripheral estrogen synthesis
Description

Cushing's syndrome
Cytadren (aminoglutethimide) is a potent reversible inhibitor of adrenal
mineralocorticoid and glucocorticoid synthesis. It partially inhibits the
enzymatic conversion of cholesterol to pregnenolone, the reaction that
initiates steroidogenesis in the adrenal cortex; as well, Cytadren blocks the
Cij, C2|, and C|8 hydroxylation of steroids. In Cushing’s syndrome of all
etiologies other than drug-induced, the inhibition of cortisol biosynthesis by
Cytadren markedly reduces excessive plasma cortisol.

Breast carcinoma
In addition to the effect on the adrenal cortex, Cytadren also inhibits the
aromatization of androgens into estrogens in peripheral tissues. The
aromatase mediated conversion of androgens into estrogens is the source of
estrogen in the postmenopausal woman; the aromatase enzyme is present in
liver, muscle, fat, and breast tissue including breast carcinoma. Cytadren
does not inhibit the formation of testosterone or dehydrotestosterone. Thus,
maintenance of androgen level with relative suppression of estrogens may be
of potential benefit. In vitro studies have shown that the blockade of
aromatization occurs at 10 times lower concentrations of Cytadren than
those required to prevent steroidogenesis. It is believed that this extra
adrenal blockade of aromatization of androgens of adrenal origin into estro
gens by aminoglutethimide is of overriding therapeutic importance in the
treatment of breast carcinoma in the postmenopausal woman.
Inhibition of adrenal-cortisol production by Cytadren leads to a reflex rise in
adrenocorticotrophic hormone (ACTH) secretion from the pituitary. The latter
overcomes the cortisol-lowering effect of Cytadren, leading to the so-called
“ adrenal escape phenomenon". The compensatory increase in ACTH
secretion can be suppressed by the simultaneous administration of a
glucocorticoid. Cytadren increases the rate of its own metabolism and that of
certain glucocorticoids, including dexamethasone, but not of hydrocortisone.
Hence, the latter is indicated as the glucocorticoid replacement therapy of
choice to maintain a long-lasting adrenal suppressant effect, i.e., to prevent
the "adrenal escape phenomenon".
Cytadren causes a rapid decrease in aldosterone secretion from the adrenal
cortex. In some patients, the signs and symptoms of hypoaldosteronemia,
such as hyponatremia, dizziness, hypotension and weakness, occur. This may
be treated by administration of a mineralocorticoid, such as fludrocortisone,
0. 1.mg orally daily or on alternate days.
Cytadren inhibits the synthesis of thyroxine by the thyroid gland. There is,
however, a compensatory increase in thyroid-stimulating hormone (TSH)
secretion which is usually of sufficient magnitude to overcome this blockade.
Thyroxine replacement therapy is therefore only occasionally required.
In spite of the TSH increase, Cytadren administration, for reasons which are
not entirely clear, has not been associated with an increase in prolactin
secretion.
Cytadren only minim ally inhibits estrogen production by the ovarian follicle
in the premenopausal woman. Hence, it is not feasible to produce a medical
oophorectomy in these women with this drug.
Indications and clinical use

Cushing’s syndrome
Cytadren (aminoglutethimide) is indicated for the palliative treatment of
Cushing’s syndrome of all etiologies other than drug-induced. It is effective
in reducing elevated plasma cortisol levels to one half or less of pretreatment
levels in 30 to 60% of treated patients. A sustained response to Cytadren is
most frequently observed in patients with Cushing’s syndrome due to
adrenal adenoma or carcinoma. However, pituitary dependent adrenal
hyperplasia does respond initially to Cytadren in up to 60% of cases.
Cytadren has no effect on the disease processes that underlie Cushing’s
syndrome. It is useful in the control of hypercortisol ism as an interim
measure until definitive therapy is instituted or where such therapy is not
appropriate. Therapy with Cytadren for longer than 3 months has been
studied only in a limited number of patients.

Metastatic breast carcinoma
Cytadren in combination with glucocorticoid replacement is indicated for the
palliative treatment of metastatic breast carcinoma in the postmenopausal
woman. Patients with estrogen receptor positive tumors are most likely to
benefit from Cytadren therapy. The remission rates appear to be the highest
in soft tissue and bone metastases; metastases in liver and lung rarely
respond to Cytadren.
Up to 30% of patients initially refractory to tamoxifen citrate may show an
objective response to Cytadren.
After remission and relapse on tamoxifen citrate, up to 48% of these patients
may experience an objective response to Cytadren.
Cytadren treatment should be continued only in those patients who have
demonstrated a response to it within the first three months.
Contraindications
Cytadren (aminoglutethimide) is contraindicated in those patients with
severe manifestations of hypersensitivity to glutethimide or aminoglutethi
mide and in premenopausal women with metastatic breast carcinoma.
Warnings
1. Cytadren (aminoglutethimide) may cause adrenocortical insufficiency
which will usually present after 24 to 48 hours of treatment. After the
initiation of Cytadren therapy and under conditions of stress, such as
surgery, trauma, or acute illness, patients should be carefully monitored
and given hydrocortisone or cortisone acetate and mineralocorticoid
supplements as indicated. Dexamethasone is not recommended because
its rate of metabolism is enhanced by Cytadren.
2. Cytadren may suppress aldosterone production by the adrenal cortex and
thereby cause orthostatic or persistent hypotension. The blood pressure
should be followed in all patients at appropriate intervals. Patients should
be advised of the possible occurrence of weakness and dizziness as
symptoms of hypotension, and of measures that could be taken should
they occur.
3. Cytadren may depress the central nervous system resulting in lethargy or
somnolence. Ataxia has been noted in some cases. These are usually
transient effects. (See Adverse reactions)
4. Cytadren can cause fetal abnormalities when administered during
pregnancy. In the earlier experience with the drug, two cases of
pseudohermaphroditism in 5000 pregnancies were reported in female
infants whose mothers took aminoglutethimide and other concomitant
anticonvulsants. When administered to rats at doses of f t and
ly i times the maximum human dose, Cytadren caused a decrease in fetal
implantation, increase in fetal deaths, and a variety of teratogenic effects.

The drug also caused pseudohermaphroditism in rats treated with
approximately three times the highest recommended human dose. If this
drug must be used during pregnancy, or if the patient becomes pregnant
while taking the drug, the patient should be advised of the potential
hazard to the fetus and the treatment continued only if the benefits
outweigh the risks.
Precautions
1. General: Cytadren (aminoglutethimide) should be administered only by
physicians who are fam iliar with its use; therapy should be initiated in a
hospital setting until a stable dosage regimen is achieved. (See Dosage
and administration)
2. Information for patients: Patients should be warned that drowsiness may
occur and that when present they should not drive, operate potentially
dangerous machinery, or engage in other activities which require mental
alertness.
Patients should also be warned of the possibility of hypotension and its
symptoms. (See Warnings)
3. Laboratory tests: Hypothyroidism may occur in association with aminoglu
tethimide; hence, appropriate clinical observations should be undertaken
and laboratory studies of thyroid function performed where indicated.
Supplementary thyroid hormone may be required.
Hematologic abnormalities in patients receiving Cytadren have been
reported (see Adverse reactions). Therefore, baseline hematologic
studies should be carried out and repeated at regular intervals.
Since elevations in SGOT, alkaline phosphatase and bilirubin have been
reported, appropriate clinical observations and regular laboratory studies
should be performed before and during therapy.
Serum electrolytes should be determined periodically and mineralocorticoids should be administered depending upon the clinical and/or
the electrolyte status.
4. Drug interactions: Cytadren accelerates the metabolism of dexa
methasone; therefore, when glucocorticoid replacement is needed,
hydrocortisone or cortisone acetate should be prescribed.
Cytadren also decreases the clinical effect of oral hypoglycemic and
anticoagulant drugs. Therefore, appropriate laboratory tests must be
performed and the doses of oral hypoglycemic and/or anticoagulant drugs
increased to maintain an optimal therapeutic effect.
5. Carcinogenesis, mutagenesis, impairment of fertility: Neither mutage
nesis studies nor animal carcinogenicity studies have been performed.
Cytadren affects fertility in female rats. (See Warnings) Whether it does so
in humans has not been determined.
6. Pregnancy: See Warnings section,
7. Pediatric use: Safety and effectiveness have not been established by
adequate and well-controlled studies in children.
Adverse reactions
Adverse reactions reported in patients treated for Cushing’s syndrome and
metastatic breast cancer include observations in 374 and 1043 patients,
respectively, who received Cytadren (aminoglutethimide) for periods ranging
from a few days to several years. Patients concurrently received glucocorti
coid and occasionally mineralocorticoid replacement therapy. Approximately
60% of patients reported one or more unwanted effects, most of which
disappeared spontaneously with continued administration of Cytadren.
A

Adverse effects most frequently encountered

The most frequent and reversible side effects were essentially from one of
the following sources:
i) Central nervous system: These side effects are related to one or
more manifestations of the known central depressant action of
Cytadren.
lethargy/somnolence
34%
Ataxia
5%
Dizziness
5%
ii) Dermatological
Skin rash (morbilliform and/or maculopapular)
26%
iii) Gastrointestinal
Nausea/vomiting
10%
iv) Systemic
Fever
2%
B. Other minor adverse effects which occurred at a frequency o f 1% or less
are: Hypoadrenalism, depression, nystagmus, dermatitis, hypothyroidism,
constipation, indigestion, diarrhea, headache, insomnia, unstable gait,
anxiety, hallucinations, poor memory, seizures, jaundice, electrolyte
changes, arthralgia, hyponatremia, hypotension, sweating, chills, and
urinary retention.
Although some of these symptoms may not be necessarily ascribed to
Cytadren therapy, they are listed as alerting information.
The following minor adverse effects which occurred at a frequency of 1% or
less are believed to be associated with the glucocorticoid replacement
therapy; Cushingoid facies, weight gain, hyperadrenalism, edema, and
hypercalcemia. Occasionally, mineralocorticoid replacement therapy pro
duces hypertension and congestive heart failure due to its marked effect
on sodium retention.
C

Hematologic abnormalities
Blood dyscrasias related to Cytadren have been reported. Most patients
studied had neoplastic involvement of the bone marrow and were receiving
other drugs when blood dyscrasias were observed. Hence, the exact
relationship of Cytadren administration to these complications could not
always be established. Nonetheless, 4 cases of pancytopenia have been
reported. In addition, rare cases of agranulocytosis and thrombocytopenia
have also been recorded.
A reduction in hemoglobin and usually a transient decrease in white blood
cell counts have been reported with chronic administration of Cytadren.

D. Clinical laboratory abnormalities
Increased bilirubin and elevation of alkaline phosphatase and SGOT have
been reported. Although the casual relationship of these abnormalities to
aminoglutethimide is uncertain, periodic liver function tests are recom
mended.
E.

Other

Some patients occasionally show clinical symptoms of hypoaldosterone
mia (i.e. dizziness, hypotension, and occasionally hyponatremia). Admini
stration of small doses of fludrocortisone (0.1 mg/day or on alternate days)
usually alleviates these symptoms.
Rarely, adrenal hematomas have been seen at surgery in patients
receiving aminoglutethimide. Cellular hypertrophy, cytoplasmic vacuoliza
tion and excessive accumulation of lipids have been observed in adrenal
tissue.
Symptoms and treatm ent of overdosage

Symptoms
The most common signs to be expected with overdosage of Cytadren
(aminoglutethimide) are ataxia, sedation, and deep coma with hyperventila
tion and hypotension. Deaths have not been reported following administra
tion of Cytadren at doses up to 7 grams.

Treatment
Gastric lavage and supportive treatment have been employed. Full
consciousness following deep coma was regained forty hours or less after
ingestion of three or four grams of Cytadren without lavage. No evidence of
hematologic, renal or hepatic effects were subsequently found. Dialysis may
be considered in severe intoxication.
Extreme weakness has been reported when patients received 3 grams/day in
divided doses.
A parenteral glucocorticoid, preferably hydrocortisone or cortisone acetate,
and/or a mineralocorticoid, such as fludrocortisone, may be indicated in the
event of extreme prostration as this may be the result of adrenocortical
insufficiency.
Dosage and administration

Cushing’s syndrome
Adults: Treatment should be instituted in a hospital setting until a stable
dosage regimen is achieved. Therapy should be initiated with a daily dose of
1000 mg in 4 equally-divided doses, preferably at 6-hourly intervals.
The response of cortisol secreting tissue to Cytadren (aminoglutethimide)
should be followed by carefully monitoring plasma cortisol levels until the
desired level of suppression is achieved. (When glucocorticoid replacement
therapy is instituted, monitoring of DHEA-S (dehydro-epi-androsterone
sulfate) levels will provide a measure of suppression of cortisol secretion.)
If adrenal suppression is inadequate, the daily dose may be increased in
increments of 250 mg each week to a maximum daily dose o f 2000
milligrams (2 grams) in equally-divided doses.
Dose reduction or temporary discontinuation may be required in the event of
adverse responses, including extreme drowsiness or severe skin rash.
Incremental increases to maintenance level can then be achieved as the
patient's condition allows. If a skin rash persists for longer than five to eight
days, or becomes severe, the drug should be discontinued. It may be possible
to reinstate therapy at a lower dosage following the disappearance of a
mild-to-moderate rash.
Hydrocortisone: Forty (40) mg per day or cortisone acetate fifty (50) mg per
day in equally-divided doses orally is suggested as replacement therapy for
frank adrenal insufficiency or when cortisol levels drop to a level where
increased pituitary ACTH secretion is likely.
Fludrocortisone: If patients show the signs and symptoms of hy
poaldosteronemia (e.g. hypotension, dizziness, and/or hyponatremia), fludro
cortisoneat a daily dose of 0.1 mg p.o. should be administered daily or on
alternate days depending on the severity of symptoms. As fludrocortisone
may have a marked effect on sodium retention, physicians should monitor
patients closely for signs and symptoms of fluid retention, hypertension,
congestive heart failure and related conditions.

Metastatic breast cancer
In order to achieve optimal therapeutic effects and to encounter the least
side effects, aminoglutethimide should be administered orally in escalating
doses together with hydrocortisone or cortisone acetate.
Aminoglutethimide: Aminoglutethimide should be administered orally in
gradually increasing doses as follows: 250 mg b.i.d. during the first week;
250 mg t.i.d. during the second week; thereafter 250 mg q.i.d. The graduated
dose approach allows time for Cytadren to induce its own metabolism and for
patients to accommodate to the soporific side effects. In exceptional cases,
the daily dose may be increased to a maximum of 2000 mg in equally-divided
doses.
Hydrocortisone: 100 mg per day orally (20 mg a.m.; 20 mgp.rn.; and 60 mg h.s.)
during the first 2 weeks; thereafter 40 mg daily (20 mg a.m., and 20 mg p.m.).
Cortisone acetate: 125 mg per day orally (25 mga.m.; 25 mgp.m.; and 75 mg
h.s.) during the first 2 weeks; thereafter 37.5-50 mg daily (25 mg a.m. and
12.5 or 25 mg p.m.). The initial high dose of hydrocortisone or cortisone
acetate reduces the severity of the skin rash which is highly steroid sensitive
and which usually occurs 10-15 days after initiation of therapy.
Fludrocortisone: If patients show the signs and symptoms of hypoaldostero
nemia (e.g. hypotension, dizziness, and/or hyponatremia), fludrocortisone at
a daily dose of 0.1 mg p.o. should be administered daily or on alternate days
depending on the severity of symptoms. As fludrocortisone may have a
marked effect on sodium retention, physicians should monitor patients
closely for signs and symptoms of fluid retention, hypertension, congestive
heart failure and related conditions.
Infrequently, patients receiving Cytadren continue to complain of persistent
lethargy, somnolence or mild lack of alertness during chronic therapy. If
facilities are available to measure plasma levels of aminoglutethimide,
allow reduction in dosage to maintain drug concentrations in the therapeutic
range of 10-15 /zg/ml. If unavailable, reduction in dosage to 750 mg Cytadren
daily with 500 mg just before sleep and 250 mg in the morning will often
alleviate this problem. It should be remembered that Cytadren is excreted
largely unchanged in the urine and patients with compromised renal
function may have high blood levels. 5% of patients cannot tolerate
Cytadren in any dosage. The skin eruption occurring with aminoglutethimide
is a maculopapular, generalized or urticarial rash often associated with fever
which commonly begins on day 10 and subsides by day 15 or 16 of treatment.
Forewarning patients of this problem alleviates anxiety should the rash
appear. The rash is responsive to a daily dose of hydrocortisone or cortisone
acetate and improves with concurrent administration of antihistamine, e.g.
diphenhydramine, 25 mg b.i.d. to q.i.d. daily. If the rash persists beyond day
16, the drug should be discontinued until the rash subsides, then restarted at
125-150 mg daily with gradual increments to full dosage.
Supplied
250 mg tablets: off-white, round, bisected, biconvex tablet with CIBA
engraved on one side and GG engraved on the other. Bottles of 100.
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Congenital Tracheoesophageal Fistula
without Esophageal Atresia
Betw een Jan. 1, 1961 and Dec. 31,
1 9 8 1 , 16 in fa n ts (9 boys, 7 girls) w ith
tracheoesophageal fis tu la w ith o u t
esophageal atresia (H -type fis tu la ) were
trea te d at the H opital S ain te -Justin e and
Centre Hospitalier de I'U n ive rsite Laval.
The mean b irth w e ig h t w a s 2 .8 kg. Five
in fa n ts were prem ature. A ll presented at
fir s t feeding w ith co ughing, ch o kin g and
cyanosis. Seven had abdom inal d iste n 
sion and six had hyp e rsa liva tio n . Mean
age at the tim e o f d e fin itive diagnosis
w a s 39.1 days. The diagnosis w a s con
firm e d radiologically in ail in fa n ts , a
mean o f 1.6 9 roe n tgenographic p ro 
cedures per pa tie nt being required. Cervic o th o ra c ic (C7 to T2) fistu la s w ere pre
se n t in 14 and th o ra c ic fis tu la s in 2 in
fa n ts . T w elve w ere operated upon
th ro u g h a cervical and 4 th ro u g h a
th o ra c ic approach. A Fogarty ca th ete r
w a s placed in tw o fistu la s preoperatively. T w o patients required g a stro sto m y.
Feeding was sta rte d again 3 days
postop e ra tive ly. One in fa n t died and one
had a recurrent fis tu la . One s u rvivo r had
2 0 episodes o f ca rd io re sp ira to ry arrest.
None had dysphagia.
The authors consider it im p era tive th a t
fis tu la s be visualized before any
operative procedure is perform ed.
C atheterization o f the fis tu la w ith a
Fogarty ca th ete r should be a tte m p te d
preoperatively. It is dangerous to dissect
a cervical fis tu la th ro u g h a th o ra co to m y.
Entre le 1er janvier, 1961 et le 31
decem bre, 1 9 8 1 , 16 bebes I9 garcons et
7 filles) s o u ffra n t de fistu le s tracheooesophagiennes sans atresie oesopha-
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gienne (fistule s de typ e H) ont e te tra ite s
a I'H o p ita l S a in te -Justin e et au C e n tre
H ospitalier de I'U n iv e rs ite Laval. Le poids
m oyen a la naissance e ta it de 2 .8 kg.
Cinq bebes eta ie nt prem atures. T ou s o n t
m anifesto au prem ier repas de la to u x ,
de I'e to u ffe m e n t et une cyanose. S e p t
avaient de la distension abdom inale e t
six, de I'h yp e rsa liva tio n . L'age m oye n au
m om e n t du d ia gnostic d e fin itif e ta it de
3 9 .1 jo u rs. Le d ia g n o stic fu t c o n firm e a
la radiologie chez to u s les bebes; une
m oyenne de 1 .6 9 exam ens rad io g ra p hiques fu re n t requis pour chaque p a tie n t.
Des fistu le s cervico-th o ra ciq u e s (C 7 a
T2) e ta ie nt presentes chez 14 b ebes e t
des fis tu le s tho ra ciq u e s chez les 2
autres. Douze o n t ete operes par un
abord cervical et 4 par un abord th o ra c ique. Une sonde F ogarty avait e te placee
dans deux fistu le s en preoperatoire.
Deux pa tie nts o n t necessite une g a stro to m ie . L 'a lim e n ta tio n p u t reprendre 3
jo u rs apres I'op e ra tio n. Un e n fan t e st
decede et un autre eut une recidive de la
fis tu le . Un su rviva n t eut 2 0 episodes
d 'a rre t cardio-respiratoire. A ucun n 'a
s o u ffe rt de dysphagie.
Les auteurs co n sid e re n t q u 'il e s t im pera tif que les fistu le s so ie n t mises en e v i
dence a va n t I'in te rv e n tio n ch irurg ica le .
On d e vra it te n te r le ca th ete rism e de la
fis tu le avec une sonde Fogarty a v a n t
I'o p e ra tio n . II e st dangereux de d isse q u er
une fis tu le cervicale a travers une
th o ra co to m ie .

Congenital tracheoesophageal fistula,
first described by Lamb1 in 1873 and
first successfully repaired surgically by
Imperatori in 1939,2 is commonly re
ferred to as the H-type fistula. It
represents 4.2% of all tracheoesophageal
fistulas.3,4 Despite the sophisticated
methods now available, making the
diagnosis remains a challenge.
We report our experience in diagnos
ing and treating this entity at the Hopital
Sainte-Justine, Montreal and at the Cen
tre Hospitalier de I’Universite Laval,
Quebec City.

Patients and Methods
Between Jan. 1, 1961 and Dec. 31,
1981, 16 infants (9 boys, 7 girls) with Htype tracheoesophageal fistula were
treated in our two centres. All underwent
surgical correction. Birth weights ranged
from 1720 to 4395 g (mean 2769 g); four
weighed less than 2000 g. There were 11
full-term and 5 premature infants, 2 be
ing of 32 weeks’ gestation. Fourteen were
delivered vaginally and 2 by cesarean sec
tion. There were three cases of twinning;
in each case the other twin was normal.
No polyhydramnios was noted.
We studied the signs, the diagnostic
methods used, characteristics of the
fistula and the surgical approach and its
results.
Findings
Six infants had associated anomalies
(Table I). The age at diagnosis ranged
from 1 to 365 days (mean 39.1 days).
Diagnosis was made in 14 infants (88%)
in the first month of life, half in the first
week.
Symptoms started at birth in every
case, frequently with the first feeding. All
infants had the triad of cough, cyanosis
and choking precipitated by feeding. Ab
dominal distension was noted in only
44% and it was never a presenting sign.
One premature baby was intubated for
respiratory distress syndrome and when
he was manually ventilated, abdominal
distension was noted. This led to the
diagnosis. Six patients had hypersaliva-

Table I—Associated Anomalies (n - 6)
Imperforate anus and rectovaginal fistula
Dextrocardia
Omphalomesenteric duct
Absent left kidney
Abnormal right collecting system
Chordee and hypospadias
Patent ductus arteriosus
Atrioventricular block
Ventricular septal defect
VATER
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non; only two had aspiration pneumonia.
Esophageal contrast roentgenographic
study recorded on video tape was the
most valuable diagnostic method. All
fistulas were visualized by this method but
the test had to be repeated in many cases
(mean of 1.69 studies per patient). Bron
choscopy and esophagoscopy were per
form ed once each for diagnostic
purposes.
The fistula was low cervical or high
thoracic, between C7 and T2, in 14 pa
tients and low thoracic in 2.
The surgical approach was cervical in
12 cases and thoracic in 4. In two cases
a thoracic approach was used for lowlying fistulas close to the carina. In one
case, the surgeon knew that the fistula
was at the cervical level but there was a
second fistula close to the carina. The se
cond was a case of surgical misjudge
ment. In every case the fistula was divid
ed and sutured.
Survival and Morbidity
Fifteen of the 16 infants (94%) survived
the operation. One with a cervical fistula
died 72 hours after operation of
respiratory distress with pneumothorax.
The operation, the first of the series, was
difficult. It was carried out through a
thoracic approach.
Intraoperative and postoperative mor
bidity were very high. Five patients had
major complications intraoperatively:
cardiac arrest, tracheal perforation,
bradycardia, accidental extubation and
laryngeal edema. Four infants had com
plications postoperatively.
In one case, the fistula was missed at
the first operation and the infant was
operated on again successfully 40 days
later. One infant had 20 episodes of
c a rd io re sp ira to ry a rrest, bilateral
pneumothoraces and an esophageal
pseudodiverticulum that had to be
resected. In this case, the level of the
fistula was cervical and the surgical ap
proach used was thoracic. This child is
well at present. The third patient had an
esophagocutaneous fistula that developed
5 days after operation. The trachea had
been perforated during operation. He had
a temporary gastrostomy; oral feeding
was restarted 2 weeks later without any
problems.
The last infant required a tracheostomy
because o f laryngeal edema that did not
respond to the usual medical treatment.
He eventually had 15 sessions of tracheal
dilatation and excision of inflammatory
granulomas. He is now well.
The infants were fed early, the majority
on the first day after operation.
Discussion
The H-type tracheoesophageal fistula
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embryologically represents the least severe
form of laryngotracheoesophageal
cleft.5,6 It is usually situated at the
thoracic outlet. According to Lynn and
Davis,7 78% of H-type fistulas are at
high thoracic or low cervical level while
22% are close to the carina. These figures
are similar to ours.
The fistula is usually directed upwards
from the anterior aspect of the esophagus
to the posterior wall of the trachea. It
decreases in calibre as it curves superior
ly. The esophageal opening is about 1 cm
lower than the tracheal opening (Fig. 1).
The clinical picture is characterized by
paroxysms of cyanosis, coughing and
choking precipitated by feeding. Other
features are less constant and include ab
dominal distension, hypersalivation and
aspiration pneumonia.
Although the diagnosis of this anoma
ly may be difficult and delayed, it is made
in the first year of life in 80% of
patients,8 as it was in all ours. H-type
fistulas have been reported in adults,911
the oldest being 63 years.
Esophagography with cinefluoroscopy,
image intensification and video tape
recording is the initial diagnostic study.
But it often must be repeated.
Endoscopy is an important aid to
diagnosis,12 especially if the esophagogram is normal. At tracheoscopy, the
fistula appears like a crater. During this
procedure, methylene blue can be instill
ed into the trachea and seen to pass into
the esophagus. The reverse injection can
be made as well. At endoscopy, the fistula
can be catheterized with a Fogarty

catheter, which facilitates identification
at operation and allows for very limited
dissection.12 This was done twice in the
series of Gans and Johnson12 and more
frequently for other recurrent trache
oesophageal fistulas. It has been found
useful.
A simple method of diagnosing and
locating the level of the fistula is to ad
vance a firm catheter down the esophagus
while its other end is immersed in water.
When the catheter tip arrives at the level
of the fistula, air bubbles can be seen in
the water. This is more evident if the child
is being ventilated or is crying.
The presence of air in the esophagus
seen on pulmonary roentgenograms sug
gests an H-type fistula.13 Korones and
Evans14 and Powers15 have diagnosed Htype fistulas by measuring the intragastric
oxygen concentration.
Surgical treatment should not be at
tempted unless the fistula has been clear
ly demonstrated. The cervical approach
is always the first choice for fistulas
situated at or above the level of T2. The
thoracic approach is indicated for lowlying fistulas. A cervical approach may
be done from both sides but it is impor
tant to emphasize that: (a) catheterization
of the fistula is very helpful, (b) minimal
dissection is essential, (c) dividing the
fistula close to the esophagus is desirable
to keep a good tracheal cuff that is easy
to close, (d) if possible without further
dissection, muscle or pleura should be in
terposed between the closed fistula
orifices, (e) drainage of the wound is
necessary and (0 the vocal cords should
be checked at the end of the procedure.
Complications of surgical treatment are
less frequent with the cervical approach.
Thoracotomy for a high-level fistula may
be followed by disastrous complications.
In the series reported by Johnston and
Hastings,16 two thirds of the patients
had complications, half of them being
recurrent laryngeal nerve lesions. No such
lesion was encountered in our series.
Pneumonia and postoperative atelectasis
are the main causes of operative death.
In the series reported by Bedard and
associates,8 25% of patients had airway
obstruction that sometimes required
tracheostomy.
Recurrence of the fistula is infrequent
but one could be missed at the first
operation.

Conclusions

FIG. 1—Lateral roentgenogram with con
trast material showing area of fistula between
esophagus and trachea (arrow).

The diagnosis of an H-type
tracheoesophageal fistula can be difficult.
Its treatment is simple and the long-term
prognosis is excellent but the operative
morbidity is considerable.
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Segmental Infarction of the Greater Omentum:
a Cause of Acute Abdomen in Childhood
Segmental infarction of the greater
omentum is an unusual cause of acute
abdominal pain in children. Over 30
years at the Hospital for Sick Children in
Toronto, this entity was encountered
nine times. All children complained of
right lower quadrant pain. They were
tender in that area and were thought to
have acute appendicitis. At operation,
the appendix was found to be normal in
all and an area of infarcted omentum
was identified as the cause of the acute
illness. Torsion of the infarcted omentum
was noted in four cases. Excision of the
omentum was curative.
L'infarctus segmentaire du grand epi
ploon est une cause inhabituelle de douleur abdominale aigue chez I'enfant. En
30 ans, cette entite fut rencontree neuf
fois au Hospital for Sick Children de
Toronto. Tous les enfants se plaignaient
d'une douleur au cote inferieur droit.
Cette region etait sensible et le tableau
suggerait une appendicite aigue. A I'operation, on retrouva dans tous les cas un
appendice normal et on identifia comme
cause des douleurs aigues, une region
infarcisee de I'epiploon. Une torsion de
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I'epiploon infarcise fut observee dans
quatre cas. L'excision de I'epiploon
amena la guerison.

Omental infarction is an unusual cause of
acute abdominal pain in children. The
symptoms are similar to those seen in
acute appendicitis and the correct
diagnosis is usually made only at opera
tion. The purpose of this study was to
determine from our experience the clinical
and pathologic features of this unusual
condition and to draw conclusions about
appropriate methods of management.
Previous authors1'24 have described
two types of infarction, that with torsion
and that without. Since there is little
evidence for any real difference between
the two types, we have chosen to sum
marize our experience collectively.
Patients and Method
A review of the medical records at the
Hospital for Sick Children in Toronto for
the 30-year period 1951 to 1981 uncovered
nine children (five boys, four girls) with
omental infarction. They ranged in age
from 4 to 15 years (mean 7.8 years); six
of them were in the age range 4 to 6 years.
The history, physical, laboratory and
operative findings, pathologic features
and results of treatment were reviewed.
The following case report summarizes the
course of the most recent patient in the
series, and is typical of the group as a
whole.
Case Report
A 4-year-old girl had a 1-day history of inter

mittent abdominal pain in the right lower
quadrant. She was nauseated but had not
vomited and had had a single loose stool. She
said that it hurt to move about and appeared
to be in pain. She was afebrile. Her pulse rate
was 112 beats/min. Tenderness, guarding and
rebound tenderness were noted in the right
lower quadrant. No mass was palpable and no
abnormality was found on rectal examination.
Bowel sounds were slightly increased. Her
hemoglobin was 11.7 g/dl; leukocyte count was
11.9 x 109/1; urinalysis gave normal results.
An abdominal roentgenogram revealed a few
air-fluid levels in the right lower quadrant.
Acute appendicitis was diagnosed.
At operation, the appendix was normal, but
a 9 x 5-cm mass was found in the right side
of the omentum, adjacent to the appendix. It
was firm, nodular, hemorrhagic and necrotic.
There was no torsion of the omentum and no
free fluid in the abdomen. No other abdominal
abnormality was noted. The appendix and the
omental mass were excised. Microscopic
examination of the appendix revealed mild
serosal reaction. The omental specimen showed
acute and chronic inflammation, vascular con
gestion and fat necrosis. A portion of the
omental specimen was sterile. The post
operative course was uncomplicated and the
child was discharged from hospital 4 days after
the operation. She was well at follow-up 1
month later.

Patient Data (Table I)

History
The duration of symptoms was 1 or 2
days in all children, except for one who
had intermittent pain over a period of 7
days. The presenting complaint of all
children was pain in the right lower
quadrant. Five patients had fever, but the
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highest temperature was only 38.3°C. Six
had anorexia although nausea or
vomiting, or both, was noted in only
three. Loose stools were also noted in
three. No child gave a history of trauma.
Physical Findings
Tenderness in the right lower quadrant
was noted in every child. Guarding was
present in seven, and rebound tenderness
in four. Four had tenderness on rectal ex
amination. A mass was not noted in any
child, either on abdominal or rectal ex
amination. Bowel sounds were not
decreased in any patient.
Laboratory Findings
Hemoglobin values and findings on
urinalysis were normal in all children.
Leukocyte count ranged from 8.5 x
109/1 to 19.3 x 109/1 (mean 13 x
109/1). In seven of the nine children, the
leukocyte count was greater than 10 x
109/1. A weight was recorded on the
chart of seven children and the mean
weight for age percentile was 71. In five
of the seven, the weight was appreciably
above the 50th percentile.
Operative Findings
Except for one patient who was observ

ed overnight, operation was undertaken
within a few hours of admission. The
preoperative diagnosis in all was acute ap
pendicitis. At operation, the appendix
was noted to be normal or minimally in
flamed. All children had a mass in the
right side of the omentum. It varied in
dimension from 3 to 11 cm. The mass was
variously described as “ hemorrhagic” ,
“ n ecro tic” ,
“ in fa rc te d ”
and
“ gangrenous” . It was found to be loose
ly attached to bowel in three cases. Tor
sion was noted specifically in four. In the
other five cases, no cause could be deter
mined. Free abdominal fluid was found
in five of the nine cases. In two of these,
bloody fluid was noted. All children were
treated by appendectomy and resection of
the omental mass. No additional abnor
malities were found.
Clinical Course
The postoperative course was un
complicated in seven patients. They were
discharged from hospital 3 to 7 days
postoperatively (mean 5.7 days). One
child had pneumonia in the postoperative
period and was hospitalized for 14 days;
another had a wound infection and stayed
in hospital for 12 days. The mean
hospitalization for all children was 7.3
days. All were well at follow-up 1 month
after discharge.

Microscopic Examination
The typical omental mass was describ
ed as exhibiting acute and chronic inflam
mation, hemorrhage and fat necrosis. The
appearance was similar in those with and
without torsion. No intrinsic lesion was
found in any of the omental specimens.
Fluid or a sample of the mass, or both,
was taken for bacterial culture in four
cases, but there was no growth in any.
Virus isolation was not attempted. Except
for minimal serosal reaction in three
cases, the removed appendices were
unremarkable.
Discussion

Credit for the description of idio
pathic omental infarction has been attri
buted to Bush (1896)1 and Eberts
(1920).2 The entity has been reported in
136 cases, mostly adults. There does not
appear to be a predilection for either sex.
In 1899, Eitel3 first described primary in
farction of the omentum associated with
omental torsion. An additional 218 cases
have been reported.4 Most affected pa
tients have been adults and males have
slightly outnumbered females. The first
cases of infarction of the omentum in
children were reported by Barsky and
Schwartz5 in 1937 and by Schottenfeld
and Rubinstein6 in 1941. In an excellent

_____________ Table 1-Patient Data in Nine Children with Omental Infarction (1951 to 1981)
Weight,
Duration
kg
of
Case Age,
(percentile symptoms,
no. yr Sex for age)
d

Presence of
--------------------------------------Nausea
and
Fever vomiting Torsion
Fluid

Time
0f gjs.
Leukocyte
count,
X 109/l Operative findings

1

5

M

N/A

1

Yes

No

Yes

Yes

8.5

2

6

F

20 (40)

2

Yes

No

No

No

16.0

3

4

F

24 (99)

2

Yes

No

No

Yes

19.3

4

11

F

N/A

1

No

No

No

No

14.5

5

6

M

17 (10)

2

Yes

No

Yes

Yes

13.6

6

5

M

25 (95)

7

Yes

Yes

Yes

Yes

9.5

7

15

M

72 (95)

1

No

No

Yes

No

12.1

8

14

M

57 (80)

1

No

Yes

No

Yes

11.8

9

4

F

18 (801

1

No

Yes

No

No

11.9

__________

4-cm mass of
twisted omentum
3 X 2 cm mass of
infarcted
omentum
5-cm mass of
gangrenous
omentum at
tached to ileum
4-cm mass of in
farcted omentum
adherent to
cecum
6-cm mass of ne
crotic omentum
3 X 2-cm mass
of infarcted
omentum at
tached to cecum
6 X 2-cm mass of
infarcted
omentum
11-cm mass of ne
crotic omentum
with hemorrhage
9 X 5-cm mass of
necrotic omentum
with hemorrhage

Pathologic features
Inflammation, fat
necrosis
Inflammation,
hemorrhage, fat
necrosis
Inflammation, fat
necrosis, infarc
tion. Sterile
culture
N/A

Hospital
course
Un
complicated
Un
complicated

charge
postop,
d
7
3

Un
complicated

6

Un
complicated

7

Inflammation,
hemorrhage
Inflammation, fat
necrosis. Sterile
culture

Un
complicated
Un
complicated

7

Hemorrhage, fat
necrosis

Wound
infection

12

Inflammation, cel
lular debris.
Sterile culture
Inflammation, fat
necrosis, con
gestion. Sterile
culture

Pneumonia

14

Un
complicated

6

4

N/A = not available.
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review of the subject, Perry7 collected 13
cases from the literature. We have found
29 additional cases.8'23 This report of
nine cases brings the total number of
published cases in childhood to 52. Of
these, only 20 have been associated with
torsion.
Since the earliest description of omen
tal infarction, most writers have gone to
great length to distinguish between infarc
tion with and without torsion. There
seems to be little evidence, however, to
support the idea that they are distinct en
tities. Our nine cases certainly presented
as a homogeneous group. The pathologic
features were similar in all and there was
no histologic evidence to support the con
cept that infarction was a result of tor
sion. Perhaps torsion followed infarction,
or perhaps it was intermittent.
Many theories have been offered to ex
plain the occurrence of omental infarc
tion. Trauma has been implicated,
although this was not a cause in our
series. Infection, likewise, does not ap
pear to be a cause. None of our patients
exhibited any evidence of vasculitis,
polycythemia or cardiac disease and none
was taking any medication. Some23 have
theorized that vascular or developmental
anomalies of the omentum, or both,
cause (or predispose to) infarction. We
could find no evidence that such a malfor
mation played any role in our series.
Obesity has been mentioned as a possi
ble predisposing factor, since many in
stances of the condition have occurred in
overweight p atien ts. It has been
postulated that the large size of the omen
tum in the obese patient places it at
greater risk of infarction. Our findings
lend some support to this association. Of
the seven patients for whom data were
available, the weight in five was above the
80th percentile for age and in three it was
above the 95th percentile.
Of all reported cases, 23% (32 of 141)
of cases with idiopathic segmental infarc
tion and 9% (20 of 222) of cases with in
farction associated with torsion occurred
in childhood. Although the number of
cases is smaller in children, it is uncertain
whether the actual risk is any less. Dur
ing the 30 years over which our nine cases
of omental infarction were seen, approx
imately 7200 cases of acute appendicitis
were also treated at our hospital, a ratio
of 1:800. It is easy to understand,
therefore, why the diagnosis was not
made preoperatively in any case in our
series.
In our experience and that of others,
the clinical picture of omental infarction
(with or without torsion) usually mimics
appendicitis. The diagnosis should be
kept in mind, especially when a normal
appendix is found at operation for appen
dicitis, or when a patient with abdominal
pain has already undergone appendecto
my.

We and others have managed omental
infarction successfully by resecting the in
volved omentum. Extensive abdominal
exploration does not appear to be
necessary when omental infarction is en
countered in childhood. Removal of the
infarcted tissue probably expedites
recovery, although there have been
reports of a favourable outcome when the
infarcted area is left in situ. Furthermore,
it is likely that other patients with un
diagnosed omental infarction have
recovered without treatment. Incidental
appendectomy appears safe and is recom
mended in all cases.
Recovery in the absence of complica
tions is usually prompt and is comparable
to that from acute appendicitis. Serious
complications have, however, been
reported, and at least one adult has died
of sepsis due to infarction o f the
omentum.24
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Conclusions
Omental infarction (with or without
torsion), which usually mimics appen
dicitis, is an unusual cause of abdominal
pain in childhood — 1 in every 800 cases
of childhood appendicitis.
The frequency of this condition in
children is similar to that in adults.
The two entities, infarction with torsion
and without, are not necessarily distinct.
Although obesity is a likely predispos
ing factor, the true cause of omental in
farction remains unclear.
The clinical course of the disease is vir
tually indistinguishable from acute appen
dicitis. The diagnosis of omental infarc
tion should be considered when a normal
appendix is found at operation, or when
a child with abdominal pain has previous
ly undergone appendectomy.
Resection of the involved omentum
with appendectomy should be curative.
Smooth recovery can be expected,
although postoperative complications, in
cluding death, have been reported.
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Hypoglycemia Associated with Pediatric Surgical Procedures
Hypoglycemia, a plasma glucose level
below 2 .2 mmol/l, was noted
perioperatively eight times in association
with 61 operative procedures performed
on 46 infants. It was most common in
children with complications of neonatal
necrotizing enterocolitis. It was related
to grossly inadequate caloric intake
perioperatively and was associated with
increased mortality. Because the glucose
requirement of the infant brain is high,
cerebral damage must be seriously con
sidered in infants with hypoglycemia
postoperatively.
Une hypoglycemie peri operatoire avec
glycemie inferieure a 2.2 mmol/l a ete
observee a huit reprises sur un total de
61 interventions chirurgicales pratiquees
chez 46 bebes. Elle etait plus frequente
chez les jeunes patients souffrant de
complications d'une entero-colite necrosante. Elle etait reliee a un apport calorique nettement insuffisant dans la periode
peri-operatoire et une mortality accrue y
etait associee. Comme les besoins en
glucose du cerveau sont eleves chez le
nourrisson, on doit envisager serieusement la possibility de dommages cerebraux en cas d'hypoglycemie.

Very little has been published on the sub
ject of hypoglycemia in children undergo
ing
o p e ra tio n ,1
and
because
hypoglycemia is not usually a problem in
such children after the neonatal period,
we do not routinely measure their blood
glucose levels. However, we encountered
two infants with marked hypoglycemia
after operation. One, 3 Vi weeks old, had
unrecognized Hirschsprung’s.disease and
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severe enterocolitis. The other, 5 months
old, had a delayed diagnosis of in
tussusception and bowel rupture. These
findings led us to investigate infants in
our neonatal intensive care nursery who
had undergone operation, and in whom
blood glucose studies are routinely done,
to see if hypoglycemia was a problem.
Patients and Methods
Forty-six children who underwent 61
operative procedures were studied
retrospectively. The incidence and level of
hypoglycemia were recorded as it occur
red preoperatively, on the day of opera
tion and postoperatively. Plasma glucose
levels below 2.2 m m ol/l were considered
abnormal.2 The diagnosis, weight, age,
oral fasting period, surgical procedure
and intravenous nutritional intake were
noted. Initial glucose levels were
measured by Dextrostix and any abnor
mality was investigated by direct blood
estimation. All estimations were of
plasma glucose. All specimens were plac
ed in ice before transfer to the laboratory
and were immediately centrifuged on ar
rival there to decrease risk of glucose
utilization by red blood cells. Sodium
fluoride was not used to prevent
glycolysis.
Results
The relatio n o f perioperative
hypoglycemia to the surgical diagnosis is
noted in Table I. Six children died. Four
of the 7 children (8 procedures) who had

hypoglycemia died, while only 2 children
out of 39 without hypoglycemia (53 pro
cedures) died.
When the diagnosis was related to the
incidence of hypoglycemia, babies with
neonatal necrotizing enterocolitis con
stituted the largest group. The patient
with gastroschisis and perioperative
hypoglycemia died of bronchopulmonary
dysplasia many months later. He had
hypoglycemia perioperatively on two oc
casions, once in association with the
gastroschisis and later associated with a
strangulated inguinal hernia. The child
with transposition of the great vessels died
2 weeks after operation but was nor
moglycemic at the time.
The diagnosis, age, weight and
operating time of children who had
hypoglycemia are set forth in Table II.
Patient no. 2 with neonatal necrotizing
enterocolitis underwent operation on the
second day of life. The others were
operated on for complications of neonatal
necrotizing enterocolitis, such as obstruc
tion, or for neonatal necrotizing
enterocolitis occurring much later, as in
patient no. 3. There was no evident rela
tion between age, weight or operating
time in these children. Plasma glucose
levels were studied in relation to the time
of surgery (Table II). The degree of
hypoglycemia was often profound, and
it sometimes recurred after apparently
adequate treatment. In patient no. 3,
hypoglycem ia developed during a
preoperative exchange transfusion for
disseminated intravascular coagulation.

Table 1-Relation between Hypoglycemia Perioperatively and Diagnosis

Diagnosis
Neonatal necrotizing
enterocolitis (NEC)
Gastroschisis-omphalocele
Transposition of great
vessels
Diaphragmatic hernia
Hydrocephalus/meningomyelocele
Imperforate anus
Tracheoesophageal fistula
Other

No. of
patients
(n - 461

No. of
procedures
In = 61)

No. of
instances of
hypoglycemia
(n = 8)

13
5

17
15

5
1

7
5
4
4
1
7

8
5
4
4
1
7

1
0
0
0
0
1
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This child also had biliary cirrhosis and
had been on intravenous alimentation for
several months. At operation, widespread
neonatal necrotizing enterocolitis was
found. The child was hypoglycemic on
the day of operation and the day after.
This patient died 1 year later of biliary cir
rhosis. Patient no. 7 underwent a
Mustard procedure for transposition of
the great vessels. While hypoglycemia oc
curred most commonly on the day of
operation, in three cases it did not occur
until 2 days later.
The operative procedures done in the
five children with necrotizing enterocolitis

many others, full intravenous alimenta
tion is usually stopped on the day of
operation and is restarted on day 2 or 3
after operation to give better control of
fluid and electrolyte balance. From the
figures in Table IV, it is clear that caloric
intake was grossly inadequate.
Similar estimations of caloric intake
and needs were calculated for the remain
ing eight children operated on for
neonatal necrotizing enterocolitis who did
not become hypoglycemic. To our sur
prise, the ratio of calories supplied to
caloric need did not differ substantially
from that in the five children with severe

and hypoglycemia are shown in Table III;
they were the same as those performed in
the remaining eight patients with neonatal
necrotizing enterocolitis who remained
normoglycemic, so there seems to be no
relation between the operative procedure
used and development of hypoglycemia.
The number of calories given by all
routes, in the perioperative period and
while in our hospital, were calculated for
the five hypoglycemic children with
neonatal necrotizing enterocolitis and for
patient no. 6 who was operated on for
gastroschisis and strangulated inguinal
hernia (Table IV). In our hospital, as in

Table II—Children Who Had Hypoglycemia
Plasma glucose levels, mmol/lt

Weight at
operation, g

NEC
NEC
NEC

Age at
operation, d
60
2
221

1940
3720
3000

Operating
time, min
120
180
45

4

NEC

34

860

70

2.4

5
6*

NEC
Gastroschisis
Strangulated
inguinal hernia

36
1

1440
740

60
90

-

41

1190

90

0 .9 -1 .8 1.8-2.6

Transposition of
great vessels

340

8400

240

Patient
no.
1
2*
3*

7'

Diagnosis

-1
—
-

-

+1

0

1.4
0 .6 -0 .6 0 .6 -1 .7
1.6

—

1 .8 -1 .4 (preop)
2 .2 -1 .1 -0 .8 -1 .1
(preop), 0.3 (postop)
1 .2 -1 .4 (preop), 3.0
(postop)
—

1.4 (preop)
0 .9 -2 .4 -2 .6 (postop)

+3
—

+2
2.1
—

—

“

—

1.0

—
0 .5 -1 .8 2.1

2.0

—

3.2

—

0.3

1 .4 -1 .9

—

—

'Died.
t - - days before operation, + - days after operation.

Table V-Comparison of Basal Daily Glucose Need
and Total Caloric Requirement_________

Table Ill-Procedures Performed in Children
with Necrotizing Enterocolitis
Who Had Hypoglycemia
Patient
no.

Procedure
Right hemicolectomy
Bowel resection, ileostomy
Laparotomy and liver biopsy
Two previous bowel resections.
Insertion of central line
for alimentation
Hemicolectomy for focal perfor
ation and widespread damage

i
2
3
4
5

Patientno.
-2
i
2
212
3

Intake, Cal*
+1

150

0
69
13
71

24
11
27

-1

_
__

4

-

13

23

5
6

__

83

25
23

-

50
26
94

Patient
no.
1
2
3
4
5
6

Basal daily glucose
requirement (6 mg/min • kg^1),
g (Cal)
16.7 (57)
32 (109)
25 (88)
7.4 (25)
12.4 (42)
6.4 (22)
10.3 (35)

Table IV—Relation of Actual Caloric Intake to Calculated
Caloric Needs and Incidence of Hypoglycemia
Daily caloric
Plasma glucose
requirements at
0
rate of 115 Cai/kg
+2
+3
223
100
—
—
1 .8 -1 .4 (preop)
428
2 .2 -1 .1 -0 .8 -1 .1
345
—
(preop), 0.3 (postop)
1 .2 -1 .4 (preop), 3.0
100
78
(postop)
—
165
37
69
1.4 (preop)
85
55
40

51
77
33
33
* - - days before operation, + - days after operation.

137

0 .9 -2 .4 -2 .6 (postop)
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Daily caloric
need at rate
of 115 Cal/kg
223
428
345
100
165
85
137

Patient
weight, g
1940
3720
3000
860
1440
740
1190

levels, mmol/l*
+1
1.4
0 .6 -0 .6 0 .6 -1 .7
1.6

+2
2.1
—

+3

—

—

—
0 .5 -1 .8 2.1
—

2.0

—

1.0
-

3.2
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hypoglycemia. There were no important
weight or age differences between the two
groups.
We consider 115 Cal/kg to be the op
timal daily caloric requirement of
stressed children under 1 year of age who
undergo operation. The healthy infant’s
basal need for glucose is usually taken as
6 to 8 mg/min-kg
in the steady state
to ensure adequate cerebral nutrition.3
Brain, erythrocytes and renal medulla can
utilize only glucose and ketones. Calcula
tion of glucose requirements and com
parison of these with the total caloric
needs in a stressed surgical patient in
dicate that the glucose requirement may
be as much as 21 m g/m in-kg^1 (Table
V). Repair and growth require fat and
protein. A central route of administration
is essential to achieve these goals.
Discussion

A blood sugar value below 2.2 mmol/1
in the first 4 weeks of life is usually ac
cepted as constituting hypoglycemia in
full-term infants. Within 2 hours of
delivery, the blood sugar level normally
decreases to about 2.8 mmol/1 and then
rises to about 3.9 mmol/1 by 72 hours of
age, after feeding has begun. Thereafter,
adult levels are reached provided
metabolism is normal and nutrition ade

quate. It rarely falls below 1.7 mmol/1.
In infants with a low birth weight, little
is known of the blood sugar values in the
first few hours. Before feeding it may fall
to 1.1 mmol/1 or less. After feeding it
rises to about 2.8 mmol/1. After that it
rarely falls below 1.1 mmol/1. Regulation
of neonatal carbohydrate metabolism is
poorly developed. Neonatal hypogly
cemia may be secondary to increased
plasma insulin levels, diminished produc
tion of hepatic glucose, inadequate caloric
intake and decreased storage of liver
glycogen.
• Increased plasma insulin concentra
tion due to disorders of the islet and B
cells most commonly occurs in the infant
with a diabetic mother. It is also seen in
hemolytic disease of the newborn, discrete
islet cell adenoma, nesidioblastosis and
adenomatosis. It may also be associated
with maternal use of medications that
stimulate both the maternal and fetal B
cells (e.g., chlorpropamide, as used in
diabetes, and benzothiadiazide diuretics).
Salicylates may also cause neonatal
hypoglycemia as does congenital adrenal
hyperplasia.
• Diminished hepatic glucose produc
tion may result from either inadequate
control with enzymatic, neural and hor
monal inadequacy or a diminished

availability of hepatic glucose substrate
as in premature infants (AGA), small for
gestational age infants (SGA), neonates
with congenital heart disease, sepsis, and
perinatal stress or anoxia, or both. In
none of our infants were maternal
diabetes or medications factors. Only two
patients (nos. 2 and 6) were operated on
in the first few days of life. The rest were
operated upon outside the neonatal
period. Weight of the children at the time
of operation varied from 740 g to 8400
g and so was not a constant factor.
• The largest group of hypoglycemic
patients were the five with acute and
chronic neonatal necrotizing enterocolitis.
They had in common, stress, continued
poor nutrition and sepsis. Review of their
perioperative caloric intake shows that it
was grossly inadequate. Surprisingly, the
caloric intake of the eight normoglycemic
children with neonatal necrotizing
enterocolitis was also inadequate and was
no different from that in the five
hypoglycemic patients. There were no
significant weight differences in the two
groups. The inadequate caloric intake was
in major part due to difficulties in main
taining peripheral intravenous lines.
These had been used for up to 60 days
before operation. A central line was us
ed preoperatively in only one case. Re-
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bound hypoglycemia was not, therefore,
a factor in our cases. We believe the con
cept of discontinuing the adminstration
of intravenous amino acids and fats in the
perioperative period when peripheral lines
are used to be erroneous. Adequate
caloric intake with glucose solutions alone
in peripheral lines is not possible and is
not practical using central lines because
glucose utilization is limited and protein
and fat are also needed.
• Liver glycogen storage in the fullterm neonate is high during the first 6
hours of life (8 to 18 g/100 g wet
tissue).4 Indeed, it is higher than at any
other time of life. While glycogen is
stored in the liver by 9 to 10 weeks’ gesta
tion, there is little information as to its
further deposition after the 20th week,
and so in the small (AGA and SGA) in
fant less is known of liver glycogen
storage than in the full-term infant.
Presumably it is much less. Assuming that
the liver weighs approximately 1/30 of the
total body weight of the infant, we have
calculated that the liver glycogen store of
a 3000 g baby will be 13 g. If the liver
glycogen is fully utilized, this store will
provide sufficient calories (45 Cal) for on
ly 3 hours in the stressed infant, whose
daily caloric requirements are 345 Cal.
Any diminution of the infant’s liver

glycogen store through prematurity,
stress, starvation or infection will decrease
the available supply below the already
small reserve. The infant, and especially
the neonatal, brain can utilize only
glucose and ketones, and ketones can on
ly be used to a very limited degree. The
capacity of the neonatal brain to oxidize
ketones is much higher than that of the
infant brain. Both neonates and infants
can oxidize four to five times as much
ketones as can adults. The infant brain
is relatively six times larger than the adult
brain and so its glucose needs are much
greater. Brain damage has been reported
in infants with blood glucose levels below
1.7 mmol/1.5

travenous lines and the difficulty and
risks of inserting a central line in small,
stressed and often infected patients.
Full intravenous alimentation should
be maintained perioperatively in these pa
tients. Fat and protein must be given as
well as glucose because of the great
demands of brain, renal medulla and
blood cells for glucose. A central line
should be used if possible.
The implications of hypoglycemia for
gross and minor cerebral damage must be
considered seriously and the child follow
ed up on a long-term basis.
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Conclusions
The occurrence of perioperative
hypoglycemia in children under 1 year of
age is not related to age, maturity, weight
or operative procedure. It is related to
gross inadequacy of caloric intake in the
perioperative period, although com
parison between hypoglycemic and
nonhypoglycemic patients revealed no
difference in the degree of the inadequacy
of the caloric intake. The inadequacy of
caloric intake is probably related to the
peripheral route of administration, the
difficulty of maintaining peripheral in
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Persistent Fetal Circulation in Neonates Postoperatively:
the Value of Manual Ventilation
Three critically ill infants who had persis
tent fetal circulation postoperatively,
retractile to tolazoline and 100% oxygen
with mechanical ventilation including
continuous positive airway pressure,
responded favourably to prolonged
manual hyperventilation. Two infants had
undergone repair of a diaphragmatic her
nia and the third had correction of a
tracheoesophageal fistula. Normal
respiratory function was documented in
two survivors. The third died 14 days
postoperatively. The use of this simple
technique indicated that perseverance
can be rewarded in the treatment of per
sistent fetal circulation unresponsive to
the usual medical management.

persists after birth. Normal fetal right to
left cardiac shunts, such as the foramen
ovale and the ductus arteriosus, remain
functional and deoxygenation of systemic
hemoglobin follows. By definition, per
sistent fetal circulation excludes any
known congenital cardiac anomalies.
This report describes three newborns
with persistent fetal circulation unrespon
sive to the accepted management but
responsive to prolonged periods of
manual hyperventilation (hand bagging).

Les trois nouveau-nes dont I'etat postoperatoire immediat etait critique ont
repondu favorablement a I'hyperventilation manuelle prolongee alors que leur
circulation fetale refractoire n'avait pas
ete influencee par la tolazoline ainsi que
la ventilation mecanique a I'oxygene pur
y compris CPAP. Deux des nourrissons
avaient ete operes pour hernie
diaphragmatique tandis que I'autre avait
subi une cure de fistule tracheoesophagienne. Le bilan respiratoire redevint normal chez les deux des trois qui
se sont retablis; le troisieme deceda 14
jours apres I'intervention. En utilisant
cette methode facile, nous avons demontre que la perseverance peut etre
recompensee en traitant ceux dont la cir
culation fetale ne repond pas aux
mesures ordinaires.

An infant weighing 3.14 kg had Apgar sco
res of 3 and 5. Rapidly increasing respiratory
distress was treated by intubation and ventila
tion with a fractional intake of oxygen (F,o2)
of 1.0. The oxygen tension of arterial blood
(Po2) was 37 mm Hg, the carbon dioxide ten
sion (Pco2) 83 mm Hg and the pH 7.02. The
clinical diagnosis of left diaphragmatic hernia
was confirmed by roentgenography. The defect
was immediately repaired surgically. During
the postoperative period, despite mechanical
ventilation and infusion of tolazoline, the
preoperative abnormalities remained, in
dicating persistent fetal circulation. This could
be corrected only by manual ventilation (hand
bagging). Unfortunately, the baby had an in
traventricular hemorrhage and died on the 14th
postoperative day.

Persistent fetal circulation or pulmonary
hypertension describes a condition in
which high pulmonary vascular resistance
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Case Reports
Case 1

Case 2
This 1.72-kg male infant was born at 32
weeks’ gestation after prolonged rupture of the
membranes. The delivery was otherwise
uneventful. Apgar scores were 7 and 8. The
baby was noted to have an esophageal atresia
with tracheoesophageal fistula and
genitourinary anomalies. In the delivery room
the child was cyanotic. The F,o2 of 0.8 pro
duced an arterial blood Po2 of 83 mm Hg. An
urgent gastrostomy was performed under local
anesthesia at the referring hospital. During the
second stage repair of the esophageal atresia,
the baby became severely cyanotic with brady
cardia. The arterial Po2 was 8 mm Hg, the
P co2 was 90 mm Hg and pH 6.9. The opera
tion was terminated after dividing the fistula.
Mechanical ventilation with an F,o2 of 1.0
failed to correct the fetal-type circulation. The
addition of a tolazoline infusion and con

tinual hand bagging for 48 hours corrected the
circulatory abnormality. The esophageal defect
was electively repaired later and the baby was
discharged.

Case 3
This 3.0-kg infant was born after 41 weeks’
gestation. The mother’s pregnancy, labour and
delivery were normal. Apgar scores were 3 and
7. A clinical and radiologic diagnosis of a
Bochdalek hernia was made. The defect was
immediately repaired. Postoperatively, the
course was complicated by hypoxia and per
sistent fetal circulation. Treatment with
tolazoline was discontinued because of
gastrointestinal bleeding. Satisfactory oxygena
tion could be obtained only by hand ventila
tion for periods of 30 minutes to 8 hours. Nor
mal pulmonary circulation returned and he was
discharged well at 10 weeks of age.

Discussion
Persistent fetal circulation was first
described by Gersony and associates1 in
1969. They presented two patients in
whom fetal circulation continued in the
absence of preexisting cardiac, pulmonary
and central nervous system disease. No
anatomical cause of death could be found
but the ductus arteriosus and the foramen
ovale were patent.
Rudolph2 has classified the causes of
persistent fetal circulation etiologically in
to three groups: group 1 — an acute in
crease in pulmonary vascular resistance
after birth, such as occurs in meconium
aspiration syndrome3 or hyperviscosity
syndrom e;4 group 2 — increased
prenatal development of pulmonary
vascular smooth muscle as seen in chronic
fetal hypoxia, intrauterine growth retar
dation or the administration of an
tiprostaglandins during pregnancy5 and
group 3 — an anatomical deficiency in the
total number o f pulmonary vessels as
found in association with congenital
diaphragmatic hernia.6
The final common pathway, however,
is increased pulmonary vascular resistance
leading to pulmonary hypertension.
Liljestrand7 suggested that hydrogen ion
concentration is the chemical stimulus for
vasoconstriction and that hypoxia pro
bably acts by promoting the release of lac
tic acid. Alkalosis appears to protect
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against the vasoconstrictive effects of
hypoxia. Drummond and associates8
claim that in persistent fetal circulation,
a pH greater than 7.60 results in impor
tant increases in arterial oxygenation.
The management of persistent fetal cir
culation has been directed towards
decreasing pulmonary hypertension and
correcting arterial blood-gas abnor
malities. Decrease in Pco2 and increase
in Po2 with correction of pH uniformly
reduce pulmonary vascular resistance
(Fig. 1). Thus, in persistent pulmonary
hypertension, vigorous therapy, using
mechanical ventilation with an F,02 of
1.0, correction of blood electrolyte, glu
cose, calcium and viscosity abnormalities
and infusion of chemical pulmonary
vasodilators, attempts to correct the fetal
circulation.9'10 Despite all treatment, the
condition of these infants often deterio
rates and the mortality has been repor
ted as high as 70%.11
In our three infants, manual ventilation
was carried out more than 48 times for
an average of 47 minutes each time (range
from 3 minutes to 8 hours). The mean
change in Po2 was 38 mm Hg, in Pco2
25 mm Hg and in pH 0.22 (Figs. 2 to 4).
Why does manual ventilation seem to
be more effective than mechanical ven
tilation? Positive-pressure ventilation in
creases intrathoracic pressure, decreases
venous return and pulmonary blood flow
and at the same time increases transmural
pressure, increasing pulmonary vascular
resistance. Simbruner and Gregory12
demonstrated that different ventilators re
quire different lengths of time to achieve
the desired respiratory volumes at set
pressures. Because expiratory times are
ventilator-dependent, the less the com-

pliance the greater is the impairment of
expiration. Gas trapping becomes a pro
blem with shorter cycle length. Ven
tilators cannot give constant volumes
when the compliance and resistance
change.
The ideal ventilator can deliver the op
timal volume with minimal pressure. It
can maintain that pressure within the lung
for the shortest time possible. It can be
varied from breath to breath. Hyperven
tilation is achieved while effects on
pulmonary flow are minimized. Our three
neonates with persistent fetal circulation
seemed to demonstrate that manual ven
tilation more closely approximates ideal
artificial ventilation than do any of the
available mechanical ventilators.
Conclusions

The life-saving value of hand ventila
tion has been demonstrated in three in
fants. The neonatal surgeon must under
stand the pathophysiology of persistent
fetal circulation and institute active ear
ly treatment to reduce the high morbidi
ty and mortality. We believe that in
neonates with established persistent fetal
circulation, early intermittent or con
tinuous hand ventilation is an integral
part of management.
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Biomechanics
of Trauma Symposium
The 1st international symposium on
biomechanics of trauma will be held
Oct. 20-21, 1983 in San Diego. Cali
fornia. Further information may be
obtained from the Institute for Med
ical Education and Research. 135
Dickinson, San Diego, CA 92103.
Clinical Application
of Hyperbaric Oxygen
I The 8th annual conference on the

FIG. 1—Cycle of persistent fetal circulation.

FIG. 2—Effect of manual ventilation (hand
bagging) on mean Po2 in persistent fetal cir
culation. Triangles = case 1, circles = case 2,
squares = case 3.

FIG. 3—Effect of manual ventilation (hand | clinical application of hyperbaric oxy
bagging) on mean P co2 in persistent fetal cir
gen will be held June 8-10, 1983 at
culation. Triangles = case 1, circles = case 2,
the Memorial Hospital Medical Cen
squares = case 3.

FIG. 4—Flffect of manual ventilation (hand
bagging) on mean pH in persistent fetal circula
tion. Triangles = case I, circles = case 2,
squares = case 3.

ter, Center for Health Education,
Long Beach. California.
This clinically oriented conference
will discuss in plenary sessions the
currently accepted uses of hyperbaric
oxygen and will also include original
papers, workshops, sound slides, and
scientific and commercial exhibits.
For more information, contact: Dr.
Michael B. Strauss, Program chair
man, Baromedical department, Mem
orial Hospital Medical Center, 2801
Atlantic Ave., Long Beach. CA
90801-1428, or call (213) 595-3613.
continued on page 260
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Treatm ent of Hyperthyroidism in Children
Thirty-three children with hyper
thyroidism, an uncommon condition in
childhood, were treated at the Hopital
Ste-Justine in Montreal during the period
1961 to 1974. Of these, 31 underwent
medical treatment initially. Fifteen were
cured by medical treatment only; the
other 18 had to undergo subtotal
thyroidectomy. When these two groups
were compared the advantage of surgery
in the treatment of this disease was
clear. There were no major complications
postoperatively. Two children became
hypothyroid. The mean follow-up was 5
years and 6 months.
De 1961 a 1974, 33 enfants souffrant
d'hyperthyroidie, une affection rare chez
I'enfant, ont 6te traites a I'Hopital SteJustine de Montreal. Parmi ceux-ci,
31 ont recu initialement un traitement
medical. Quinze ont ete gueris par le trai
tement medical seul, les 18 autres ayant
a subir une thyroidectomie partielle.
Quand ces deux groupes ont ete compa
res, les avantages de la chirurgie dans le
traitement de cette maladie etaient evidents. On n'a constate aucune complica
tion postoperatoire majeure. Deux
enfants sont devenus hypothyroidiens.
La periode moyenne de surveillance des
suites therapeutiques etait de 5 ans et 6
mois.

Hyperthyroidism in children is not com
mon. O f all patients with hyper
thyroidism, 1% to 5% are younger than
18 years of age.1 However, because of its
possible effects on growth and mental
From the department o f surgery, Hopital
Ste-Justine, University de Montreal,
Montreal, PQ
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Hopital Ste-Justine, 3175 Cote SteCatherine, Montreal, PQ H3T 1C5
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development, hyperthyroidism is of par
ticular importance to the pediatric
surgeon.
The treatment of hyperthyroidism may
be medical or surgical. To our knowledge
the different modes of treatment have not
yet been evaluated in Canada.
The treatment of hyperthyroidism at
the Hopital Ste-Justine, in Montreal, be
tween 1956 and 1982 has been reviewed
and is now reported.
The results following operation con
firm the effectiveness and safety of this
type of treatment as recently reported by
Wesley and associates2 and suggest a cer
tain advantage in children for surgery
over treatment with radioactive iodine or
long-term administration of antithyroid
drugs.
Patients

Thirty-three patients (8 boys, 25 girls)
treated medically and surgically for
hyperthyroidism between 1961 and 1974
form the basis for this report.
The age of these patients ranged from
6 to 20 years (mean 12.4 years). The mean
age of patients at the time of operation
was 13.8 years.
The diagnosis of hyperthyroidism was
based on the history, physical findings
and results of laboratory tests.
All children had an enlarged, palpable
thyroid gland. The enlargement was dif
fuse in 29 and nodular in 4. The gland
varied from 1.5 to 5 times the normal size.
No correlation could be found between
the size of the gland and the severity of
hyperthyroidism.
Mild to moderate exophthalmos was
present in 85% of patients. Other findings
were tachycardia and fine tremors.
In all patients the findings of at least
three of the common thyroid function
tests, such as serum protein-bound iodine,
thyroxine, uptake of iodine-131,
triiodothyronine and thyroid-releasing
hormone levels, were abnormal. An
tithyroid antibodies were present in 18 of
the 25 patients studied, with a very high
titre in 14.
There was a family history of hyper
thyroidism in 55% of the 33 patients.
Thirty-one underwent medical treatment
initially; 2 refused long-term medical

treatment. Of these 31 patients, 16 subse
quently underwent operation; 13 because
medical therapy failed and 3 because of
agranulocytosis following medical
treatment.
Treatment and Results

Patients treated medically received
principally propylthiouracil, but carbimasol, reserpine and propanolol were
also prescribed occasionally in dosages
appropriate to the child’s age, severity of
the disease and response to treatment.
In 15 of the 31 children, medical treat
ment was successful; they remained
euthyroid after a follow-up of 5 years.
Of the 18 children (5 boys, 13 girls) who
were operated on, all were first brought
to a euthyroid state with propylthioura
cil. A few children received reserpine and
two were medically prepared for the
operation with propranolol. Iodine
therapy in the form of Lugol’s solution
was begun in each patient 2 weeks before
the operation.
Patients underwent subtotal bilateral
thyroidectomy, the surgical technique of
which is well known. Important technical
points include the visualization of the
recurrent laryngeal nerve and respecting
the blood supply to the parathyroid
glands. A cube of gland 2 or 3 cm in size
should remain in each side. It is our firm
belief that there is no indication for total
thyroidectomy.
There were no deaths, no injury to the
recurrent or laryngeal nerve and no local
complication such as hemorrhage or in
fection. One patient early in the study had
a tracheotomy because of laryngeal
edema. Today this patient would pro
bably be treated by intubation. Two
children had a transitory hypocalcemia.
Two became hypothyroid and required
m edication postoperatively. The
postoperative hospital stay was usually 4
to 5 days.
All patients have been observed post
operatively for 3 to 15 years (mean 5 years
and 6 months). There has been no recur
rent hyperthyroidism. The same results
were obtained in a further series of 26 pa
tients treated surgically for hyper
thyroidism at Ste-Justine Hospital be
tween 1975 and 1982.
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Discussion
The diagnosis of hyperthyroidism in
children is usually not a problem, but the
treatment is still controversial. In some
centres2 the initial selection of operation
or long-term antithyroid medication as
the primary treatment is determined by
the individual preference of the en
docrinologist in consultation with the
family and the patient.
A success rate of 40% to 50% has been
reported following prolonged medical
treatment.34 At the Hopital Ste-Justine
the success rate following medical treat
ment was 48%. Major complications
following medical therapy are uncommon
but are serious and potentially lethal.
Three patients had a tran sito ry
agranulocytosis which was corrected by
discontinuing the propylthiouracil.
On the other hand, there is increasing
support for operation as the primary
treatment for hyperthyroidism.5-6 It of
fers a definitive solution with minimal
failure and complication rates, and with
little or no mortality. The reported mor
tality is between 0% and 3% ,5,7 the
recurrence of the hyperthyroidism 0% to
12% and permanent hypothyroidism
from 4% to 50%.5,8,9
None of our surgically treated patients
showed any sign of recurrent hyper

thyroidism after a follow-up of 5 years.
The primary goal of the operation is to
remove enough thyroid tissue to control
the hyperthyroidism. Two patients are
hypothyroid, an 11% incidence; some
authors5,8,9 have reported an incidence of
30% even when a generous remnant of
thyroid gland is left. No correlation could
be established between the size o f the
thyroid remnant and the incidence of
postoperative hypothyroidism. Lymphoid
infiltration was greater in the thyroid
glands of patients who becam e
hypothyroid.
A few centres have proposed radioac
tive iodine as the definitive treatment; the
questions of carcinogenic and genetic
hazards for young patients are not yet
answered, and even if we eliminate these
hazards, this form of treatment is far
from ideal.10 The reported incidence of
hypothyroidism following this form of
treatment is as high as 80%11 compared
with our incidence o f 11% after
operation.
We believe that primary subtotal
thyroidectomy should be considered in
the treatment of hyperthyroidism for a
number of reasons.
• Medical treatment gives a 50%
failure rate and is of long duration.
• There is a low incidence of secon
dary hypothyroidism after operation.

• There is no mortality and no recur
rence of hyperthyroidism following
operation.
• Treatment with radioactive iodine
may have harmful side-effects in children.
• There is a high incidence of
hypothyroidism following the use of
radioactive iodine.
• The postoperative hospital stay is
short.
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Bon Mot — Reminiscence
I referred once before to Dr. J.C. A r
mour, a legend at the Royal Victoria
Hospital in Montreal even in his own day.
He was given to open, innocent remarks,
often with some sexual connotation. He
was a huge man and the usual scrub suits
could not cover his frame; he wore
specially-made operating overalls. The
cross-over flaps of the fly would open
when he leaned over the scrub-sink. When
his resident (the late, lamented I.
Shragovitch) discreetly, and in a low
voice, warned him of what might happen,
Dr. Armour bellowed, loudly and cheeri
ly, “ a dead bird never fell out of its nest” .
On rounds he would ask me, the lowly in
tern, if 1 had any problems to report.
When 1 said “ I have two things —” he
quickly cut me off and said that he was
glad I had them and to keep it that way.
Another legendary figure was Wilder
Penfield. He could wither an intern with
a look that would sink him through the
floor when he failed in a detail. With the
patient already anesthetized before ex
ploration for a possible pituitary tumour,
I was asked about his libido, an impor
tant point in the differential diagnosis. I
had no idea. For that reply I was reward-

ed with one of those icy stares. But I was
reinstated a few minutes later when I
reassured Dr. Penfield that the patient’s
libido was intact. How could I be sure?
I had run into the man’s room where his
wife was waiting and asked her.
Dr. William T. Green, my chief at the
Children’s Hospital Medical Center in
Boston, was another brilliant but tough
task-master who had no mercy on
residents, especially at grand rounds. At
lunch one day after a particularly tough
grand rounds the talk of the older men
was about the institutional meals o f the
old days when a whole turkey or a whole
salmon was carved by the chief at the
residents’ dinner table. The resident who
had suffered through that morning was
heard to murmur with as much strength
as he could muster “ today a whole resi
dent was carved by the chief” .
Bronson Crothers, neurologist at the
Massachusetts General Hospital, was
another unforgettable character. His
clinical experience was vast. When asked
whether he had ever seen a child with
multiple sclerosis, he said it was so rare
that he had seen only two and they both
turned out to have something else.

But there were other teachers who were
more forgettable, although some of their
“ teachings” are not. Did you know that
an important clue to the diagnosis of
rheumatic fever is the odour of oil of
wintergreen that was applied to the red
flannel bandages used to wrap the
inflamed joints? Did you know that the
reason why som e p a tie n ts with
rheumatoid spondylitis walk so bent over
is that their canes are usually too short?
Some of our teachers were stand-up
comics, while others rarely cracked a
smile. Lyman D u ff, p ro fesso r of
pathology at McGill, was a marvellous
teacher but always dead serious, at least
while lecturing. One class was shaken by
the single witticism that I heard him ut
ter in the 4 years that I knew him. He
described the frontal sinus o f the
acromegalic as being “ large enough to
hold a hen’s egg” . But in all his years of
searching he said he had not found a
single egg in an acromegalic sinus.
J.L. SHUGAR, MD, FRCS[C]
Senior associate editor
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An important
surgical tool:
Ensure*
complete nutrition

Protein-calorie malnutrition threatens almost 50% of
hospitalized patients '. Its consequences - slow healing,
anemia, increased susceptibility to infection, wound
dehiscence - can compromise the outcome of treatment or
surgery and even jeopardize the patient’s life.
ml

Ensure, complete nutrition for hospitalized patients
Before surgery, to help build up the patient’s strength and
immunocompetence2.

by mouth or by tube

ENSURE

After surgery, to help restore a positive nitrogen balance
and help speed recovery3.
References:
1. Bistrian BR et al. JAMA 1976; 235:15. 2. Chandra RK et al. Nutrition Research 1982;2:223-232
3. Hoover C J e ta l. JPEN 1977; 14A(1).

complete liquid nutrition

Helps surgical patients
back to good health

Total commitment to nutrition
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MONTREAL. CANADA HAP 1AS
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►

Atlantoaxial Arthrodesis to Treat Odontoid Fractures
►

►

The authors revie w e d 1 3 2 cases o f cer
vical spine fra c tu re o ve r a 1 0 -ye a r period
and fo u nd 24 cases o f fra c tu re o f the
o dontoid process. Using th e cla ssifica 
tio n o f A nderson and D 'A lo n z o , th e y
fo u n d 20 patients w ith typ e II fractu re s
and 4 w ith type III injuries. S ixteen pa
tie n ts w ith type II fra c tu re s and 1 w ith
ty p e III u n d erw e n t p o sterio r atla nto a xia l
fu sio n by the Gallie m ethod or a
m od ifica tio n o f it. Im m o b ilizatio n fo llo w 
ing arthrodesis w a s by s o ft ce rvica l ru ffs
and a fo u r-p o ste r collar. Solid fu sio n was
obtained w ith in 3 to 6 m o n th s in 1 5 of
th e 16 ty p e II fra c tu re s; one pa
tie n t w as lost to fo llo w -u p . The one pa
tie n t w ith a typ e III fra c tu re ob tain e d a
solid fusion w ith in 3 m on th s. One pa
tie n t had the fu sio n revised at 1 m onth
fo r progressive d isplacem ent; o th erw ise
there w ere no n otable c o m p lica tio n s. It
is alm ost im possible to d eterm ine
w h e th er the fra c tu re fra g m e n ts had
united b u t this is n o t im p o rta n t as long
as there is a solid fu s io n . W h e th e r tre a t
m ent o f acute o d o nto id fra ctu re s, par
ticu larly typ e II, should be o p e ra tive or
nonoperative is c o n tro ve rsial, b u t from
th is review the a uthors believe th a t
prim ary trea tm e nt o f ty p e II o d o n to id
fra ctu re s by posterior a tla n to a xia l ar
throdesis w ith its lo w m o rb id ity and high
fu sio n rate is superior to no n op e ra tive
trea tm e nt.

From the department o f surgery, St.
Michael’s Hospital, Toronto, Ont.

Les auteurs o n t passe en revue 1 3 2 cas
de fra ctu re s de la colonne cervicale survenues au cours d 'u n e periode de 10 ans
e t its y o n t d e co uve rt 2 4 cas de fra c tu re
de I'apophyse o d ontoide. D 'apres la cla s
sifica tio n d ’ Anderson et d 'A lo n z o , 2 0
patien ts avaient une fra c tu re de ty p e II
et 4 de typ e III. Seize p a tien ts avec une
fra ctu re de typ e II et 1 avec une fra c tu re
de typ e III o n t subi une arthrodese
atloido-axoidienne posterieure selon la
m ethode de Gallie ou une m o d ifica tio n
de celle-ci. Apres I'arth ro d e se , I'im m o b ilisation fu t obtenue par un collet ce rvica l
m ou et un collier a quatre tiges. Des
fu sio n s solides o n t ete reussies en 3 a 6
m ois pour 15 des 16 fra ctu re s de ty p e
II; un patien t fu t perdu de vue. Le p a tie n t
qui avait une fra ctu re de typ e III a
obtenu une fusion solide en m oins de 3
m ois. Un p a tien t s u b it apres 1 m ois une
revision de I'arth ro d e se rendue necessaire par un glissem ent progressif; autrem ent, on n 'en re g istra aucune co m p lic a 
tio n notable. II est p ra tiq u e m e n t im p o s s i
ble de determ iner si les fra g m e n ts
osseux so n t reunis, m ais cela est sans
im portance en a u ta n t q u ’ il y a une fu sio n
solide. Que le tra ite m e n t des fra ctu re s
odontoides, p a rticu lie re m e n t celles de
typ e II, so it ch iru rg ica l ou pas est su je t
de controverse. T o u te fo is, a la su ite de
c e tte revue, les auteurs croie n t que
I'arth ro d e se atloid o -a xo id ie n n e p o s te 
rieure, avec sa faible m o rb id ity et sa
fo rte p ro p o rtion de fu sio n s reussies, d o it
etre consideree superieure aux soins non
ch iru rg ica ux com m e prem ier tra ite m e n t
des fra ctu re s odo nto id e s de type II.

Fractures of the odontoid process account
for 15% to 25% of all bony injuries to
the cervical spine. Although these injuries
are well recognized and have been studied
extensively, it is thought-provoking to
note the controversy that exists regarding
appropriate treatment.
In an early literature review,
Nachemson1 noted that most authors
followed three distinct modes of treat
ment: (a) conservative only; (b) conser
vative with adjunctive surgery in cases of
nonunion and redislocation; (c) operative
in all cases. Early conservative treatment
consisted of plaster immobilization in
Minerva type casts, or reduction and im
mobilization by skeletal traction with
various types of skull tongs until union
was obtained.2,3
The halo apparatus, introduced in 1959
by Perry and Nickel,4 quickly became
the most popular device for the
nonoperative immobilization of odontoid
fractures because fixation seemed effec
tive and the prolonged bed rest imposed
by skeletal traction was abolished.
A generally accepted classification of
fractures of the odontoid process of the
axis was introduced by Anderson and
D’Alonzo in 1974:5 type I — an oblique
fracture through the proximal part of the
odontoid process itself, type II — frac
ture at the junction of the odontoid pro
cess with the vertebral body, type III —
a fracture of the odontoid and extension
into the vertebral body (Fig. 1). These
types were further classified as displaced
or undisplaced. This classification cor
related well with prognosis; 36% of type
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II fractures treated conservatively did not
unite.5 Since then, it has become ap
parent that most of the problems of heal
ing occur in type II fractures (Fig. 2).
Even with supposedly rigid halo im
mobilization, the rate of nonunion has
been unacceptably high for these
fractures.6’7
In an effort to overcome this shortcom
ing of conservative treatment, primary
atlantoaxial arthrodesis has been
advocated.811 At our centre, odontoid
fractures are treated by primary posterior
fusion of Cl-2 and we review here our ex
perience with this mode of therapy.

2 were transferred for treatment from
other areas and 1 patient presented with
chronic instability at an indeterminate
time following her injury. All four pa
tients with type III fracture were managed
primarily at our hospital. At the time of
the initial radiologic examination, seven
type II fractures had 3 mm or more of
anterior displacement, two fractures had
posterior displacement, seven fractures
were undisplaced and one fracture was
missed for 2 weeks because the patient
had multiple injuries. No type III frac
ture was displaced.
Treatment

Patients

In the 10-year period from Jan. 1, 1971
to Dec. 31, 1980, 132 patients with cer
vical spine fractures were seen at St.
Michael’s Hospital in Toronto. From this
group, 24 patients (17 men, 7 women)
with fractures of the odontoid process of
the axis were found. They ranged in age
from 19 to 87 years and 11 were older
than 50 years.
Fourteen patients were injured in
motor vehicle accidents, while 8 sustain
ed their injuries in various types of falls.
In two cases, the cause of the injury could
not accurately be determined — one
because of alcohol abuse and the other
because of advanced age, language bar
rier and length of time since injury — but
it is likely that they had also sustained
falls. All patients injured in falls, but one,
were over 50 years of age.
Associated injuries were common
(50%). They included concussion in four
patients, mandibular fracture in two,
depressed skull fracture in one and a
bursting fracture of Cl in one patient.
According to the classification of
Anderson and D’Alonzo, there were no
type I fractures, 20 type II and 4 type III.
Of the 20 patients with type II injuries,
17 were initially managed at our centre,

Sixteen of the 20 patients with type II
fractures were treated by posterior atlan
toaxial arthrodesis of Gallie type12 or a
modification of it. Following reduction
of the fracture and a posterior approach
to the upper cervical spine, a 1.5 x
2.5-cm corticocancellous graft, harvested
from the iliac crest, was rigidly wired in
the midline between the arch of Cl and
the spinous process of C2. The arch of
the atlas and lamina of the axis were
decorticated and extra cancellous chips
were placed. The method of wiring is im

portant: one loop of no. 18 wire is pass
ed under the arch of Cl from an inferior
to superior position. The graft is placed
appropriately and the wire loop drawn
over the graft and around the C2 spinous
process. The loose ends are then pulled
tight, passed through notches in the sides
of the graft and tied over its posterior
aspect (Fig. 3). An alternative is to pass
two wires beneath the arch of Cl and the
lamina of C2 and to tie the ends firmly
over the posterior aspect of the graft,
which is placed in the midline (Fig. 4). In
14 of our patients, the arthrodesis was
performed as the primary treatment,
within 10 days of injury. Two patients
underwent fusion at a later date, one after
undergoing skeletal traction for 6 weeks
with no sign of union at the fracture site,
and the other after presenting with
evidence of chronic instability. One pa
tient underwent an occiput to C2 fusion
because of a concomitant bursting frac
ture of C l. This procedure was performed
5 months after injury following initial
tong traction that was unsuccessful.
In 3 of the 20 patients, the fracture was
treated nonoperatively. The first, an
80-year-old man, was treated with tong
traction followed by immobilization with

Fig. 3b
FIG. 2—Type II fracture of odontoid.
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FIG. 3—Gallie method of fixation.
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a four-poster collar. A planned C l-2 fu
sion was abandoned after severe hypoten
sion developed during the induction of
general anesthesia. His fracture did not
unite and he had pain. The second pa
tient, an 87-year-old woman, was treated
by immobilization with a four-poster col
lar. She was a poor operative risk because
she had congestive heart failure and lym
phoma; the bone did not unite. The third
patient was a 59-year-old woman with
multiple injuries whose odontoid fracture
was missed for 2 weeks. She was treated
with tong traction for 8 weeks followed
by a halo vest. Four months later her frac
ture was united.
The four patients with type 111 frac
tures were all treated nonoperatively at
first. Two had bed rest followed by place
ment of a four-poster collar; one fracture
healed without complication in 3 months
but the other did not unite and the pa
tient required a Cl-2 fusion, which was
successful. The other two patients were
treated with skeletal traction for 4 and 6
weeks respectively followed by use of a
four-poster collar in one and a halo vest
in the other. Both fractures healed in 4
months.
Following the arthrodesis, tong traction
was resumed for varying short periods to
aid recovery from the immediate effects
of the operation. Because fixation was
thought to be quite rigid, a four-poster
collar was used in most cases after
removal of skull traction.

Results
There were no deaths in our series at
tributable to the injury, nor was there any
permanent neurologic damage suggestive
of cervical spinal cord injury. Two pa
tients had transient quadriparesis. One
complained of paresthesia in both arms,
and one, the patient with chronic in
stability, complained of numbness in her
left hand and of difficulty swallowing. All
patients complained of neck pain,
although it was minimal in some cases.
Fifteen of the 16 patients treated by ar
throdesis obtained a solid fusion within
3 to 6 months. One patient was lost to
follow-up. The one patient requiring an
occiput to C2 arthrodesis also had a suc
cessful result.
Complications
In one patient the fusion had to be
revised after 1 month because of pro
gressive displacement that was considered
unacceptable, although the patient had no
symptoms. The second procedure resulted
in solid fusion. Two points were of in
terest in this case: first, the patient had
been immobilized in a Minerva cast after
the initial procedure and in spite of this
there was appreciable displacement, but
at reoperation the fusion mass was unex
pectedly solid; second, the patient had a
congenital fusion of C2-3-.

Fig. 4b
FIG. 4—Alternative method for wiring graft.

One procedure was complicated by
fracture of the spinous process of C2.
This fusion was augm ented by
methylmethacrylate and the fracture
healed without complication. Other com
plications were minimal.
There were no infections or any cases
in which a late myelopathy developed
after successful fusion.

Discussion
Anderson and D ’Alonzo’s5 classifica
tion of odontoid fractures correlates well
with prognosis. Type 1 fractures are rarely
seen, and whether union occurs with
treatment or not is unimportant, as in
stability does not result. Type III frac
tures, because of the large amount of
cancellous bone present at the fracture
site, also pose little problem in treatment.
The fracture unites successfully in more
than 90% of cases without operation.
However, there is still controversy over
the treatment of type II fractures.
Nonoperative treatment with skull tong
traction and prolonged bed rest was not
universally popular, because motion
could not be adequately restricted and
nonunion rates were high.3,1113 The halo
apparatus, either vest or brace, is much
more effective, and good results in trea
ting odontoid fractures have been re
ported.6-1314 Schweigel14 reported the
best results, with 21 of 22 fractures of the
odontoid healing successfully in a halothoracic brace. However, he did not cor
relate these results with the type of
fracture.
The halo apparatus, however, is no
panacea for type II injuries, as proven by
an increasing number of reports in which
nonunion rates are as high as 75%.
Donovan6 reported 13 nonunions in 17
fractures. Pierce and Barr7 stated that
type II fractures often did not heal with
halo immobilization. Donovan6 and
Pierce and Barr7 suggested primary fu
sion for type II injuries. Other disadvan
tages of the halo apparatus have been
reported. It only restricts 75% of atlan
toaxial motion, allowing 25% of normal
m otion to occur at the C l-2
articulation.15 Distraction forces of be
tween 9 and 13.6 kg exist in the halo vest
or cast when the position is changed from
lying to sitting.13 Southwick16 expressed
no surprise that certain fractures fail to
unite when treated with halo immobiliza
tion and stated that the halo brace is not
adequate for type II fractures.
Since there are a number of obvious
problems in attaining healing of type II
fractures of the odontoid nonoperative
ly, many prefer internal fixation with fu
sion as their primary method of treat
ment. The concept of open reduction of
the displacement and internal fixation was
first proposed in 1910 by Mixter and
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Radial Shortening for Kienbock' s Disease
The subjective and objective results in
seven patients with symptomatic Kienbock's disease treated by radial shorten
ing demonstrate that this procedure is
simple and effective in the early stages
of the disease, when there is no ar
throsis, wrist collapse or translation. By
decompressing the shear stress imposed
on the lunate bone, pain was relieved
and function improved in almost all
patients.
Les resultats subjectifs et objectifs obtenus de sept patients souffrant de maladie de Kienbock et traites par accourcissement du radius demontrent que cette
technique est efficace dans la maladie a
son debut, quand il n'y a pas encore de
signes evidents d'arthrose ou de bouleversements architecturaux du poignet.
Par un mecanisme de decompression des
forces agissantes sur le semi-lunaire, la
douleur a disparu et la fonction s'est
amelioree pour presque tous les patients.

Since Kienbock described lunatomalacia,
numerous procedures have been ad
vocated to alter the course of the disease
towards degenerative arthritis. Treatment
ranges from rest, excision of the lunate
bone with or without replacement with
Silastic,1 ulnar lengthening2 and radial
shortening to arthrodesis. We report the
results of radial shortening performed at
the Centre Hospitalier Universitaire in
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Sherbrooke since 1975. The rationale for
shortening the radius is based on the
observed association between Kienbock’s
disease and negative ulnar variance.3-4
Patients and Methods
Since 1975, seven patients have been
admitted to the Centre Hospitalier
Universitaire of Sherbrooke with symp
tomatic Kienbock’s disease and treated by
three orthopedic surgeons. All patients
had disabling wrist pain and some had un
dergone conservative treatment. There
were four males and three females, rang
ing in age from 15 to 56 years. The mean
follow-up was 36 months (range from 6
to 16 months). In all cases the disease was
unilateral. Roentgenographically, three
patients showed condensation and four
fragmentation of the carpal lunate bone.
None had either carpal collapse or car
pal translation as measured by the
method of Youm and associates.5 There
were no signs of degenerative arthritis in
the wrist. The ulna was shorter than the
radius in six of the seven affected wrists.
Radial shortening was performed
through a dorsal approach by making an
osteotomy in the distal metaphyseal
region; a bone block was removed in an
attempt to restore a more physiologic
positive ulnar variance at the wrist.
Although the osteotomy site was secured
by Kirschner wires in three cases and no
complications were encountered, the use
of a compression plate, as in four of our
cases, is recommended. The wrist was im
mobilized in a short-arm cast for 6 to 8
weeks.
The clinical and radiologic findings in
the seven patients were reviewed.

tion improved after operation in two pa
tients but remained the same in five, with
decreased motion ranging from 20° to
40°, compared with the other wrist. The
radiologic examination showed resorption
of necrotic bone and partial revasculariza
tion in five patients and no changes in two
(Figs. 1 and 2).
Discussion
Radial shortening is a simple, effective
procedure for managing symptomatic
Kienbock’s disease. Our results are in ac
cordance with those o f o th ers.6-7
Absence of degenerative arthritis, carpal
collapse and translation in the early stages

FIG. 1—Partial revascularization after
osteotomy in 35-vear-old man.

Results
Although most patients noted some
pain with strenuous activity, otherwise six
had complete relief of pain; one had par
tial relief, particularly at rest. Three of
the four men whose work involved heavy
labour were able to return to their
previous activities without retraining. The
clinical examination showed improved
grip strength in three patients but no im
provement in the other four. Wrist mo

FIG. 2—Marked revascularization after
osteotomy in 34-year-old man. Functional
result was good despite radial tilling.
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of the disease is a prerequisite for a suc
cessful outcome; before operation, the
measurements of carpal height and width
described by Youm and associates5 must
be made to rule out any collapse or
translation.
Why should such a procedure be effec
tive? An association between the presence
of Kienbock’s disease and negative ulnar
variance, as in six of our seven patients,
is well known;4 in addition to the
restoration of a more anatomical position
to the wrist, relief of pain is likely obtain
ed by decreasing the shear stress on the
lunate bone.6
Despite preoperative measurements,
the shortening was not so precise as to
restore to the wrist a relationship similar

to the asymptomatic one; nevertheless,
relief of pain was obtained in a reproduc
ible manner, suggesting that it was achiev
ed mainly by decreasing the compression
forces acting on the lunate itself.
Conclusions

Radial shortening in symptomatic
Kienbock’s disease is simple and effective
provided that there are no signs of
degenerative arthritis. The procedure is
recommended in the early stages of the
disease. It has the advantage of keeping
other options open should further treat
ment be necessary.
The authors thank Dr. A. Trias for his
assistance in preparing the manuscript.
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Use and Abuse of Mammography in the
Early Diagnosis of Breast Cancer
In the 8 years before 1 9 8 0 , 3 9 5 8
w om en w ere exam ined in the S t.
M ich a e l's Hospital breast clin ic in
Toro nto. O f 3 02 w om en w ith breast
can cer, 8 7 (2 9 % ) had norm al m am m o
gram s. Breast can cer w a s found in 3 4
after at least one clin ica l and m am m ographic exam ination had given norm al
results. O f these, 6 (1 8 % ) ca n ce rs were
d etected only by m am m ograp h y while,
p a ra d o xically, 23 (6 8 % ) w ere detected
only by clinical exam ination. Norm al
m am m ogram s are sig n ifica n tly (p
< 0 .0 0 1 ) more frequent in young
w om en w ith breast can cer and in those
w ith sm all palpable breast can cers.
M am m ography is m ost p roductive when
used a s a routine stu d y in older wom en
w ho have clinically norm al breasts. All
w om en should start havin g them around
the age of 4 0 to 4 5 years. H o w often
th ey sho uld be repeated is debatable.
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There is no evid en ce that they should be
repeated annually. Under 3 5 years of age
m am m ography for any reason is unre
warding. B io p sy of a breast lump that is
solid on aspiration should never be
delayed b ecau se of a norm al m am m o
gram . Biopsy of a rad iologically s u sp i
cio u s lesion in the breast should never
be delayed becau se the fin d in g s on clin i
cal exam ination are norm al.
D an s les 8 annees qui ont precede 19 8 0 ,
3 9 5 8 fem m es ont ete exam inees a la Cli
nique du sein du S t. M ich a el's Hospital
de Toronto. S u r 3 0 2 fem m es ayant un
can cer du sein , 8 7 (2 9 % ) avaient une
m am m ographie norm ale. Un can cer du
sein fut d ecouvert ch e z 3 4 fem m es
apres qu'au m oins un exam en clinique et
une m am m ographie eurent donnes des
resultats norm aux. C h e z ce lle s-ci, 6
(1 8 % ) ca n ce rs furent decou verts a la
m am m ographie seulem ent alors que,
paradoxalem ent, 2 3 (6 8 % ) furent d e ce 

Examination
Initial
After one
normal
examination

it s a I'exam en clinique seulem ent. Les
m am m ographies norm ales son t significativem ent plus frequentes (p < 0 .0 0 1 )
chez les jeunes fem m es ayant un cancer du
sein et dans cedes ayant de petits cancers
du sein palpables. La m am m ographie est
surtout fructueuse quand elle e st utilisee
com m e exam en syste m atiq u e chez les
fem m es plus agees dont les sein s sont
norm aux a I'exam en clinique. Toutes les
fem m es devraient com m encer a s 'y soumettre a com pter de 4 0 a 4 5 ans. La fre 
quence des e xam en s est d iscutable. II
n 'e xiste aucune preuve q u 'ils devraient
etre repetes annuellem ent. En deca de
35 ans, la m am m ographie faite sans rai
son n'en vaut pas la peine. On ne devrait
jam ais retarder la biopsie d ’une tumeur
m amm aire, solide a I'asp iratio n, a cause
d'une m am m ographie norm ale. On ne
devrait pas non plus retarder la biopsie
d'une lesion m am m aire radiologiquem ent
susp e cte parce que les resultats de I'examen clinique sont norm aux.

Table 1-Detection of Breast Cancer in 302 Women
Clinical
Clinical
examination
examination and
Mammography
only, no. (%)
mammography, no. (%)
only, no. (%)
64 (24)
194 (72)
10 (4)
23 (68)
87 (29)

5 (14)
199 (66)

6 (18)
16 (5)

Total
268
34
302
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Although there is unequivocal evidence
that mammography can demonstrate
some breast cancers in women whose
breasts appear normal on clinical
examination,1claims that 49% of breast
cancers are detected in this way, that a
further 47% are detected by a combina
tion of mammography and clinical ex
amination, and that only 3% are detected
by clinical examination alone (normal
mammogram) are unrealistic.2 Such
overpromotion of the efficiency of mam
mography has led to the widespread
misconception that mammography can
detect most breast cancers before they
become palpable, and if a mammogram
is normal, breast cancer is rarely present.
Subjects and Findings

In the 8 years before. 1980, 3958 women
were referred to the St. Michael’s
Hospital breast clinic in Toronto. Breast
cancer was identified in 268 patients and
in 64 (24%) of these the mammogram was
normal (Table I). Approximately 1000
high-risk subjects (those with previous
breast cancer, close maternal family
history of the disease, nulliparity, late
primiparity and previous atypical
hyperplastic lesions on biopsy) who had
negative findings on clinical and mammographic examinations initially were
followed up for 5 years. All were trained
in breast self-examination and 90% prac
tised it monthly. Clinical examinations
were repeated at least once a year. Mam
mography was repeated every 2, 3 or 4
years. No patient was allowed to go more
than 4 years without repeat mammo
graphy. When a lump (mass lesion) was
found it was aspirated. If the lump was
solid, mammography was repeated for
comparison with the previous normal
study and the lump was then excised for
biopsy purposes. If less than 6 months

FIG. I—Frequency of positive (solid line)
and negative (broken line) mammograms by
age in 275 women with palpable breast cancers.
Mammograms were normal (negative) in 53%
of women under 45 years of age and in 23°7o
over 45 years. Mean age for negative mam
mograms was 49.3 years and for positive mam
mograms 58.3 (p < 0.001, unpaired, two-tailed
f-test).

had elapsed since the previous normal
mammogram, the examination was not
repeated before biopsy. In the women
whose breasts remained clinically normal,
any suspicious shadow that appeared on
subsequent mammograms was followed
by excision of the suspicious tissue for
biopsy. Of the 34 cancers detected in these
1000 women, 6 (18%) were not palpable.
Twenty-three (68%) women had a
palpable tumour but a normal mam
mogram on their repeat examination
(Table 1). Of the 302 patients with cancer,
275 had a palpable mass lesion. Normal
mammograms were recorded in 82 (36%)
of these 275 patients; they occurred more
frequently in young women and in
women with small palpable lesions (Figs.
1 and 2).
Discussion

In any breast cancer screening pro
gram, the number of cancers detected at
the time of the first visit (“ prevalent”
cancers) will include some tumours that
have been present for a relatively long
time and will be approximately three
times the number detected at any subse
quent visit (“ incident” cancers).2 Ap
proximately 25% of all the women with
breast cancer who pass through screen
ing clinics are passed as normal and their
cancer is detected at some other facility
before their next regular visit to the
screening centre (“ interval” cancers).2'4
These may be tumours with a clinical sign
that was ignored because the mam
mogram was reported as normal or they
could be rapidly growing cancers that
were undetectable at the time of the
previous screening visit, but since breast
cancer is usually a slow-growing disease,
we suspect that the former explanation is
the more likely and our results tend to
confirm it.
Because the 1000 high-risk women we
studied all had baseline normal findings
on clinical and mammographic examina
tion, the 34 cancers that subsequently
developed would be designated as inter
val and incident cancers in a breast cancer
screening program. Of these women, 68%
had a normal mammogram. However,

FIG. 2—Frequency of positive (solid line)
and negative (broken line) mammograms by
size of primary in 275 women with palpable
breast cancers. Mean size of lesion in negative
mammograms was 2.12 cm and in positive
mammograms 3.33 cm (p < 0.01).

these patients are highly selected and the
actual percentage are relatively meaning
less. The number of truly occult cancers
will probably increase to at least 25% as
mammography is repeated over the next
few years in women who remain clinically
normal. What is important is that at least
50% of cancers that would be classified
as interval and incident cancers in a screen
ing situation should be detected only by
clinical examination, while, paradoxi
cally, at least 18% should be detected by
mammography alone. This is in sharp
contrast to a published report that only
3% of breast cancers are discovered on
the basis of clinical examination alone.2
In a screening study in which mam
mography was used as the sole method
of examination, 149 cancers were detected
after the first visit (incident and interval
cancers) (Holland R: Personal com
munication, 1982); 44% (66) of these
were classified as interval and at the time
of detection all but one of these patients
were “ symptomatic” (i.e., had some
clinical finding that led to a biopsy).4
We have a rigid protocol of manage
ment for women in whom the only clinical
finding is a palpable breast lump. All
masses are aspirated and if the tumour is
solid it is excised for biopsy. Such a pro
tocol ensures that no cancers mas
querading as innocuous lumps in the
breast will go undetected. Of 1020 such
biopsies, 862 (85%) proved to be benign.
The increased number of biopsies per
formed in women in whom the only find
ing is a palpable solid lump is a price that
must be paid if early diagnosis of breast
cancer is to be achieved.
Mammography is an imaging te tnique, so it should come as no surprise that
its efficiency decreases with smaller mass
lesions and in young women whose nor
mal breast parenchyma has not yet been
replaced by fat. We have performed
mammograms on 1946 women under 35
years of age. Very few demonstrated
significant fatty replacement. We have
identified breast cancer in 12 women
under 35 years of age. The mammogram
was positive in four of them but in those
four patients the clinical mass was huge
and the mammogram did not aid in the
diagnosis. We believe mammography
under the age of 35 years is unrewarding
and we no longer use it for women in this
age category. Many young women with
painful breasts undergo mammography
to reassure them that they do not have
cancer. It has become fashionable to
report their normal breast parenchyma as
marked or dense “ dysplasia” . The un
justified assumption that this signifies a
premalignant condition may lead to fur
ther unnecessary mammography in these
women. Mammography is very efficient
in older women in whom fatty replace
ment of breast parenchyma is well under
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way. We believe all women whose breasts
are clinically normal (not just those in
high-risk categories) should have the
benefit of routine mammography. The
only questions are, at what age should
mammography first be done and how
often should it be repeated? We have
arbitrarily chosen the age of 40 to 45 years
for the first routine mammogram and
arbitrarily have been repeating the pro
cedure every 4 or 5 years. If dense breast
tissue is present at the time of the first ex
amination, more frequent repetition is not
fruitful. If there has been some fatty
replacement of the breast parenchyma,
m am m ography probably could be
repeated in less than 4 years. There is no
evidence to support the arbitrary recom
mendation that routine mammography
should be repeated annually.5

quent in young women with breast can
cer and in those with small palpable breast
cancers. Mammography is most produc
tive when used as a routine study in older
women who clinically have normal
breasts. All women should start to
undergo mammography around the age
of 40 to 45 years. How often it should be
repeated is debatable. There is no evi
dence that the procedure should be repea
ted annually. Under the age of 35 years,
mammography for any reason is unre
warding. Biopsy of a breast lump that
is solid on aspiration should never be
delayed because of a normal mammo
gram, and biopsy of a suspicious lesion
on m ammography should never be
delayed because the findings on clinical
examination are normal.

Summary and Conclusions

References

Of 302 women with breast cancer, 87
(29%) had normal mammograms. Breast
cancer developed in 34 after at least one
clinical and mammographic examination
gave normal findings. Of these, 6 (18%)
cancers were detected only by mam
mography while, paradoxically, 23 (68%)
were detected only by clinical examina
tion. Normal mammograms are more fre

1. H enderso n IC, C a n e l l o s GP: Cancer of the breast:
the past decade (first of two parts). N Engl J M ed 1980;
302: 17-30
2. SMART CR, Be a h r s OH: Breast cancer screening results
as viewed by the clinician. Cancer 1979; 43: 851-6
3. Ma rtin JE, Moskow itz M, M ilbrath JR: Breast
cancer missed by mammography. A JR 1979; 132: 737-9
4. H o lla n d R, M rav una c M, H endriks JHCL, Bek
KER BV: So-called interval cancers o f the breast:
pathologic and radiologic analysis of sixty-four cases.
Cancer 1982; 49: 2527-33
5. THIER SO: Breast cancer screening: a view from outside
the controversy (E). N Engl J Med 1977; 297: 1063-5

SESAP IV Question
131. Preoperative preparation of the thyrotoxic patient with propranolol
(A) must be supplemented with conventional antithyroid drugs
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. Lung Cancer — 1 9 8 3
The frequency of lung cancer, com m on
in both m en and w om en, se e m s to be in
creasin g rapidly, particularly in w om en.
The main causative factor appears to be
cigarette sm oking. D ia g n o sis and sta ging
have not changed notably in the last few
years, although the advent of c o m 
puterized tom ograp hy and gallium s c a n 
ning have been of som e help in identify
ing mediastinal tum ours, w h ich are unresectable. Further refinem ents in
these techniques m ay allow u s to avoid
m e d iastin oscop y but, at present, this is
still usually ne ce ssary before operation
for lung cancer.
O peration is the major form of therapy
for non-sm all cell cancer w h en this is
m edically and technically possible. A d ju 
vant therapy in the treatm ent of this
type of lung cancer has so far been of
little help.
Radiotherapy a s prim ary treatment,
although occasionally curative, shou ld be
u se d only if patients refuse operation or
clearly have medical contraindications for
thoracotom y. Radiotherapy is very useful
for palliation.
Chem otherapy is of little value in
treating advanced, non-sm all cell lung
cancer, although re sp o n se s can be seen
in up to 4 0 % of patients. T h is d o e s not
translate into important, long-term s u r
vival, but responders do su rviv e longer
than non-responders. Patients w ith small
cell lung cancer shou ld be treated with
com bination chem otherapy, w ith or
w ithou t thoracic irradiation and w ith or
w ithou t cranial irradiation. The latter tw o
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modalities have not yet been proved to
prolong survival, but m ay reduce the
morbidity.
Im m unotherapy has not been s h o w n to
benefit those with non-sm all cell lung
cancer. T h ym osin w a s beneficial in one
controlled trial in patients w ith small cell
lung cancer, but this m u st be confirmed.
In the future, m any new a p p ro a ch e s will
be necessary to control or eradicate this
steadily increasing c a u se of cancer
death.
La frequence du cancer du poum on,
com m un chez I'h o m m e co m m e chez la
femme, sem ble etre en p ro gre ssion
rapide, particulierement chez la femme.
Le principal facteur etiologique sem ble
etre la cigarette. Le d iag n o stic et I'etablissem ent du stade d e v o lu tio n n 'o n t
pas change sensiblem ent au co u rs des
d e m is e s annees, bien que I'apparition
de la tom ographie tran sve rse axiale sur
ordinateur et de la scintigraphie au ga l
lium ait aide a ('identification des
tum eurs d a n s le m ediastin (alors q u'elles
ne sont pas resecables). D e s am eliora
tio ns plus p o u sse e s de ce s techniques
n o u s permettront peut-etre d 'e vite r la
m ediastinoscopie mais, pour I'instant,
elle est encore necessaire a va nt ('opera
tion d 'u n cancer du poum on.
La chirurgie est le traitem ent principal
quand il ne s 'a g it pas d ’un cancer a petites cellules et quand (’intervention est
medicalement et techniquem ent possible.
D a n s ce type de cancer du poum on, la
chimiotherapie adjuvante s 'e s t revelee
ju sq u 'a maintenant de peu d'utilite.
La radiotherapie utilisee com m e traite
m ent primaire, bien qu'elle soit curative,
doit etre utilisee uniquem ent lorsque le
patient refuse I'operation ou q u 'il existe
des contre-indications m edicales a la thoracotomie. La radiotherapie est tres utile
com m e traitement palliatif.
La chimiotherapie est de peu d'int6ret
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d a n s le traitement des ca n c e rs a va n ce s
du poum on qui ne so n t pas a petites cel
lules, bien q u 'u n e re ponse puisse-t-etre
observee dans ju sq u 'a 4 0 % d e s cas.
Ceci ne se traduit pas par une survie
importante a long terme, m em e si les
patients qui repondent su rviv e n t plus
longtem ps que ce ux qui ne reagissent
pas. Les patients porteurs de cancer a
petites cellules devraient etre traites par
polychimiotherapie, avec ou s a n s irradia
tion thoracique. et a vec ou s a n s irradia
tion cranienne. II n 'a p a s encore ete
dem ontre que ce s deux dernieres modalites de traitement pouvaient prolonger la
survie, m ais elles peuvent reduire la
morbidity.
L'im m unotherapie n 'a pas sem ble avoir
d'effet dans les cancers du poum on
excluant les cancers a petites cellules.
D a n s une etude controlee, la thym osine
s 'e s t montree benefique chez des
patients porteurs d 'u n cancer a petites
cellules, m ais ceci reste a etre confirme.
D a n s I'avenir, plusieurs no uvelles approches seront ne ce ssaires pour maitriser ou
faire disparaftre cette ca u se croissante
de deces.

Extensive information has accumulated
on lung cancer in the last few years.1 In
this paper, 1 shall present some of the
highlights and review recent developments
and controversies.

Epidemiologic Considerations
In the United States the lung is now the
most common site of cancer in men
(22% ) and the fourth most common site
in women (9% ). It is the most frequent
cause of cancer death in men (34% ) and
the second most frequent cause in women
(16% ), second only to breast cancer, and
by 1985 it is expected to overtake breast
cancer. A similar frequency has been
noted in Canada.
The cause of lung cancer is almost cer
tainly multifactorial, but the most impor
tant factor is tobacco. There is a very high
frequency of this malignant tumour in
smokers; in addition there appears to be
a passive effect and increased incidence
in the occupants of households exposed
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to smokers. Asbestos and other occupa
tional materials also play a part in this
disease.
Histologic Classification
A lthough elab o rate, pathologic
classifications of lung cancer exist,2 such
as that developed by the World Health
Organization, a simple classification is
much more practical (Table I). Squamous
cell carcinoma is the most common type,
adenocarcinoma and small cell car
cinomas being less frequent. Adenocar
cinoma has recently been observed more
frequently throughout the world, for
unexplained reasons. For therapeutic con
siderations, to be discussed later, one can
divide the types into small cell and non
small cell, the subtypes of the latter be
ing less important.
Screening
The screening of populations at high
risk for lung cancer has been attempted
in order to detect the disease earlier.
There is good evidence that the cure rate
for the earlier stages of the disease is
much higher. The largest screening study
with the longest follow-up is that of the
Mayo Clinic.3 The subjects are middleaged sm okers. Serial chest roent
genograms and examination of sputum
are carried out. When the cytologic find
ings are positive or suggestive, bron
choscopy and other investigations are car
ried out as indicated. This trial has re
vealed a larger number of tumours in the
screened group compared with the
nonscreened group, but this has not
translated into a longer survival for the
screened group since many of the tumours
are small cell carcinoma of the lung,
which has a much poorer prognosis than
other types. This finding may yet become
important but, for the moment, routine
screening of even high-risk subjects
(smokers, asbestos and uranium workers)
is not indicated.
Diagnosis
The investigation of a patient with
possible lung cancer usually begins when
there are symptoms or an abnormality is
detected on a routine chest roent
genogram . D etails o f the symp
tomatology of this disease, such as cough,
hemoptysis and shortness of breath, are
well known. Standard methods of in
vestigation and staging include history,
physical exam ination, chest roent
genography, tomography, cytologic ex
amination of sputum, bronchoscopy,
mediastinoscopy and, when indicated,
scalene or supraclavicular node biopsy.
Metastatic lesions may also be biopsied,
if they are easily accessible. Pulmonary
arteriography is used before operation in
some cases. Local staging is particularly

important in non-small cell lesions, which
are potentially resectable and give the pa
tient the greatest chance of long-term sur
vival. The major controversies that exist
in the staging of this disease relate to some
of the new, noninvasive techniques, such
as gallium scanning and computerized
tomography of the thorax.4'7 Gallium
scans give many false-negative results.7
When positive, they appear to be specific;
a positive gallium scan may obviate the
need for mediastinoscopy. Computerized
tomography gives rise to much more con
troversy. It will reveal many but not all
lesions. It will show enlarged nodes in the
mediastinum that may not be due to
tumour, and it will not show normal
sized or small nodes that are involved with
tumour. At present, it does not replace
mediastinoscopy, although with improved
technology this may change. More studies
with mediastinoscopy and surgical stag
ing are necessary to define the place of
these new, noninvasive techniques.
Percutaneous fine-needle aspiration
biopsy, particularly of peripheral lesions,
has become a common diagnostic aid.8
The aspiration biopsy will accurately dif
ferentiate between malignant and nonmalignant lesions but is not always ac
curate for a specific histologic type, par
ticularly in small cell carcinomas of the
lung. In some cases, a definitive staging
procedure, such as mediastinoscopy or
open biopsy, may result in the diagnosis
of non-small cell malignant tumours that
can be resected. If one were to rely only
on the original needle biopsy in such
cases, one would not operate and this
could affect long-term survival. Per
cutaneous fine-needle biopsy results in
very few complications, pneumothorax in
about 10% of cases and occasionally
hemoptysis.
Staging
Most commonly, surgical staging uses
the TNM classification of either the
American Joint Commission for Cancer
Staging and End-Results Reporting or the
Union internationale contre le cancer.
The disease can then be further subdivi
ded into stage I, II or III lesions. Stage
I, according to the American Joint Com
mission, consists of T|N 0, T,N, and
T2N0 diease. T, lesions are less than 3 cm
and T2 lesions are greater than 3 cm in
greatest dimension. N, lesions involve
hilar or intralobar nodes. Stage II disease
Table 1—Major Histologic Types of Lung Cancer
Cell type*
%
Squamous cell (epidermoid)
40
Adenocarcinoma
25
Small cell (oat cell)
20
Large cell (anaplastic)
15
Others (e.g., bronchoalveolar)
1-3
*2% to 4% are mixed adenosquamous.

includes only T2N, lesions. The stage III
category is more advanced than stage II
and not all such tumours are resectable.
I shall not discuss this subgroup in detail.
Patients with stage I disease have a good
outcome with approximately 70% being
alive at 5 years. Survival of patients with
T,N 0 disease is particularly good, being
more than 85% at 5-years. Survival with
stages II and III disease is not as good but
tumours in patients with stage II and
resectable stage III disease are still worth
resecting, since this procedure offers the
best hope for long-term survival. In
general, patients with positive findings on
mediastinoscopy should not have resec
tion for cure, although exceptions to this
rule exist.
Treatment
Operation
For patients with non-small cell
tumours that are potentially resectable,
operation is still the best approach for
long-term survival.9' 11 There have been
no recent m ajor, technical advances in
pulmonary surgery, other than use of the
stapler. Survival is related to the TNM
staging.
Radiotherapy as Primary Treatment
Radiotherapy can be used when there
are serious co n train d icatio n s to
thoracotomy or the patient refuses to
undergo operation.12'13 There is up to
30% 5-year survival in some series but
these are exceptions. However, this ap
proach is not recommended if operation
is possible. Radiotherapy has been used
occasionally as the only treatment for
small cell lung cancer; today it probably
should not be used alone but combined
with chemotherapy. Radiotherapy is
useful for palliation in all types of lung
cancer.
Chemotherapy
There is no evidence that chemotherapy
is of benefit in the treatment of non-small
cell lung cancer, although 30% to 40%
o f p a tie n ts respond to c u rre n t
chemotherapy combinations.14,15 There
is some evidence that responders to
ch em o th erap y live longer th an
nonresponders, but the former may be
patients who have a better prognosis.
Chemotherapy is the major form of
therapy in small cell lung cancer, which
will be discussed later.
A djuvant Therapy
Although many randomized trials have
been carried out in the past, and others
are ongoing, there is no definite evidence
that chemotherapy, radiotherapy or im
munotherapy are beneficial when added
to complete surgical resection.1011 Ongo
ing or future trials may demonstrate a
place for these therapies.
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Treatment o f Smalt Cell Carcinoma
This disease has historically been divid
ed into lim ited (confined to the
hemithorax and ipsilateral supraclavicular
nodes) and extensive (beyond the defini
tion of limited disease). Untreated pa
tients, in studies done in the late 1960s,
had a median survival of approximately
6 to 8 weeks and therefore the results of
present studies should take this into
account.
This cell type accounts for approx
imately 20% of all lung cancer. Im
provements in treatment of small cell car
cinoma of the lung have evolved in the
last few years.16' 18 The Medical Research
Council in the United Kingdom showed
in the late 1960s that radiotherapy is
preferable to operation, and thus it
became the standard form of therapy for
this disease. A number of studies show
ed the benefit of chemotherapy in addi
tion to radiotherapy, and thus it gained
a place in the treatment of this obviously
systemic tumour. Combination chemo
therapy with active agents, including cy
clophospham ide, A driam ycin, vin
cristine, etoposide (VP-16), cis-platinum,
procarbazine, lomustine (CCNU) and
methotrexate has been used. These agents
are all active singly and more active in
combination. Common combinations in
clude cyclophosphamide, Adriamycin
and vincristine (CAV), cyclophos
pham ide, CCNU and m ethotrexate
(CCM) and CAV and VP-16 as well as
VP-16 and cis-platinum. Recently, such
chemotherapy combinations have been
used with irradiation of the chest and, in
some cases, with prophylactic cranial ir
radiation. In randomized trials of
thoracic irradiation, there is only limited
evidence that this treatment is of value,
particularly in patients with extensive
disease.19 There is evidence for im
proved, long-term survival in patients
with limited disease treated with thoracic
irrad iatio n in addition to chem o
therapy.20 The place of this approach is
still uncertain. Prophylactic cranial ir
radiation has reduced relapses in the cen
tral nervous system in a number of con
trolled trials but has not affected survival.
It is often recommended only for patients
in complete remission.
The various approaches presently
available result in an 80% to 85%
response rate in patients with limited
disease (approximately 40% to 60%
achieve complete remission) and approx
imately 70% in patients with extensive
disease (10% to 35% of patients achieve
complete remission). The median survival
of patients with limited disease is approx
imately 1 year, while that of patients with
extensive disease is approximately 9
m onths.20 The 2-year disease-free sur
vival rate is approximately 20% for pa
tients with limited disease and 4% to 5%
268

for those with extensive disease. Similar
5-year survival rates have been noted in
some series but in most studies it is too
early to conclude that long-term cure has
been established. Other approaches that
we and others have studied include: the
value of adjuvant total parenteral nutri
tion, very high-dose chemotherapy and
alternating versus sequential chemo
therapy combinations. None of these ap
proaches has proven of greater benefit
than established methods. Treatment with
very high doses of chemotherapy along
with autologous bone-marrow transplan
tation has also been studied. It may have
potential, particularly in patients who
achieve remission and whose disease may
be arrested by very aggressive therapy, in
cluding bone-marrow transplantation.
However, this approach would probably
fail as initial induction therapy for un
treated patients. One of the major pro
blems is the frequency of bone-marrow
involvement, which results in a high pro
bability that tumour cells will be reinfus
ed when the patient’s marrow is used.
Newer techniques are being developed
that may offset this problem.
The value of maintenance chemo
therapy is not established. Some studies
have strongly suggested that a shorter
form of therapy, from 3 to 6 months,
may be all that is necessary in this disease.
We have recently treated over 360 patients
with small cell lung cancer with six
courses of chemotherapy (CAV), thoracic
irradiation and prophylactic cranial ir
radiation, and have found that their
response and survival are identical to
those in our previous study of 161 patients
who were treated with oral maintenance
chemotherapy for 1 year. Our survival
data are also similar to those of other
studies in the literature, using various ap
proaches. Moreover, other studies using
short-term therapy have reported equal
ly good results, but a proper randomized
trial has yet to be completed. Some re
cent, anecdotal experience has suggested
that resection of the initially involved
tumour following a remission may be of
some value. There is evidence that small
peripheral nodules (less than 3 cm in
diameter), without hilar or mediastinal
node involvement, probably do best with
operation. Additional chemotherapy and
radiotherapy may also be indicated. Ran
domized studies are about to begin in the
United States to test the hypothesis that
operation is beneficial to the patients who
obtain a response from chemotherapy.
The value of other forms of therapy, in
addition to operation, of peripheral
nodules must also be studied.
O f paramount importance is the
discovery of new active drugs that may
improve the results of treatment. Since
small cell lung cancer is responsive to a
large number of agents, all potentially ac

tive agents should be tested in phase 2
studies in previously treated patients. At
least one randomized trial has shown that
the immunologic stimulant thymosin has
some value. This, however, must be con
firmed by others before it can become
part of the treatment of lung cancer.
There is no other evidence that im
munologic stimulants are of value.
Cancer of the lung may well become
one of the highly curable tumours, but
so far there have been only minor
improvements.
I thank Mrs. Jean Russell for preparing the
manuscript.
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2. Adjuvant Therapy of Breast Cancer
Long-term survival of patients with
breast cancer treated by operation alone
has not improved despite many varia
tions in local or regional treatment.
Undetectable micrometastases present at
the time of initial local treatment are the
cause for later failures. Adjuvant
systemic treatments have been intro
duced in the hope of reducing recurrence
and mortality. In a series of protocols,
the National Surgical Adjuvant Breast
Project evaluated sequentially escalating
drug therapies and noted a striking
change in the natural history of the
disease. Breast cancer is a heteroge
neous group of diseases with different
outcomes. Many of the therapies provide
appreciably prolonged disease-free survi
val and ultimate survival for subsets of
patients. Efforts should be made to
recruit patients for further clinical trials
in order to define better the most suita
ble treatments for the different subsets
of patients.
La survie a long terme des victimes du
cancer du sein traitees par chirurgie seulement ne s'est pas amelioree en depit
de plusieurs variations apportees au traitement local ou regional. Des microme
tastases non decelables, presentes au
moment du premier traitement local, sont
la cause des echecs subsequents. Les
traitements adjuvants systemiques ont
ete ajoutes dans I'espoir de reduire les
recidives et la mortalite. Dans une serie
de protocoles, le National Surgical Adju
vant Breast Project a evalue sequentiellement des chimiotherapies d'intensite pro
gressive qui ont modifie de facon manifeste I'histoire naturelle de cette maladie.
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The findings of this report were made
possible by the collaboration of in
vestigators (Appendix 1) of the Na
tional Surgical Adjuvant Breast
Cancer Project (NSABP), Dr. Bernard
Fisher, chairman.
Le cancer du sein est compose d'un
groupe de maladies heterogenes ayant
des consequences differentes. Plusieurs
des traitements prolongent de facon
appreciable la survie exempte de maladie
et assurent la survie definitive de cer
tains sous-groupes de patientes. Les
efforts devraient maintenant porter sur
I'inclusion de patientes dans de nouvelles
etudes visant a mieux definir quels sont
les traitements les plus appropries pour
les differents sous-groupes de patientes.

Although 5- and 10-year survival is com
mon in patients with breast cancer, it has
become clear that the figures do not tell
the whole story. Long-term follow-up in
dicates a steady attrition of such patients
until 18 or 20 years after the initial opera
tion. By extrapolation, it is possible to
compute that the overall long-term sur
vival rate for patients with breast cancer
is approximately 18%, and for the
favourable stages I and II it is in the
range of 30% to 40%.' Indeed, there is
one subset of patients with breast cancer
who die very rapidly, and the survival
curve for these patients can be superim
posed on a curve drawn for untreated pa
tients at the Middlesex Hospital in Lon
don in the 19th century. These patients
obviously have metastases before opera
tion is performed. Clearly, no discussion
of local or regional variations in treat
ment can benefit these patients. Others
with longer survival who eventually die
of cancer must also harbour
micrometastatic disease at the time of
operation, and it is these occult foci of
metastases that eventually develop into
the clinical recurrence that proves fatal.
With the understanding that breast
cancer is a biologic, systemic process,
rather than an anatomical, localized,
regional one, it is obvious that successful
treatment must involve both local and

systemic approaches. The first systemic
adjuvant treatment was carried out by the
National Surgical Adjuvant Breast Pro
ject (NSABP) in 1958. It consisted of
thiotepa given intravenously for 4 days,
beginning at the time of operation.
Although this treatment was aimed at
eliminating circulating tumour cells
dislodged by the surgeon, it is now ap
parent that any effect this treatment had
was more likely on the established
micrometastases than on circulating cells.
Although most patients did not show
substamial benefit, premenopausal pa
tients who had four or more nodes in
volved had a better 10-year survival than
did control patients.2
Subsequently, a prospective trial was
undertaken, comparing standard mastec
tomy (radical or modified radical) with
mastectomy plus L-phenylalanine
mustard (L-Pam) given in prolonged
cyclic therapy for 2 years. Interim results
indicated that there was substantial
benefit by 18 months for the treated
group compared with the placebo
group.3 Therefore, the placebo arm was
withdrawn, and a sequential stepwise
evaluation of drug therapies was under
taken. In a subsequent protocol (protocol
7) patients were treated with L-Pam or lPam and 5-fluorouracil (5-FU) (PF).
Following this, patients were treated with
PF or PF plus methotrexate (PMF). Fur
ther studies involved comparison of PF
to PF plus tamoxifen (PFT) and PF plus
Coryrtebacterium parvum (PF-CP).
This stepped sequence of randomized
prospective studies can be compared in a
cross-protocol fashion4 and results in
dicate that premenopausal patients,
especially those with one to three positive
nodes, derive apparently equal benefit
from all drugs. Although there is a trend
towards better survival and disease-free
survival with combinations of drugs,
there is no significant difference between
a single drug therapy and the combina
tions for the premenopausal patients.
Postmenopausal patients do not seem
to benefit from single-drug therapy but
those with four or more nodes involved
show significantly longer survival and
disease-free survival when treated with PF
or PMF.
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No advantage was found for post
menopausal patients with one to three
positive nodes. However, even untreated
patients in this group have better than
80% survival by 3 years, so it is unlikely
that any difference would be detected,
even if it were there, until more time has
gone by.
The addition of tamoxifen to the PF
program appeared to improve disease
control when compared with PF alone.
The benefit from tamoxifen was greater
if the patient’s tumour was estrogenreceptor positive, and there was a direct
correlation between the estrogen-receptor
level and the improvement in disease-free
survival. On the other hand, patients who
were premenopausal and had negative
estrogen-receptor or progesteronereceptor values showed no benefit from
the addition of tamoxifen, and may even
have an adverse outcome as a result.4
With the additional benefit apparent
ly due to tamoxifen, the question of
mediation of the chemotherapeutic effect
through a medical oophorectomy is once
again raised. To evaluate this, the
NSABP examined menstrual history,
serum estrogen and serum folliclestimulating hormone levels in the various
subgroups of premenopausal patients.
The most conspicuous effect in terms of
lessened menstrual activity, and increas

ed serum follicle-stimulating hormone
and decreased serum estrogen levels was
apparent in the subgroup of patients
aged 40 to 49 years. Most patients aged 30
to 39 years showed little or no change
from normal in these values. However,
the most conspicuous improvement in
disease-free survival was in the patients
aged 30 to 39 years. Therefore, there is
a clear lack of correlation between altered
ovarian function and benefit from the
chem otherapy, indicating that the
chemotherapy does not mediate its effect
through the medical oophorectomy
phenomenon.5
The final question for these interim
results is whether they represent a delay
in recurrence or whether there is a true
diminution in the recurrence rate and,
therefore, a true improvement in overall
survival. To address this, the NSABP
looked at treatment failure rates follow
ing completion of therapy for patients
who had not shown treatment failure to
that date. If there were simply a delay of
recurrence due to chemotherapy, then the
treated patients would show an ac
celerated recurrence rate following cessa
tion of therapy, when compared to un
treated patients. The results of this ex
amination, however, showed no increas
ed treatment failure rate in this group of
patients compared to controls.6 Thus, in

the 3 years after therapy ceased, there
were no significant differences between
treated or control groups. These results
must still be considered preliminary, but
up to 5 years following operation, there
seems to be no increase in failure rate and
there is a sustained benefit for the treated
patients in the subsets described. This in
dicates that it may not be overly op
timistic to conclude that there is probable
benefit from the chemotherapy resulting
in improved cure rates due to this systemic
adjuvant chemotherapy.
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Appendix I — Institutions Actively Contributing to NSABP Protocols as of June 1982
Current
principal investigator

NSABP institution

Albany Regional Cancer Center, Albany, NY
Albert Einstein College of Medicine, Bronx, NY
Albert Einstein Medical Center, Philadelphia, PA
Allentown Hospital, Allentown, PA
Berkshire Medical Center, Pittsfield, MA
Boston University, Boston, MA
Cross Cancer Institute, Edmonton, AB
Daniel Freeman Hospital, Inglewood, CA
Dekalb General Hospital, Decatur, GA
Denver General Hospital, Denver, CO
Downstate Medical Center, Brooklyn, NY
Ellis Fischel State Cancer Hospital, Columbia, MO
Geisinger Medical Center, Danville, PA
Group Health Medical Center, Seattle, WA
Harbor General Hospital, Torrance, CA
Hennepin County Medical Center, Minneapolis, MN
Highland Hospital/University of Rochester, Rochester, NY
Hopital Avicenne, Paris, France
Hotel-Dieu, Quebec City, PQ
Jewish General Hospital, Montreal, PQ
Kaiser Permanente, Harbor City, CA
Kaiser Permanente, Portland, OR
Kaiser Permanente, San Diego, CA
Letterman Army Medical Center, San Francisco, CA
Louisiana State University, New Orleans, LA
Louisiana State University, Shreveport, LA
Manitoba Cancer Foundation, Winnipeg, MB
Marin General Hospital, San Rafael, CA
McMaster University, Hamilton, ON
Medical College of Virginia, Richmond, VA
Medical College of Wisconsin, Milwaukee, WI
Memorial Cancer Research Foundation, Culver City, CA
Michael Reese Hospital, Chicago, IL
Michigan State University, East Lansing, MI

270

T. Cunningham
H. Volk
S. Levick
D. Prager
J. Spector/H. Zimbler
P.J. Deckers/M. Feldman
S. Paterson
E. Hinkes
S.A. Wills
G. Moore
B. Gardner
W. Kraybill
P. Breen
R. Bourdeau
D. State/M.M. Shabot
C. Hitchcock
S. Sobel
L. Israel
L. Dionne
R. Margolese
E. Pollack
A. Glass
T. Campbell
D. Gandara
I. Cohn
L. Goldman
D. Bowman
P. Eisenberg
S.
E. O’Brien
W. Lawrence
W. Donegan
D. Plotkin
R. Desser
N. Dimitrov/L. Suhrland

VOLUME 26, NO. 3, MA Y 1983 / THE CANADIAN JOURNAL OF SURGERY

Montefiore Hospital & Medical Center, Bronx, NY
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U.S. Naval Hospital, Oakland, CA
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University of Pittsburgh, Pittsburgh, PA
University of Texas, San Antonio, TX
University of Vermont, Burlington, VT
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Washington University, St. Louis, MO
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White Memorial Medical Center, Los Angeles, CA
Wilmington Medical Center, Wilmington, DE
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3. Colorectal Carcinoma
Current efforts to reduce the morbidity
and mortality of colorectal adenocar
cinoma are directed mainly to earlier
diagnosis and the development of effect
iv e surgical adjuvant treatment. The
most generally available screening
technique is the identification of fecal
occult blood, but numerous false
negative and false-positive findings, and
the large population at risk, suggest that
more effective but time-consuming
screening methods, such as endoscopy.
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should be reserved for high-risk groups.
More extensive pelvic and para aortic
lymph-node dissections for rectal
adenocarcinoma have not resulted in
consistently improved survival rates.
Radiotherapy reduces the frequency of
pelvic recurrence when given as either
preoperative or postoperative adjuvant
therapy for rectal cancer but has not yet
produced any major improvement in sur
vival. No effective adjuvant chemo
therapy for colorectal adenocarcinoma
has yet been identified.
Primary radiotherapy can control a pro
portion of rectal carcinomas and may
reduce the need for colostomy in some
cases.
Les efforts presentement deployes pour
reduire la morbidity et la mortality reliees
a I'adenome du colon et du rectum, sont
surtout diriges vers le diagnostic plus
precoce et la mise au point d'un traitement adjuvant efficace. La technique de
depistage la plus largement repandue est
('identification du sang occulte dans les

selles; toutefois le nombre eleve de
resultats faussement positifs ou negatifs
et I'etendue de la population a risque,
indiquent que des methodes plus efficaces mais qui prennent plus de temps, telles que Tendoscopie, devraient etre
reservees pour les populations a risque
eleve.
Dans I'adenome rectal, des dissections
plus etendues des ganglions pelviens et
para-aortiques n'ont pas entrafne une
amelioration constante des taux de survie. Dans le cancer du rectum, la radiotherapie reduit la frequence des r£cidives
pelviennes quand elle est administree en
traitement adjuvant pre ou postoperatoire, mais elle n'as pas encore entraine
une amelioration importante de la survie.
Aucune chimiotherapie adjuvante effi
cace n'a encore ete identifiee pour I'ade
nome du colon et du rectum.
La radiotherapie primaire peut maftriser
un certain nombre de cancer du rectum
et diminuer dans certains cas, la neces
sity d'une colostomie.
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This presentation highlights selected areas
of current progress and controversy in the
management of adenocarcinoma of the
colon and rectum. For a comprehensive
review, recent publications such as those
by Sugarbaker and colleagues' and
Duncan2 should be consulted.
Although, occasionally, individual in
stitutions have reported some improve
ment in survival after surgical resection
for cancer of the colon or rectum over the
past 25 years, the age-standardized m or
tality in Canada for the period 1931 to
1973 remained relatively constant for men
at about 20/100 000 population for col
onic cancer and 10/100 000 for rectal
cancer. The rate for women fell only from
23 to 20/100 000 for colonic cancer and
from 8 to 6/100 000 for rectal cancer.
Most staging systems for adenocarcinoma
of the colon and rectum are based on the
extent to which the primary tumour
penetrates the bowel wall and on the in
volvement of the regional lymph nodes.
Considerable variation in outcome may
be reported from centre to centre; in six
reports the 5-year survival ranged from
61% to 81% when tumour was confined
to the bowel wall, from 25% to 64%
when it penetrated the serosa or beyond
and from 6% to 28% when lymph nodes
were involved. Despite this variation, the
overall 5-year survival for patients who
underwent curative resection ranged from
46% to 56%. However, potentially
curative resections are usually possible in
only 50% to 75% of all patients at the
time they present.
Screening

Since the probability of survival
depends strongly on the extent of the car
cinoma at the time of diagnosis and treat
ment, major efforts have been made to
identify either “premalignant” polyps, or
asymptomatic cancers that have not yet
penetrated beyond the muscularis propria
of the large intestine. Only about 15% of
carcinomas that cause symptoms are con
fined to the bowel wall at the time of
diagnosis. Muto and associates3 have
presented evidence in favour of the in
testinal adenomatous polyp to cancer se
quence. Adenomatous polyps are usual
ly found in 5% to 10% of those over 40
years of age although autopsy series often
report higher rates. Malignant change oc
curs in 40% of villous adenomas and in
5% of tubular adenomas, but three
quarters of all adenomatous polyps are
of the tubular variety. It has been
estimated that an adenoma may take
from 4 to 15 years to undergo malignant
change, and the risk of malignant change
correlates with increasing polyp size.
Screening techniques should detect all
or most tumours without a high false
positive or false-negative rate, be easily
applicable to a large population and be
272

cost-effective. In practice, such ideal
techniques are not yet available.
No suitable blood tumour marker has
been discovered. Carcinoembryonic an
tigen is elevated in a number of malignant
and benign conditions, and although it
may be valuable in following the progres
sion of established colorectal carcinoma,
it is elevated in fewer than half those with
carcinoma confined to the bowel wall and
it is not usually elevated in patients with
benign adenomatous polyps. Circulating
immune complexes have been identified
in early stage carcinoma and may even
tually be evaluated in screening programs.
The most widely studied screening
techniques include fecal occult blood
testing, endoscopy and barium enema.
The oxidation of chromogenic in
dicators such as guaiac by hematin forms
the basis of the Hemoccult (Smith Kline
Diagnostics) and similar tests for fecal oc
cult blood. A blood loss of more than 10
to 15 ml is needed to obtain over 90%
positive Hemoccult tests, and irregular
bleeding patterns, and the effects of dry
ing and rehydrating the slides may all af
fect the test results. Hemoccult is also sen
sitive to false-positive reactions from
animal meat hemoglobin and vegetable
peroxidases, and to false-negative reac
tions due to the reducing action of ascor
bic acid. Consequently, a controlled diet,
and testing over several days, are usually
recommended. Hardcastle and Vellacott
suggested that false-negative Hemoccult
tests may occur with as many as 60% to
70% of adenomatous polyps, and 30%
or more of proven carcinomas.2 Com
pliance rates in the population may vary
widely, but they considered that fecal oc
cult blood testing in those over 40 years
of age could detect approximately 1.5 to
4.5 cancers per 1000 population screened.
It must also be that although hemorrhoids
are common, they are not necessarily the
source of rectal bleeding; in one German
series, 83 of 117 patients with occult
bleeding had hemorrhoids, and 7 of the
13 patients found to have colorectal car
cinoma also had hemorrhoids.
Endoscopy offers a relatively simple
means of evaluating the patient with

either overt or occult rectal bleeding.
Although there has been some increase in
the proportion of right-sided colonic car
cinomas in recent years, the majority of
adenomatous polyps and carcinomas still
lie in the rectum and sigmoid colon and
are accessible by the 60-cm fiberoptic
sigmoidoscope. It has been estimated that
the time required by a trained endoscopist
for adequate examination of the lower
colon following a single preparatory
enema is approximately 5 to 30 minutes
compared to 2 to 5 minutes with the
shorter 25-cm rigid sigmoidoscope. Flex
ible colonoscopy requires access to
radiologic facilities, some sedation of the
patient and more elaborate bowel
preparation. Endoscopy is not a practical
general screening method.
The double-contrast barium enema is
more effective than the standard enema
in detecting abnormalities of the colon,
although some studies still report a false
negative rate ranging from 5% to 30%.
The necessary preparation, the medical
manpower requirements and the 30 to 45
minutes required for the procedure do not
permit use of the barium enema as a
general screening technique. However,
barium enema and endoscopic examina
tion are complementary procedures in
symptomatic patients, and in those
selected by simpler screening methods
such as the Hemoccult test.
In the 1981 census there were 6.8
million Canadians between the ages of 40
and 70 years. Although there are
unresolved problems with presently
available techniques and the logistics of
screening the general population make it
impractical, it is logical to attempt to
identify tumours, at least in high-risk
groups, at the earliest possible time in
their natural history, especially when
many may be removed endoscopically.
Possible investigation schedules for dif
ferent patient groups are outlined in Table
I. Patients with specific diseases that are
associated with a high risk of colorectal
cancer, such as multiple polyposis or
ulcerative colitis, present special manage
ment problems and are excluded from
these general guidelines. A recent detail-

Table 1—Guidelines for Screening General Population for Colorectal Cancer
Interval between tests, yr
Group
Fecal occult blood Proctosigmoidoscopy
Colonoscopy
Asymptomatic, standard
risk, >40 yr
1
3 to 5
Asymptomatic, high risk
Previous colorectal
cancer or polyp
1
3 to 5
Female with history of
genital or breast
cancer
1
3 to 5
Family cancer syndrome
1
(? reliable)
—
3 to 5

Barium enema

3 to 5

(? role)
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ed review of screening is provided by
Winawer and colleagues.4
Extenl of Surgical Resection
Surgery remains the major method of
treatment for colorectal carcinomas and
the general principles of adequate resec
tion for most tumours require that the
primary tumour and its local lymphatic
and vascular connections be removed.
The resection of other pelvic organs, such
as the ovaries, and the effects of malig
nant and inflammatory adhesions on
surgery have been discussed by Sugarbaker and colleagues.1
Since survival correlates closely with
lymph-node involvement, some in
vestigators have tried to determine
whether more extensive node dissection
will improve the survival rates for patients
with rectal carcinoma. Tumour involve
ment of the internal iliac nodes appears
to be infrequent and less common than
spread to the mesenteric system. The in
ternal iliac nodes in patients with middle
and lower rectal carcinomas are not fre
quently dissected, although this has
recently been advocated by Enker and
colleagues who opine that a protocol in
cluding wide excision of the regional
lymph nodes reduces the risk of local
tumour recurrence. However, experience
with extended pelvic lymph-node dissec
tion at the Memorial Sloan-Kettering
Centre showed that only 11 of 122 pa
tients had extramesenteric node involve
ment, and the improvement in survival
compared with those who underwent
“ conventional” surgical resection was of
borderline significance. Bacon similarly
found that aortoileopelvic dissection in
creased survival by only about 5% for
those with rectal cancer. These more ex
tensive dissections were also accompanied
by an increase in the number of complica
tions. Similar attempts to increase the ex
tent of the proximal node dissection in the
region of the aorta have been unrewar
ding, although Nicholls suggested that
ligating the inferior mesenteric artery
flush with the aorta rather than distal to
the origin of the left colic artery was an
advantage when the most proximal node
was not involved, and when four or fewer
nodes were involved (5-year survival 65%
versus 47%).2 None of the studies were
randomized. Overall, however, there is
little evidence that more extensive node
dissection will improve the survival of pa
tients with rectal cancer.
Bowel continuity can be restored after
tumour resection by a variety of tech
niques, including stapling devices,
although abdominoperineal excision and
colostomy are probably still necessary in
nearly 50% of patients with rectal
carcinoma.5 The minimal length of nor
mal bowel distal to the primary tumour
that must be removed to reduce the risk

of local recurrence remains controversial,
but is clearly an important factor in deter
mining whether end-to-end anastomosis
is feasible. Local tumour recurrence ap
pears to be related not only to the extent
of retrograde intramural tumour spread
but also to the grade of the tumour, to
involvement of the pelvic lymphatics and
possibly also to the technical difficulties
of resection. Hence, although some ad
vocate resection of only 2 cm of normal
tissue in all directions from the tumour,
since studies have shown retrograde in
tramural spread of greater than 1 to 2 cm
in fewer than 5% of patients, most
recommend that 5 cm of clinically nor
mal mucosa should be removed. In a
review of 902 patients from the Mayo
Clinic, the local recurrence rate was only
5% (less than in other series, which have
reported up to 25% anastomotic recur
rences), but 60% of these recurrences oc
curred when the distance between the
tumour and the anastomosis was less than
5 cm.
Radiotherapy
Radiotherapy has been evaluated both
as a method of treating primary rectal
carcinomas to reduce the need for pro
cedures such as abdominoperineal resec
tion and as an adjunct to established
surgical procedures.
Intrarectal superficial irradiation, often
referred to as the “ Papillon technique” ,
involves the introduction of a low energy
x-ray tube into the rectum. For technical
and biologic reasons, this method is ap
plicable only to the treatment of super
ficial, exophytic, well- or moderately welldifferentiated adenocarcinomas less than
3 to 5 cm diameter and situated in the
distal 10 cm of the rectum. These criteria
select as far as possible only those
tumours that have not penetrated the rec
tal wall and have not spread to regional
lymph nodes. Local control rates and
5-year survival rates of better than 80%
have been reported by several centres,
showing that selection of early stage
tumours is feasible. The criteria pro
posed for this technique are similar to
those for other local treatments such as
excision or fulguration. Unfortunately,
fewer than 5% of all patients present with
carcinomas suitable for local treatment.
External beam irradiation has not been
used widely for the radical treatment of
rectal carcinomas, except when the
tumour has been unresectable. However,
at the Princess Margaret Hospital, 56 pa
tients who had clinically mobile rectal car
cinomas, but who, for many reasons, did
not undergo radical surgery, were treated
by external beam irradiation. The ob
served 5-year survival rate in that group
was 38%, and 21 of the 56 had their
tumour controlled by irradiation alone.6
None of these patients met the criteria for

intrarectal irradiation. More extensive
trials are needed to determine whether ex
ternal beam irradiation can consistently
control rectal carcinoma and produce
results comparable to those of radical
surgery.
Adjuvant irradiation, either before or
after radical surgery for rectal cancer, has
been evaluated in an attempt to improve
survival rates and reduce the incidence of
pelvic tumour recurrence, which frequent
ly causes severe symptoms. Preoperative
irradiation is intended to reduce the risk
of local or distant growth by tumour cells
inadvertently left behind or released into
the circulation and to reduce the size of
the primary tumour to facilitate surgical
removal. Several studies have suggested
that the incidence of involved regional
lymph nodes is also reduced. These ef
fects, and the lack of a staging system that
is not dependent on surgicopathologic
findings, make accurate comparison of
irradiated and nonirradiated groups dif
ficult. For this reason, some prefer to
defer irradiation until after surgery when
it is possible to identify those at highest
risk of local recurrence (those with
tu m o u r p en etratio n th ro u g h the
muscularis propria or with involved
lymph nodes). Controlled trials of
preoperative irradiation have shown im
proved survival for some patients,
although the results are not striking and
are not always consistent (Table II).
Pelvic recurrence rates have been reduc
ed in many series and the higher the
preoperative irradiation dose the lower is
the likelihood of recurrence. A temporary
colostomy appears necessary to allow
healing of any bowel anastomosis if the
radiation dose is greater than about 4500
rad in 4 to 5 weeks.
Postoperative adjuvant irradiation has
been studied in several uncontrolled trials
using doses of 4500 to 5500 rad in 5 to
6 weeks. Pelvic recurrence rates have been
reduced to 5% to 10% compared with the
historical experience of 25% to 65% in
those centres. Distant metastases still oc
curred in at least 25%, and long-term
follow-up is not yet available. In one ran
domized study by the Gastrointestinal
Tumour Study Group, pelvic recurrence
rates at a minimum follow-up of 24
months have been decreased to 11% by
irradiation of 4000 to 4800 rad in 4 to 5
weeks alone or plus 5-fluorouracil (5-FU)
and
m ethyl-cyclohexyl-chlorethyl
nitrosourea (MeCCNU), compared with
19% following surgery alone or with
chemotherapy. The most im portant tox
ic effect of pelvic adjuvant irradiation is
damage to the small bowel in the pelvis,
although this can be minimized by careful
planning of the radiation dosage.
Neither preoperative nor postoperative
adjuvant irradiation for rectal carcinoma
should be regarded as standard treatment.
The variations in survival and in pelvic

VOLUME 26, NO. 3, M A Y 1983 / THE CANADIAN JOURNAL OF SURGERY

273

recurrence rates reported from different
centres make it essential that whenever
possible trials of different treatment
regimens should be controlled, and that
a contemporary control group treated by
surgery alone should be included.
No large scale studies of adjuvant ir
radiation for carcinoma of the colon have
been reported. However, experience in the
treatment of ovarian carcinoma suggests
that radiation doses capable of control
ling microscopic disease throughout the
abdomen are tolerable.
Adjuvant Chemotherapy

There is no adjuvant chemotherapy for
colorectal adenocarcinoma that is ap
propriate for routine use. The most ex
tensively studied single agents have been
the fluorinated pyrimidines 5-fluorouracil
(5-FU) and fluorodeoxyuridine (FUDR).
No controlled trial has confirmed the oc
casional claims for substantial advantage
from these agents, although several
studies have shown increases in 5-year
survival of less than 10% which usually
do not reach commonly accepted levels
of statistical significance and which must
be offset against the potential toxicity of
adjuvant chemotherapy. Although the
use of adjuvant 5-FU by most schedules
and of intrahepatic infusion chemothe
rapy against established colorectal
metastases have both proven disappoin
ting, one recent study7 of adjuvant in
trahepatic 5-FU has been sufficiently pro
mising that others are attempting to
duplicate the results. Taylor and
associates7 used intrahepatic 5-FU
delivered through an indwelling umbilical
vein catheter during the first 7 days after
operation. At the time of reporting, only
2 of 66 (3%) patients treated by
chemotherapy subsequently had liver
metastases compared with 13 of 73 (18%)
who underwent surgery alone. The possi
ble effects of the heparin used in the
treated patients and the proximity of the
chemotherapy to the time of surgery are

factors that distinguish this study from
many others in which 5-FU was used.
The development of adjuvant combina
tion chemotherapy has been relatively re
cent and no conclusive results either for
or against such combinations have been
reported. Nearly all such regimens are
associated with acute morbidity of vary
ing degree, and there is little data on
possible long-term toxicity. If a treatment
regimen needs a response rate of about
50% against advanced disease to be ef
fective as an adjuvant, as has been sug
gested by Carbone, then the current trials
are likely to be disappointing. For exam
ple, the combination of 5-FU and MeCCNU, with or without vincristine, has been
reported to produce response rates of
from 11% to 45% in patients with ad
vanced disease. The Eastern Cooperative
Oncology Group recently reported the in
terim results of their study of adjuvant
5-FU and MeCCNU for carcinoma of the
colon and showed no advantage up to 4
years after first treatment.
The benefits of adjuvant treatment can
not be recognized in the individual pa
tients, who might well have been cured
by surgery alone. However, the sideeffects of adjuvant therapy may be very
apparent in the individual, and may be
not only physical, but also financial and
emotional. The proper place of adjuvant
therapy at present lies in appropriately
designed trials.
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cedures, and to evaluate their safety and
effectiveness.
For further information contact
Michael J. Bernstein, Rm. 216, Building
1, National Institutes of Health,
Bethesda, MD 20205; (301) 496-1143.
Advances in Gastrointestinal
Surgery

“ Advances in gastrointestinal surgery”
will be the major topic at the 47th annual
surgery course to be held June 15-18, 1983,
at the University of Minnesota. The for
mat will include lectures, moderated panel
discussions, audience participation panels
and films of specific surgical procedures.
Registration fee is $400 ($200 for medical
residents) and accreditation will be 30
hours in Category 1—AMA/ACCME.
For more information contact the Of
fice of continuing medical education,
University of Minnesota, Hospital Box
293, 420 Delaware St. SE, Minneapolis,
MN 55455; (612) 373-8012.
Surgery of the Shoulder

Over 200 orthopedic surgeons from
around the world are expected to attend
the 2nd International Conference on
Surgery of the Shoulder to be held May
29 to June 1, 1983 at the Park Plaza Hotel
in Toronto, Ont.
Speakers for this conference will
include Dr. N. Gschwend of Zurich, Swit
zerland; Professor Lipmann Kessel of
London, England; Dr. Ryuji Yamamote
of Yokohama, Japan; Dr. Ian Macnab of
Toronto; and Dr. Charles Neer of New
York.
The conference will cover all aspects of
| shoulder surgery, reconstructive problems
for arthritis, sports injuries and trauma.
Topics that have not previously been
discussed in open forum will include
management of nerve and muscle
disorders, problems with nerve injuries,
biomechanics of the shoulder and the ap
plication of new investigative techniques.
There will be exhibits by major surgical
supply companies.
For information contact Bennett
Solway Public Relations, Ste. 1700, 22 St.
Clair Ave. E, Toronto, Ont. M4T 2S3;
(416) 961-5355.
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Adenocarcinoma of the Vermiform Appendix:
Retrospective Study and Literature Review
Adenocarcinoma of the vermiform ap
pendix is a rare clinical entity, fewer
than 2 0 0 cases having been reported.
The authors carried out a retrospective
review over a 25-year period and found
five patients admitted to the Vancouver
General Hospital with primary appen
diceal adenocarcinoma. Four other pa
tients, initially reported as having appen
diceal adenocarcinoma, were found after
critical microscopic review to have had
either benign disease or mucinous car
cinoid. Primary epithelial neoplasms of
the appendix demonstrate a wide variety
of histologic types and because of the
different clinical behaviour, an accurate
diagnosis must be made. For the benign
tumours, appendectomy alone will suf
fice but for adenocarcinoma of the
appendix, right hemicolectomy is
recommended.
L'adenocarcinome de I'appendice vermiculaire est une entite clinique rare,
moins de 2 0 0 cas ayant ete signales
dans la literature. Les auteurs ont realise
une etude retrospective couvrant une
periode de 25 ans qui leur permit d'identifier cinq patients qui furent hospitalises
au Vancouver General Hospital souffrant
d'un adenocarcinome appendiculaire
primaire. Pour quatre autres patients
ayant un diagnostic initial d'adenocarcinome appendiculaire, un examen
microscopique critique identifia soit une
lesion benigne, soit un carcinoide
mucineux. Les neoplasies epitheliales
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primaires de I'appendice montrent une
vaste gamme de types histologiques.
Considerant les comportements cliniques
differents de chacun, un diagnostic
precis doit etre pose. Dans les cas de
tumeurs benignes, I'appendicectomie
seule suffit, mais pour les adgnocarcinomes appendiculaires. une hemicolectomie droite est recommandee.

Adenocarcinoma of the vermiform ap
pendix is a rare clinical entity. Fewer than
200 cases have been reported.15 The first
authentic description was by Beger6 in
1882, also cited by others.2-1A Collins9
provided the most comprehensive study
of the appendix in his report of the
pathologic findings in 71 000 specimens
o f the human appendix removed over a
40-year period. Of these, 958 primary
malignant tumours accounted for 1.35%
of the lesions. The incidence of primary
appendiceal adenocarcinoma was 0.08%.
Schmutzer and associates,10 reporting on
a series of 8699 specimens of the appen
dix, found 101 tumours; 17 of these were
malignant and only 2 were primary
appendical adenocarcinomas.
Patients and Methods
This retrospective study covers the
25-year period from 1954 to 1978. Dur
ing that time at the Vancouver General
Hospital five patients (three men, two
women), ranging in age from 38 to 84
years, were found to have primary appen
diceal carcinoma (Table I).
Original reports of pathologic findings
were obtained and in all except two cases
microscopic slides and tissue blocks were
available. Additional fresh sections were
prepared and stained with hematoxylin
and eosin, mucicarmine, periodic acidSchiff and by the Grimelius technique"
for neuroendocrine granules. These slides
were then re-evaluated without knowledge
of the clinical details of the case.
A histologic review was made of four
other patients who had an initial
microscopic diagnosis of appendiceal

adenocarcinoma. Two of these were con
sidered to have benign disease and two to
have mucinous carcinoid.
Findings
Initial Treatment
In three patients, appendectomy was
performed initially. One patient (case 3,
Table I) had a right hemicolectomy as the
primary procedure because of gangrene
of the terminal ileum and cecum secon
dary to abscess formation. One patient
(case 5, Table I) had abdominoperineal
resection of the rectum initially. At autop
sy, 3 years later, primary carcinoma of
the appendix was found.
Pathologic Features
The diagnosis of appendiceal adenocar
cinoma was confirmed in all cases. In one
(case 1, Table I) there was evidence that
the tumour originated in a pre-existing
cystadenoma. The morphology of appen
diceal adenocarcinoma was identical to
adenocarcinoma arising elsewhere in the
large bowel (Fig. 1). The adjacent
epithelium, classified as cystadenoma
(Fig. 2), consisted of noninvasive
papillary proliferation of well-differeniated tumour cells, similar to a villous
adenoma.
Subsequent Management
In p atien t no. 1 a salpingooophorectomy and partial cecotomy were
performed as a second operation 2
months after the appendectomy. No
residual carcinom a was found on
histologic examination of the specimen.
There were no metastases in the right
ovary and tube.
Patient no. 2 underwent a right
hemicolectomy as a second procedure
follow ing histologic diagnosis of
adenocarcinoma. There was no evidence
of metastases to the lymph nodes.
The other three patients had no further
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surgery, but patient no. 5 had
radiotherapy to the perineum and to the
lip for squamous cell carcinoma.

A primary adenocarcinoma of the appen
dix was found at autopsy.
Discussion

Survival
One patient was lost to follow-up. Of
the other four, patient no. 2 was alive and
free of recurrence 3 years after operation.
Patient no. 3 died of an acute myocardial
infarction 1 year after right hemicolec
tomy. Hepatic metastases were present at
autopsy. Patient no. 4 died 2 years after
appendectomy, of sepsis complicating
surgery for a fractured cervical spine. Pa
tient no. 5 died of pulmonary metastases
3 years after abdominoperineal resection.

Preoperative
diagnosis

Patient
no.
1

Age,
Yt
38

Sex
F

2

67

M

Acute
appendicitis

3

73

M

Appendiceal
abscess

4

84

F

Appendiceal
abscess

5

57

M

1. Rectal
carcinoma
2. Squamous
cell carcinoma
of lip

Acute
appendicitis

Carcinoma of the appendix is clinical
ly important because it is rare. The
diagnosis is infrequently m ade
preoperatively and is usually made by the
pathologist.1,4,12,13 According to some,
the diagnosis has never been made
preoperatively,3'8,14' 17 as was the case in
this review.
Stiehm and Seaman13 reported four
cases in which appendiceal carcinoma was
demonstrated preoperatively by roent
genography after barium enema. It has

to be appreciated, however, that many
cecal lesions can mimic the radiologic ap
pearance of appendiceal carcinoma, thus
limiting the use of this examination as a
diagnostic aid. A review of the literature
reveals that the most common mode of
presentation is as acute ap p en d i
citis.2'4'8' 10,16 Two o f our patients
presented with acute appendicitis, two
with appendiceal abscess and in one the
diagnosis was made at autopsy.
Some authors report no sex difference
with respect to the incidence of adenocar
cinoma of the appendix,12,17 while others
report a definite male preponderance.2,7
In this series there were three men and
two women. Patients presenting with ap-

Table 1-Data on Five Patients with Appendiceal Adenocarcinoma
Pathologic diagnosis
1. Initial
Subsequent treatment
2. Authors’
Initial operation
Laparotomy 2 mo
1. Malignant mucocele
Appendectomy
later. Partial ceco2. Adenocarcinoma
tomy and right salarising in a cysta
pingo-oophorectomy
denoma
Right hemicolectomy
1. Infiltrating
Appendectomy
4 d later
adenocarcinoma
2. Adenocarcinoma
None
1. Infiltrating wellRight
differentiated adeno
hemicolectomy
carcinoma with regionnal node metastases
None
1. Well-differentiated
Appendectomy
infiltrating
adenocarcinoma
Abdominoperineal
resection of
rectal
carcinoma

1. Adenocarcinoma of
rectum. Squamous cell
lip carcinoma

FIG. 1—Case 1. Adenocarcinoma of appendix (hematoxylin and
eosin, reduced by 43% from x 400).

Radiotherapy to lip
and perineum

Results and survival
Laparotomy 2 yr later
negative for recurrence.
Patient lost to follow-up
Alive and free of recurrence
at 3 yr
Died 1 yr later of myocar
dial infarction. Autopsy
showed hepatic metas
tases
Died following surgery for
fractured femoral neck
complicated by sepsis.
Survived 2 yr
Died 3 yr after abdomino
perineal resection of lung
metastases. Autopsy
showed adenocarcinoma
of appendix as incidental
finding. No evidence of
carcinoma being metastatic
in origin. Review confirmed
adenocarcinoma of
appendix

FIG. 2—Case 1. Cystadenoma of adjacent epithelium (hematoxylin
and eosin, reduced by 43% from x 100).
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pendiceai carcinoma are usually in their
fifth decade, the incidence increasing with
advancing age.2'7'8'12-14 The average age
in our series was 57 years, the youngest
patient being 38 and the oldest 84 years.
The histologic classification of appen
diceal neoplasms is given in Table II. This
has recently undergone revision, with the
recognition of new entities and the
redefinition of older terms. One of the
most important changes is the recognition
of mucin-producing carcinoids (Figs. 3
and 4).18-20 Another lesion to be con
sidered in the diagnosis of appendiceal
tum ours is the mucocele. It has been
shown21 that in 55% of mucoceles, the
underlying cause is neoplastic (48%
cystad en o m a and 7% cystadenocarcinoma).
P rim a ry epithelial appendiceal
neoplasms demonstrate a wide variety of
histologic types, and because of the dif
ferent clinical behaviour, it is essential
that an accurate diagnosis be made. Two
m ajor groups can be defined: benign
tumours for which treatment by ap
pendectomy alone will suffice and car
cinomas for which right hemicolectomy
is recommended.
Histologically, adenocarcinomas of the

Table II—Histopathologic Classification
of Primary Epithelial Appendiceal
Neoplasms
Benign
Adenoma
Villous adenoma
Adenomatous polyp (tubular adenoma!
Cystadenoma
Carcinoid
Usual type
Mucus-secreting type
Malignant
Adenocarcinoma
Malignant carcinoid

appendix resemble those found elsewhere
in the colon, even to the extent that there
may be evidence of origin in a pre-existing
benign tumour. Attempts to differentiate
between the malignant mucocele and the
primary appendiceal carcinoma have been
m ade.9-22'23 We accept the view of
McGregor and McGregor24 that these
are minor histologic variants but the
tumours differ in their natural history and
prognosis.
One of the commonest benign appen
diceal tumours is the cystadenoma. This
may have marked papillary epithelial pro
liferation but lacks the nuclear atypism
characterizing a malignant tum our.20
Rupture and pseudomyxoma peritonei
formation do not constitute criteria for
the diagnosis of malignant change.
Appendiceal carcinoids are most com
monly recognized as small yellowish
nodules at the tip. Their presence may on
ly be apparent on histologic examination.
The mucinous carcinoid (Figs. 3 and 4)
is similar grossly to appendiceal adenocar
cinoma, but differs histologically. Many
mucinous carcinoids may have been
misdiagnosed in earlier series as car
cinomas, before this variant was recog
nized. This was the case with two tumours
in our group.
Malignant carcinoids of the appendix
are extremely rare and constitute only
8.8% of tumours. They may be recog
nized grossly by their large size (more
than 2.0 cm) but have no specific
histologic features.25 The presence of
mucus within carcinoids from all areas of
the bowel is now well recognized. This
finding has been used to support the con
cept that the cell of origin is derived from
endoderm rather than the neural crest.26
There is unanimous agreement that
the treatment of choice of appendi
ceal carcinoma is right hemicolec
tom y.I’2,7’8’13' 15'17’27 In 1963, Hesketh12
published convincing evidence that right

hemicolectomy prolongs survival. In his
series, 19 were treated by appendectomy
alone; 14 died of malignant spread and
4 survived for 5 years or more. In con
trast, of 31 patients treated by right
hemicolectomy, only 10 died of the
disease and 19 survived for 5 years or
more.
Recommendations
In patients in the fifth decade of life
and beyond, presenting with what ap
pears to be acute appendicitis, carcinoma
should seriously be considered
preoperatively.
All specimens removed surgically
should be carefully scrutinized for
carcinoma.
If possible the appendix should be
palpated at every laparotomy and any
palpable masses should be subjected to
frozen-section biopsy. If malignant cells
are found, a right hemicolectomy should
be performed, preferably as a primary
procedure.
If carcinoma of unknown origin is
discovered at laparotomy, the appendix
should be considered as a possible
primary site.
The treatment of choice for appen
diceal adenocarcinoma is right hemicolec
tom y, as a primary or secondary
procedure.
We thank the medical records staff of the
Vancouver General Hospital for their
assistance and Misses Cathy Dennill, Gayle
Henderson, Vicki Mah and Lindsay Fisher
for their assistance in preparing the
manuscript.
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BOOK REVIEWS
ACETYLSALICYLIC ACID. New Uses for
an Old Drug. Edited by H.J.M . Barnett, J.
Hirsh and J. Fraser M ustard. 278
pp. Illust. Raven Press, New York;
Sterling Drug Ltd., Aurora, Ont., 1982.
Price not stated. ISBN 0-89004-647-6.

This book is based on the proceedings of a re
cent conference on acetylsalicylic acid in which
each of the many experts participating ad
dressed a single topic.
Of the two main sections in the book, the
first reviews the roles of prostaglandins in in
flammation, hemostasis and thrombosis. The
pharmacologic actions of acetylsalicylic acid
on platelet-vessel-wail interactions, patent duc
tus arteriosus, uterine contraction and gastric
mucosa are comprehensively reviewed. The
ability of acetylsalicylic acid to inhibit the syn
thesis of prostaglandins is recognized in the
general review of its effects. However, great
care is taken to present a balanced view of the
relevant role that prostaglandins may play in
various pharmacologic actions of acetylsalicylic
acid.
The second section provides a comprehen
sive account of the numerous clinical trials in
volving acetylsalicylic acid as an antithrombotic
agent in patients with coronary artery disease,
cerebrovascular disease and in the prevention
of venous thrombosis. The difficulties in
designing, performing and interpreting such
clinical trials are discussed, as are the specific
problems encountered in each of the reported
trials. The currently available data suggest that
acetylsalicylic acid is modestly effective as an

antithrombotic agent in men but is relatively
ineffective in women.
Although the book represents the pro
ceedings of a conference, it avoids the usual
pitfalls of this format. The quality of the in
dividual presentations is excellent and each is
accompanied by a superb synopsis. The ques
tion periods following each “ conference” elicit
answers of the same calibre as the formal
presentations.
The editors and participants are to be con
gratulated on producing a standard reference
on acetylsalicylic acid, prostaglandins and
clinical drug trials.
M.A.
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Ste. 395,
6000 Cote des Neiges Rd.,
Montreal, PQ
CARDIAC SURGERY. Edited by Dwight C.
McGoon. Cardiovascular Clinics. Edited
by Albert N. Brest, editor-in-chief. 242 pp.
Illust. F.A. Davis Company, Philadelphia,
1982. $40. ISBN 0-8306-5982-2.

In this state-of-the-art book of cardiac surgery
in 1982, 17 authoritative and concise chapters
have been prepared by recognized experts. The
scene is set by Dr. McGoon’s excellent open
ing chapter describing the history o f heart
surgery and the curtain falls with his final
chapter that predicts continued progress in car
diac surgery, particularly in the area of endstage cardiac failure.
continued on page 295
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c o n v a le s c e n c e and adva nced age. To p ro v id e s u p p le 
m e n ta ry d ie ta r y fib e r in specia l d ie t pro g ra m s, and as
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m a n a g e m e n t o f h e m o rrh o id s and f o llo w in g a n o re c ta l
surgery.

CONTRAINDICATIONS
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e ffe rv e s c e n t m ix tu r e s h o u ld be ta k e n w ith o u t dela y.
An a d d itio n a l 2 4 0 m l (8 o z ) glass o f liq u id b y its e lf is
recommended.
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SUPPLIED
METAMUCIL INSTANT MIX -contains dietary fiber (a natu
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husk o f the p s y lliu m seed (Plantago ovata). Premeasured
single dose packets of 6.4g each, containing 3.6 g of psyl
lium h y d ro p h ilic m ucilloid with effervescent and flavouring
e x c ip ie n ts . Each s in g le dose p a c k e t c o n ta in s 0 .2 g o f
s odiu m (as bicarbonate), 0.4 g sucrose, and ca lciu m and
sodium cyclam ate, and also furnishes approximately 2 cal
o rie s . L e m o n -lim e fla v o u r a v a ila b le in 150g b o ttle s or
boxes o f 1 5 single-dose packets. Single-dose packets are
a v a ila b le to h o s p ita ls in boxes o f 100. O ra n g e fla v o u r
available in boxes of 15 single-dose packets.
METAMUCIL P ow der- contains dietary fiber (a natural, glu
ten-free grain substance) derived from the refined husk o f
the p s y lliu m seed (P lantago o v a ta ). Each rounde d tea
spoonful o f buff-coloured powder (6.1 g of powder contain
ing approxim ately 3.0g o f psyllium h y d ro p h ilic m ucilloid)
contains 38% sucrose and 12% hydrous dextrose, has no
add ed s o d iu m and fu rn is h e s 12 c a lo rie s . A v a ila b le in
170g, 3 4 0 g and 600 g containers. Single-dose packets are
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As an adjunct to surgery
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can dram atically reduce
the risk o f antibiotic failure
in anaerobic infections
consistently bactericidal
against virtually all clinically
important anaerobes. In fact, Flagyl
500 Inj. is “ the only compound...
with consistent bactericidal activity
against anaerobic bacteria, including
B. fragilis} ”

Comparative efficacy o f 4 antimicrobial agents
against isolates o f Bacteroides in a mouse model
o f sc abscesses
Decrease vs.
controlsf
(log cfu)

Statistical
analysis*

Clindamycin

5.0± 0.6

2

Moxalactam

3 .8 ± 0 .6

2,3

Cefoxitin

3.5+0.5

3

DRUG

penetrates
rapidly into colonic tissue, achieving a
significant reduction in B acteroides
content of the colon within one hour.2
Flagyl 500 Inj. is distributed in all
body tissues and fluids, including
abscesses.3,4

concentrates
at bactericidal levels in wound tissue.
In an animal study comparing Flagyl
500 Inj. with clindamycin and
cefoxitin, only Flagyl 500 Inj.
achieved therapeutic concentrations in
both fresh and healing colonic tissue.5

eradicates
pathogens from within the abscess
cavity, achieving significantly greater
reductions in B acteroides count than
clindamycin or cefoxitin.4

+Mice given no antibiotic had mean (± SEM) counts o f
lQ 9.9±0 .3c fu pe,. abscess at five days.
*Results for drugs with the same numerical designation were
not significandy different (P >0.05) by Student’s t- test of
independent means.

Excellent safety profile
Flagyl 500 Inj. is well tolerated, with a
low incidence of side effects.6
Pseudomembranous colitis is unlikely
to occur, as Flagyl 500 Inj. is highly
effective against C. difficile?’8 which is
usually associated with this disease5
Clindamycin and cefoxitin, on the
other hand, show little activity against
C. difficile 7’8
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A selective anaerobicide
ACTIONS
Flagyl (metronidazole) is bactericidal against
anaerobic bacteria, it exerts trichomonacidal activity
and is also active against Giardia lamblla and
Entamoeba histolytica. Its exact mechanism of action
has not been entirely determined as yet. It has been
proposed that an intermediate in the reduction of
metronidazole, produced only in anaerobic bacteria
and protozoa is bound to deoxyribonucleic acid and
proteins, and inhibits subsequent nucleic acid
synthesis.

INDICATIONS AND CLINICAL USES
Bacterial Infections: The treatment of serious
anaerobic abdominal infections due to susceptible
anaerobic bacteria, such as Bacteroldes fragills (and
other species of Bacteroides), Clostridium,
Fusobacterium, Peptococcus, and Peptostreptococcus
species.
Culture and susceptibility studies should be
performed to determine the causative organisms and
their susceptibility to metronidazole. Based on clinical
judgment and anticipated bacteriological findings,
therapy may be started while awaiting the results of
these tests. In mixed aerobic and anaerobic infections,
consideration should be given to the concomitant
administration of an antibiotic appropriate for the
treatment of the aerobic component of the infection.
(See Warnings).
Flagyl (metronidazole) has also been used in the
treatment of a small number of cases of brain or lung
infections (some with abscesses) caused by anaerobic
bacteria.

CONTRAINDICATIONS
Flagyl (metronidazole) is contraindicated in
patients with a prior history of hypersensitivity to
metronidazole or other nitroimidazole derivatives.
Flagyl should not be administered to patients with
active neurological disorders or a history o f blood
dyscrasia, hypothyroidism and hypoadrenalism.

WARNINGS
Flagyl (metronidazole) has no direct activity
against aerobic or facultative anaerobic bacteria. In
patients with mixed aerobic/anaerobic infections,
appropriate concomitant antibiotics active against the
aerobic component should be considered.
Known or previously unrecognized moniliasis may
present more prominent symptoms after treatment
with Flagyl.
Studies in rats and mice have provided some
evidence that metronidazole may cause tumors in
these species when administered orally for a long
period at high doses. The relevance o f these findings
in humans is not known.
Severe neurological disturbances (i.e. convulsive
seizures and peripheral neuropathy) have been
reported in patients treated with Flagyl (administered
orally or intravenously). These have been observed
very infrequently.

PRECAUTIONS
Patients taking Flagyl (metronidazole) should be
warned against consuming alcohol, because of a
possible disulfiram-like reaction. For the same
reason, patients receiving Flagyl should not be
administered disulfiram concomitantly.
Transient eosinophilia and leukopenia have been
observed during treatment with Flagyl. Regular total
and differential leukocyte counts are advised if
administration for more than 10 days or a second
course of therapy is considered to be necessary.
Metronidazole crosses the placental barrier.
Although Flagyl has been given to pregnant women
without apparent complication, it is advisable that
oral administration be avoided in pregnant patients
and Flagyl be withheld during the first trimester of
pregnancy. In serious anaerobic infections, if the
administration of Flagyl to pregnant patients is
considered to be necessary, its use requires that the
potential benefits be weighed against the possible
risks to the fetus.
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Metronidazole is secreted in breast milk in
concentrations similar to those found in plasma.
Intravenous or oral administration o f Flagyl should be
avoided in the nursing mother.
Metronidazole has been reported to potentiate the
anticoagulant effect of warfarin resulting in a
prolongation of prothrombin time. This possible drug
interaction should be considered when Flagyl is
prescribed for patients on this type of anticoagulant
therapy. Clinical experience in children is very limited.
The monitoring of this group of patients is particularly
important. The safety and effectiveness of intravenous
Flagyl in children has not been established.
A rare case of reversible but profound neurological
deterioration has been reported following a single oral
dose of Flagyl; it is therefore advisable that a patient
taking Flagyl for the first time not be left unattended
for a period of two hours. The appearance of abnormal
neurologic signs demands prompt discontinuation of
Flagyl therapy and, when severe, immediate medical
attention. Gastric lavage may be considered if no
more than two or three hours have elapsed since
administration of the drug.
Treatment with Flagyl should be discontinued if
ataxia or any other symptom of CNS involvement
occurs.
Patients with severe hepatic disease metabolize
metronidazole slowly with resultant accumulation of
metronidazole and its metabolites in the plasma.
Accordingly, for such patients, doses of Flagyl below
those usually recommended should be administered
and with caution. The determination of serum
glutamic oxaloacetic transaminase (SGOT) by the
Technicon SMA 12/60 system in blood samples from
patients receiving Flagyl may give abnormally low
values. This abnormality is artifactual and caused by
the absorption of metronidazole at the wavelength
where the enzymatic reaction is monitored
spectrophotometrically.

ADVERSE REACTIONS
Gastrointestinal: diarrhea, nausea, vomiting,
anorexia, epigastric distress, dyspepsia, constipation.
Month: furred tongue, dry mouth, unpleasant
metallic taste.
Hematopoietic: transient eosinophilia or
leucopenia.
Dermatologic: rash and pruritus.
Cardiovascular: palpitation and chest pain.
Central Nervous System: convulsive seizures,
peripheral neuropathy, transient ataxia, dizziness,
drowsiness, confusion, insomnia and headache.
Peripheral neuropathies have been reported in a few
patients on moderately high to high-dose prolonged
oral treatment with metronidazole. It would appear
that the occurence is not directly related to the daily
dosage and that an important predisposing factor is
the continuation of oral and/or I.V. medication for
several weeks or months. Profound neurological
deterioration, within 2 hours after Flagyl
administration has been reported. The occurrence is
not directly related to the dosage level.
Metabolic: An antithyroid effect has been reported
by some investigators but three different clinical
studies failed to confirm this.
Local Reactiona: Thrombophlebitis has occurred
with I.V. administration.
Other: Proliferation o f Candida albicans in the
vagina, vaginal dryness and burning; dysuria;
occasional flushing and headaches, especially with
concomitant ingestion of alcohol; altered taste of
alcoholic beverages. Darkening of the urine has been
reported. This is probably due to a metabolite of
metronidazole and seems to have no clinical
significance.

SYMPTOMS AND TREATMENT OF
OVERDOSAGE

Symptoms
Massive ingestion may produce vomiting and slight
disorientation.
Treatment
There is no specific antidote. Early gastric lavage
may remove a large amount of the drug; otherwise,
symptomatic treatment.

DOSAGE AND ADMINISTRATION
TREATMENT OF ANAEROBIC
INFECTIONS
Treatment should be initiated by the I.V. route. Oral
medication may be substituted when it is feasible
and/or practical. Duration of therapy depends upon
clinical and bacteriological assessment. Treatment for
seven days should be satisfactory for most patients.
However in cases where infection sites cannot be
drained or which are liable to endogenous
recontamination by anaerobic pathogens, a longer
treatment may be required.

I. V. ADMINISTRATION:
100 mL (500 mg) by intravenous infusion every 8
hours. The injection should be infused intravenously
at the rate of 5 mL per minute.
Flagyl injection is compatible in a volume ratio of
1:5 with normal saline, dextrose-saline, dextrose 5 per
cent w/v or potassium chloride injections (20 mmol
and 40 mmol). It should not be mixed with sodium
lactate injection 5% w/v, or dextrose injection 10%
w/v.

AVAILABILITY
Injection 0.5% w/v in Viaflex* plastic bags of
100 mL (500 m g) for intravenous infusion.
FULL PRODUCT MONOGRAPH AVAILABLE ON
REQUEST.
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Ureter within a Sliding Inguinal Hernia
Large sliding inguinal hernias may con
tain a variety of either intraperitoneal or
retroperitoneal anatomical structures.
A ureter within a sliding inguinal hernia
has been reported rarely. The author
presents such a case to alert the unwary
surgeon of this possibility and to indicate
a successful method of treatment.
Pyelography is indicated as a routine
preoperative diagnostic procedure in
morbidly obese patients with large ir
reducible inguinal hernias, particularly if
the patient complains of frequency or
other urinary symptoms.
The ureter should be carefully
dissected with its blood supply from the
sliding tissues and laid back in the
retroperitoneal space with resection or
reimplantation. The hernia may then be
repaired by standard methods.
The patient described in the report is
well and free of symptoms 10 years
after the operation.
Les hernies inguinales larges par glissement peuvent renfermer diverses struc
tures anatomiques intraperitoneales.
On a rarement rapporte une uretere a
I'interieur d'une hernie inguinale par glissement. L'auteur decrit un tel cas afin
d'eveiller I'attention du chirurgien qui ne
serait pas sur ses gardes sur cette possi
bility et aussi de proposer un mode de
traitement efficace.
La pyelographie est indiquee comme
mesure diagnostique preoperatoire
d’usage chez les patients souffrant
d'obesite pathologique qui presentent
une hernie inguinale large irreductible,
particulierement quand ils se plaignent de
frequence exageree des mictions ou
d'autres symptomes urinaires.
L'uretere et ses vaisseaux sanguins
doivent etre soigneusement disseques
des tissus de glissement et replaces dans
I’espace retroperitoneal par resection ou
reimplantation. La hernie peut alors etre
reparee par les methodes
conventionnelles.

From the department o f surgery,
Metropolitan General Hospital, Windsor,
Ont.
Accepted fo r publication Oct. 22, 1982
Reprint requests to: Dr. W.L. Percival,
Ste. 103, 700 Tecumseh Rd. E, Windsor,
Ont. N 8X 4T2

Le patient decrit dans cet article se
porte bien et est exempt de symptomes
10 ans apres I'operation.

The wanderings of the ureter are probably
more varied than is generally recognized
and deserve noting to protect this very im
portant structure from damage caused by
the unwary operator.
Only 53 herniations of the ureter into
the inguinal or scrotal area have been
reported.1’19 The case reported here will
bring to the attention o f surgeons a rare
anatomic accompaniment o f sliding
hernias.

Case Report
A 58-year-old man was referred with a huge
right inguinal hernia. He was 173 cm tall
and weighed 125 kg. He appeared in excellent
health except for his obvious hernia and obesi
ty. The hernia was inguinal and scrotal and was
the size of a large coconut. It could not be
reduced when he was lying down.
The patient said he had worked hard since
he was 15 years old. He regularly lifted more
than 135 kg and he could easily lift 90 kg up
to his shoulder with one hand.
About 20 years earlier he had noticed a swell
ing in the right groin. He had a “ tired pain”
in that area, which gradually became worse as
the hernia enlarged, but he never wore a truss
or other support.
About 3 years earlier, he found he could not
empty his bladder properly. He had to sit to
urinate; the stream became smaller and he was

FIG. 1—Preoperative roentgenogram show
ing right ureter in hernial sac.

urinating 12 to 15 times each day and getting
up 2 or 3 times at night. On each occasion the
quantity of urine passed was small.
A retrograde pyelogram showed that the
right ureter was in the hernial sac (Fig. 1). At
operation a large retroperitoneal slide of fat
was identified. The ureter was readily iden
tified. It was of normal size and had normal
peristalsis. It was dissected with its blood supp
ly and the large excess of fat and some
peritoneum were removed. The peritoneum
was closed and the partially herniated bladder
returned to the retroperitoneal space along with
the ureter. The ureter was simply placed in
reasonable alignment without kinking it. A
standard McVey repair was performed com
pletely closing the internal ring; an orchiectomy
was also done on that side.
The patient made a smooth recovery and was
discharged 4 days after operation.
One month later, retrograde pyelography
showed normal excretion of dye from the right
ureter (Fig. 2). The patient was asymptomatic.
He could void standing and urinated only five
or six times each day and not during the night;
the stream was much better.

Comment
Lecroix in 188010 reported a case o f a
ureter in a hernia at autopsy. In 1937
Dorm ashkin6 collected 37 cases o f
ureteral herniation; in 1948 W atson18
augmented this in a classic series o f 102
carefully documented cases. In some cases
the ureter had herniated into the sciatic
foramen or into the space between iliac
vessels and psoas muscle. Nearly half o f

FIG. 2— Postoperative view with right ureter
replaced.
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SOME LAXATIVES WAS
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PRODIEM AND PRODIEM PLAIN
Pleasant mintflavoured
granules are
taken with any
beverage,
cool or warm:
fruit juice, milk,
tea, coffee or
bouillon.

A S EASY
TO TAKE
A S WHAT
YOU TAKE
THEM
WITH.
Just put a level
teaspoonful of
granules (5 mg) in
the mouth and
follow with a
warm or cool
drink.

PRODIEM AND PRODIEM PLAIN FOR MORE THAN
ONE KIND OF CONSTIPATION.
PRODIEM

PRODIEM PLAIN

Bulk forming only for:
Bulk forming with added mild
• Constipation associated with
peristaltic stimulus for:
Irritable Bowel Syndrome and
• Acute and obstinate constipation
diverticular disease
• Initial laxative therapy
• Constipation during
for severe ‘simple
pregnancy and postpartum
constipation’
• Constipation causing
• Atonic constipation of
discomfort of hemorrhoids
the elderly
and anal fissures.
• Patients being weaned
off harsh laxatives.
Rorer Canada Inc.
Bramalea, Ontario L6T 1C3
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Prodiem
Indications:

The relief of acute and obstinate constipa
tion, the early stages of more severe simple
constipation and constipation of the elderly
caused by loss of muscle tone and neuro
musculature reflex. For use in patients being
weaned off harsh laxatives or where a
straight bulk forming preparation has failed
to provide regular bowel evacuation.
Contraindications:

The presence of nausea, vomiting, abdomi
nal pain or symptoms of an acute abdomen
or fecal impaction.
Precautions:

For patients with a history of esophageal dis
orders. If mild cramping occurs, dosage
should be reduced.
Dosage:

Adults -1 to 2 level teaspoonfuls (5 g to 10 g)
should be placed in the mouth and swal
lowed unchewed with at least 240 ml of any
cool beverage including juice, milk or water.
This dose may be taken before breakfast
and/or in the evening depending on the con
dition being treated, its severity and indivi
dual responsiveness.
Children - Forchildren aged 6 to12 years, the
dosage is half the adult dose.
Supplied:

Each 5 g (1 level teaspoonful) of dark brown
minty-tasting granules contains 2.71 g of
psyllium hydrophilic mucilloid and .62 g of
sennapod,1.5mgofsodium,30 mgofpotassium and furnishes 3.5 calories.
Available in 100g and 250g canisters.

all herniations of the ureter were inguinal,
scrotal or femoral. Femoral herniation
occurs primarily in women and the inguinoscrotal type predominantly in men.
There is a marked predilection for the
right side in both femoral and inguinoscrotal hernias. The ureter may be
herniated with the bladder or a bladder
diverticulum.
Lindbom12 described sciatic herniation
associated with hydroureter requiring
resection or reimplantation into the blad
der. On the other hand, Beck and
associates2 reported sciatic herniation
that was successfully reduced without
resection.
Mallouh and Pellman13 described suc
cessful resection and anastomosis in two
boys with congenital anomalies of the
genitourinary tract with herniation. The
younger boy was 3>/2 years old.
To rule out the possibility of this
anomaly, intravenous pyelography should
be included in the preoperative assessment
of obese patients with large inguinal
hernias.
The illustrations are reproduced by courtesy
of Michael Cogliati, chemistry department,
Metropolitan General Hospital, Windsor, Ont.
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Prodiem Plain
Indications:

The relief of simple, chronic and
spastic constipation and for constipation as
sociated with pregnancy, convalescence
and advanced age. For use in special diets
lacking in residue fibre and in the manage
ment of constipation associated with irritable
bowel syndrome, diverticulitis, hemorrhoids
and anal fissures.
Contraindications:

The presence of nausea, vomiting, abdomi
nal pain or symptoms of an acute abdomen
or fecal impaction.
Precautions:

For patients with a history of esophageal
disorders.
Dosage:

Adults -1 to 2 level teaspoonfuls (5g to10g)
should be placed in the mouth and swal
lowed unchewed with at least 240 ml of any
cool beverage including juice, milk or water.
This dose may be taken before breakfast
and/or in the evening, depending on thecondition being treated, its severity and indivi
dual responsiveness.
Children - For children aged 6 to 12 years,
the dosage is half the adult dose.

SESAP IV Critique
ITEM 131
Propranolol is an adrenergic blocking agent that interferes with beta-stimulation
by competing for available beta-receptor sites in areas such as the heart and
the smooth muscle of the blood vessels and bronchi. This beta blockade nega
tes many of the effects of circulating T, and T4, rendering the patient clinically
euthyroid despite elevated thyroid hormone levels.
Propranolol can therefore be used without antithyroid drugs as well as
without elemental iodine because it does not increase thyroid vascularity. Preop
erative preparation is usually accomplished in two weeks or less, compared with
the six to eight weeks required for thioureas. T, and T4 blood levels will re
main elevated postoperatively for up to seven days, and propranolol should
therefore be continued for seven to ten days postoperatively. This drug is con
traindicated for patients with asthma because it diminishes smooth-muscle res
ponse to bronchodilators. Thyroid storm does not occur in patients prepared
with propranolol. Propranolol constitutes a major part of the recommended
therapy for thyroid storm.
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Supplied:

Each 5g (1 level teaspoonful) of light brown
minty-tasting granules contains 3.25 g of
psyllium hydrophilic mucilloid, 1.5 mg of so
dium, 30mg of potassium and furnishes 3.5
calories.
Available in 100 g and 250 g canisters.
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La tamponnade tardive apres chirurgie cardiaque:
un redoutable piege diagnostique
A I’o ccasion de la survenue de trois tamp on n a d e s tardives apres chirurgie cardia
que sur une serie de 2 5 0 operations a
coeur ouvert consecutives, les auteurs
ont revu la litterature concernant cette
com plication.
Q uatre-vingt-dix-neuf observations
so n t colligees. La frequence de la tam 
pon nad e tardive est de 0 . 6 2 % des inter
ventions de chirurgie cardiaque et cette
com plication est fatale dans 1 6 . 2 % des
cas. Le delai d'apparition varie de 3 jours
a 3 m ois, la m oyenne se situant aux
alentours de 1 4 .5 ± 7.8 jours. Le
tableau initial est insidieux et polym orphe, ce qui constitue le danger de la
tam ponnade tardive. Les sign e s sont respiratoires: d ysp ne e et douleurs thoraciques: digestifs: anorexie et vom isse m ents; cerebraux: confusion mentale,
voire com a. La paleur avec chute de I'hem atocrite chez le malade s o u s anticoagu
lants est su gg e stiv e d 'u n e spoliation s a n 
guine. Le diagnostic definitif repose sur
le catheterism e droit et I'echographie
m ono et bidimensionnelle. La tom ographie tran sve rse axiale avec ordinateur
n o u s paraft etre un exam en non invasif,
interessant et fiable quand il peut etre
pratique en urgence. Enfin, la ponction
pericardique est une technique a la fois
d iagnostiq u e et therapeutique d a n s un
tiers d es cas; elle est faussem ent ne ga
tive d a n s 1 2 % des cas. Les diagnostics
diffdrentiels evoq u es sont ceux de I'em bolie pulmonaire, de I'in su ffisa n ce myocardiaque et du ch oc septique. La tam 
pon nad e tardive repondrait a deux meca-
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nism es: soit un hem opericarde par surd osa g e des anticoagulants, soit une form e
exacerbee du synd rom e post-pericardoto-

anticoagulan ts or an exacerbated form of
the post-pericardiotom y syndrom e.
E m e rge ncy treatm ent is a lw a y s

mie.
La conduite therapeutique a tenir est

n e ce ssary.
Pericardiocentesis is a useful
d ia g n o stic aid and p ro vides tem porary
stabilization preoperatively. A w ide
surgica l approach is a lw a y s indicated.
T h e mortality in untreated patients is
1 0 0 % . The frequency of im m ediate
relapse or, occasionally, of delayed
relapse is estim ated to be 1 1 % ; relapse

toujours urgente.
La pericardiocentese trouve sa place
d a n s le diagnostic et d a n s I'am elioration
tem poraire pre-chirurgicale. Le traitement
chirurgical large s 'im p o s e toujours. La
mortality chez les patients non traites est
de 1 0 0 % . La frequence des recidives
im m ediates et parfois tardives est estim ee a 1 1 % ; elles representent un d anger
mortel.
In a series of 2 5 0 consecutive openheart operations, three ca se s of late ca r
diac tam ponade were noted follow ing
the operation. T h is led the authors to
review the literature pertaining to this
com plication.
Ninety-nine ca se s were collected. The
fre quen cy of late tam ponade a ssociate d
w ith cardiac surgery w a s 0 . 6 2 % and
w a s fatal in 1 6 . 2 % of those cases. The
delay before the tam ponade appeared
varied from 3 d a ys to 3 m onths (m ean
1 4 .5 ± 7 .8 days). The initial clinical pic
ture is insidiou s and vague, and this c o n 
stitutes the danger of late cardiac tam 
ponade. The clinical sig n s
are of the respiratory (dyspnea,
ch e st pain), gastrointestinal (anorexia,
vom iting) and central ne rvous (mental
con fusion, even com a) system s. Pallor
w ith a drop in hematocrit in patients on
anticoagulant therapy su g g e s ts occult
bleeding. A definitive diag n o sis depends
on catheterization of the right side and
on m ono- and bidim ensional echocar
diography. The authors believe that c o m 
puterized axial tom ograph y represents an
interesting n o nin va sive and reliable e x 
am ination technique w hen it can be u se d
during em ergency treatment. Pericardial
puncture, w h ich is both a diagnostic and
therapeutic technique, w a s useful in one
third of the cases; it produced a false
negative result in 1 2 % . The resulting dif
ferential d ia g n o se s are pulm onary em 
bolism . m yocardial insufficiency and se p 
tic shock. Late cardiac tam ponade m ay
be produced by one of tw o m echanism s:
hem opericardium due to overdo sage of

m a y be lethal.

Survenant dans la phase postoperatoire
immediate et bien que potentiellement
fatale, la tamponnade pericardique aigue
est d’un diagnostic relativement facile.
La tamponnade pericardique tardive,
decrite initialement par Prewitt et
collaborateurs1 en 1968, est une entite
differente. Plus rare, survenant vers le 14e
jour postoperatoire et en phase de surveil
lance moins etroite chez un patient sur
pied et convalescent, la tamponnade tar
dive n’en est que plus traitresse. Elle cons
titue un piege diagnostique redoutable si
l’on n’y pense pas systematiquement.
L’etude des cas repertories dans la
litterature1’22 permet d ’en degager les
caracteristiques. Nous rapportons trois
cas de tamponnade tardive observes entre
juin 1980 et novembre 1981, dans une
serie de 250 operes a coeur ouvert
consecutifs.
Donnees Cliniques

Observation 1
Le patient, age de 60 ans, a subi le 10 septembre 1980 un remplacement valvulaire aortique (Bjork-Shiley no. 25) pour insuffisance
aortique compliquee d’episodes de decompen
sation cardiaque gauche.
Les suites operatoires sont simples. Un drain
retrosternal est retire apres 48 heures et une
therapie anticoagulante a l’heparinate de cal
cium est commencee a la dose de 5000 U a chaque 12 heures; au 3e jour, le relais est pris par
une antivitamine K. Les electrodes d’un stimulateur cardiaque sont retirees au 7e jour et le
patient obtient son conge 9 jours apres
[’operation.
Au depart, la fonction valvulaire est bonne
et il n’y a pas d’insuffisance cardiaque. Le
temps de prothrombine est equilibre a 27 secon-
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des par rapport a un temoin de 11.8 secondes.
L ’hemoglobine plasmatique est a 10.7 mg/dl
et l’hematocrite a 31%.
Le 20 septembre, apparait un essoufflement
a l’effort avec orthopnee et gene a [’inspira
tion profonde. Trois jours plus tard, le patient
est rehospitalise en urgence devant l’aggravation du tableau dinique. A l’entree, il paraTt
asthenique, pale et il a les extremites froides.
La tension systolique est de 95 mm Hg. Il y
a turgescence des jugulaires en position demiassise et hepatomegalie douloureuse a deux travers de doigts sous le rebord costal. On per?oit un pouls paradoxal, signe d ’une tamponnade (chute tensionnelle rythmee par l’inspiration). L’auscultation revele un assourdissement des bruits du coeur. La radiographie thoracique de face objective une cardiomegalie
avec aspect en “ soupiere” et un rapport cardiothoracique de 60% (fig. 1), alors que les radiographies precedentes montraient un rapport de
50% (fig. 2). La pression veineuse centrale
s’etablit a 30 cm H20 . Une demi-heure apres
l’arrivee du patient a l’hopital, la tension arterielle chute a 70 mm Hg. Un echocardiogramme pratique d’urgence confirme la pre
sence d’un epanchement pericardique. Le bilan
biologique revele une anemie avec chute de
l’hemoglobine plasmatique a 9.9 mg/dl et un
hematocrite a 28%. Le patient est tres hypocoagule: son temps de prothrombine est a 55
secondes pour un temoin a 12 secondes. Par
ailleurs, on constate une polynucleose a 10 x
109 cellules/l.
Un drainage sous-xyphoTdien pratique en
urgence permet d’evacuer 1300 ml de liquide
sero-hemorragique. Immediatement, l’hemodynamique du patient se retablit avec chute
de la pression veineuse centrale a 10 cm H20
et augmentation de la tension systolique a 150
mm Hg. La diurese reprend (130 ml/h pendant
les 6 premieres heures). Les chiffres de creatininemie qui etaient augmentes durant la tamponnade se normalisent.
A la sortie le patient est asymptomatique,
cicatrise, afebrile. La pression veineuse centrale
est de 7 cm H20 . La tension systolique est a
120 mm Hg et la diastolique a 70 mm Hg. On
constate une bonne fonction valvulaire et la
normalisation des chiffres de creatininemie. Le
controle de l’hemostase est a 26.7 secondes de
temps de prothrombine pour un temoin a 12.3
secondes. La radiographie pulmonaire montre
un rapport cardio-thoracique normalise a 48%.
En resume, il s’agit d’une tamponnade tar
dive survenant au 13e jour postoperatoire chez
un patient ayant subi un remplacement valvu
laire aortique et en etat de surdosage des antivitamines K.

Au lOe jour, le rapport cardio-thoracique est
a 55% avec un arc inferieur gauche signant une
hypertrophie ventriculaire gauche. La patiente
est a nouveau hospitalisee 14 jours apres sa sor
tie, soit 24 jours apres l’intervention. Le 4 mars
1981, elle est adressee pour dyspnee d ’effort
avec orthopnee de repos (avec deux oreillers),
nausees, palpitations et douleurs abdominales
non specifiques. Elle est anorexique depuis 3
jours et tres anxieuse. On constate une polypnee a 40 cycles/min avec cyanose peripherique
et diaphorese.
L’examen montre une tension systolique a
85 mm Hg, et une diastolique a 60 mm Hg.
11 y a tachyarythmie a rythme ventriculaire
rapide de 150 pulsations/min. La prothese val
vulaire fonctionne bien. On retrouve la pre
sence d ’un reflux hepato-jugulaire, une tension
des jugulaires en position demi-assise et une
hepatomegalie a trois travers de doigts sous le
rebord costal.
L ’electrocardiogramme objective une fibril
lation auriculaire avec hypertrophie ventricu
laire gauche. On constate un micro-voltage des
complexes dans les derivations precordiales. La
prise de la pression veineuse centrale montre
des chiffres eleves oscillant entre 35 et 40 cm
H20 .
Le bilan biologique montre une hypocoagulabilite importante, le temps de prothrombine
etant a 123 secondes pour un temoin a 12
secondes. 11 y a presence d’une anemie avec 9.3
mg/dl d ’hemoglobine plasmatique, d’une poly-

nucleose a 14.1 x 109 cellules/l et d’une
oligo-anurie depuis 12 heures. La creatinine
mie est a trois fois la normale. La radiogra
phie thoracique de face montre une silhouette
cardiaque augmentee, un rapport cardiothoracique a 70% avec une petite lame d’epanchement pleural droit (fig. 3).
Devant la tamponnade, une ponction peri-
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H G . 2—Observation 1. Echographie objectivanl I’epanchemenl pericardique. E.P. =
epanchement pericardique; V.M. = valve
mitrale; ENDO. = endocarde; EPI =
epicarde; P.P. V.G. - paroi posterieure du
ventrieule gauche.

Observation 2
La malade, agee de 64 ans, a subi le 20 janvier 1981 un remplacement valvulaire mitral
(Bjork-Shiley no. 31), avec une plastie tricuspidienne pour insuffisance mitrale et tricuspidienne (fraction regurgitee de 76%) consecu
tive a une degenerescence myxomateuse. Les
suites operatoires sont simples mais il y a persistance d ’une fibrillation auriculaire preexistante. A la sortie, il n’y a pas d ’insuffisance
cardiaque et la fonction valvulaire a l’auscultation est bonne. L’hemoglobine plasmatique
est a 12.8 mg/dl, l’hematocrite a 36.4%.
Le traitement anticoagulant par antivitamine
K est adequat, le temps de prothrombine etant
le double du temoin.
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Fig. lb

Fig. 3b

FIG. 1—(a) Cliche Ihoracique de face,
preoperatoire. (b) Cliche Ihoracique lors de la
tamponnade au 13e jour postoperatoire, apres
remplacement valvulaire aortique.

FIG. 3—Observation 2. (a) Radiographie de
face preoperatoire. (b) Radiographie de face
lors de la tamponnade, 3 mois apres un
remplacement valvulaire mitral.
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cardique sous-xyphoidienne permet de ramener un epanchem ent sanglant signant
l’hemopericarde.
Devant l’aggravation rapide de l’etat
hemodynamique, on pratique sous anesthesie
generale une fenetre pericardique sousxyphoidienne d ’ou Ton evacue 650 ml de sang
hemolyse avec depots fibrino-cruoriques loca
lises au point d ’insertion de l’electrode
epicardique.
Des la decompression cardiaque, survient
une amelioration hemodynamique rapide avec
normalisation tensionnelle: la tension systolique passe de 70 mm Hg a 110 mm Hg et la pression veineuse centrale chute a 14 cm H20 . La
diurese reprend et la creatininemie se norma
lise dans les 48 heures. Au 7e jour, la polynucleose est reduite a 7.5 x 109 cellules/1.
Au total, il s’agit d’une tamponnade tardive
survenu au 43e jour d ’un remplacement valvulaire mitral avec correction d ’insuffisance tri-

H

cuspidienne par plastie. On constate une hypocoagulabilite importante. Le traitement se fait
par drainage sous-xyphoidien chirurgical d ’un
hemopericarde. Les suites operatoires sont
simples.

Observation 3
Le patient age de 59 ans, a subi le 30 juin
1981, un double pontage aorto-coronarien pour
angor de grade 4 instable. Les suites operatoi
res sont simples et le drain retrosternal est
enleve a la 48e heure.
Le patient recoit 5000 LI I d’heparinate de cal
cium chaque 12 heures pendant 48 heures audela desquelles les anticoagulants sont totalement arretes, Le malade sort au 7e jour en bon
etat Clinique et hemodynamique.
Sur le cliche de face, le rapport cardiothoracique est a 50°7o. L’electrocardiogramme
est correctement volte. Le patient est readmis
en urgence le 13 juillet 1981 pour dyspnee avec

| | ft*.
Fig. 4a

m
Fig- 4b

FIG. 4—Observation 3. (a) Radiographie thoracique de face postoperatoire immediate,
(b) Radiographie postoperatoire au 13e jour apres double pontage aorto-coronarien, lors de
la tamponnade.

palpitation a l’effort modere. Cet etat date de
24 heures.
Parallelement sont apparues des douleurs
parasternales gauches moderees et une sensa
tion de pesanteur epigastrique soulagee par la
position assise. L’examen permet de retrouver
une orthopnee avec deux oreillers, une polypnee a 40 cycles/min, une vasoconstriction peripherique avec paleur des extremites et une ten
sion arterielle systolique abaissee a 95 mm Hg.
Une tachycardie reguliere a 100/min est installee. 11 y a presence d ’un etat de subfebrilite
avec tem perature rectale a 38°C et un pouls
paradoxal est perceptible. 11 n ’y a pas d ’hepatomegalie. On constate une discrete turgescence
des jugulaires en position demi-assise et un
microvoltage electrocardiographique dans les
derivations precordiales. Sur le cliche thoraci
que de face, la silhouette cardiaque a un aspect
en “ soupiere” avec un rapport cardiothoracique a 65% — les enzymes myocardiques
seriques sont normaux (fig. 4). La pression vei
neuse centrale est a 25 cm H20 . Une tomographie transverse axiale avec ordinateur realisee
en urgence permet de confirmer un epanche
ment pericardique evalue a environ 800 ml,
locule a la face anterieure du coeur (fig. 5).
Apres une corticotherapie de 24 heures, [’in
tervention est decidee devant l’aggravation de
l’etat clinique. Un abord sous-xyphoidien per
met d ’evacuer un epanchement serohematique
d ’environ 700 ml. Des lors il y a amelioration
clinique et hemodynamique avec retour de la
tension systolique a 150 mm Hg. La pression
veineuse centrale chute a 9 cm H20 . Sur la
radiographie pulmonaire de face, le rapport
cardio-thoracique est de 45%. L ’histologie
pericardique permet de diagnostiquer une pericardite inflammatoire non specifique.
Au total: tam ponnade tardive au 13e jour
apres double pontage aorto-coronarien sans
anticoagulation postoperatoire. La tomographie transverse axiale avec ordinateur offre une
bonne visualisation de l’epanchement. Un drai
nage chirurgical sous-xyphoidien permet d’eva
cuer un epanchement sero-hematique.

Fig. 5a

Fig- 5b

FIG. 5—Observation 3. Tomographie transverse axiale avec ordinateur (a) visualisation de I’epanchement (fleches) au niveau des differentes
coupes du thorax. L’epanchement est essentiellement anterieur. (b) Visualisation de I’epanchement (fleches) a la face anterieure du ventricule.
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Discussion

La tamponnade tardive est rare. Dans
notre pratique, la frequence de cette com
plication est estimee a 1.5%. La revue de
la litterature1'22 permet d ’en denombrer
96 cas auxquels s’ajoutent les 3 cas decrits
dans le present article.
Par rapport au nombre total d ’operations cardiaques, la frequence globale de
la tamponnade tardive est de 0.62%, soit
78 cas observes sur 12 480 interven
tions.2,6’8’9’n '13’15' 19’21’22 Cette frequence
varie, selon les equipes, de 0.1% 15 a
3.2% .7 En ce qui concerne l’operation de
Waterston, Radley-Smith et collaborateurs8 signalent cinq tamponnades tardives sur un total de 45 interventions.
Bien que rare, cette complication est
grave puisqu’elle s’est averee fatale dans
16.2% des cas (16 deces rapportes sur 99
observations).1-22
Le delai d’apparition de la tamponnade
tardive varie selon les auteurs de 3
jours11'16 a 3 mois.12 Pour 55 patients
recenses, et si Ton exclut les 2 patients qui
ont presente une tamponnade tardive
apres 3 mois, le delai d’apparition moyen
apres l’intervention a ete de 14.5 ± 7.8
jours (fig. 6).1'3'6'10'12'15' 18'20'21
L’analyse de la symptomatologie en
phase de tamponnade permet de retrouver l’association chute tensionnelle,
hypertension veineuse centrale, oligoanurie. Le diagnostic devient alors evident
si 1’on y pense systematiquement.
Cependant, dans ses premiers signes
d ’apparition, la tamponnade tardive est
insidieuse et tres polymorphe. Ceci repre
sente le danger essentiel car le diagnostic
est alors facilement meconnu. L’analyse
de 92 cas1'3'6’8'22 denombres, y compris
les notres, rend compte de la diversity des
signes cliniques.
Une diaphorese ainsi qu’un etat de
malaise general, presents dans 42% des
cas, font souvent partie des signes initiaux
et sont facilement imputes a la fatigue
postoperatoire.3’6’9'11,16' 19’21 L 'hyperthermie (32%) et une polynucleose (11%),
signes d’un epanchement sanguin dans le
pericarde,1’3'8'12'13'15'16 sont parfois faussement interprets comme des stigmates
d ’infection.31516 La dyspnee (31%), sou
vent a type de polypnee, est associee plus
volontiers chez l’enfant8-10 a une cyanose
(10%). Ces signes respiratoires sont
accompagnes d ’une douleur thoracique
diffuse (31%) souvent irradiee aux deux
epaules.1'3'6'8'10' 12'14'20-22 Prise isolement,
cette douleur peut etre imputee a une algie
post-sternotomie ou a un syndrome post
pericardiotomic; associee a la dyspnee,
elle evoque plus volontiers le diagnostic
d ’embolie pulmonaire.3'6'14' 17'19'21
La coexistence d ’une hemoptysie15 est
un element de plus pouvant fausser le
diagnostic.
L ’anorexie, la dyspepsie et les vomissements (15%) apparaissent souvent au
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tout debut et orientent vers le diagnostic
d ’un surdosage therapeutique.810'1618 Un
hoquet persistant signera une reaction
pericardique.
L ’hypoperfusion cerebrate consecutive
au faible debit sanguin, provoque un etat
de confusion mentale avec stupeur et
ralentissement de 1’ideation (24%) et par
fois un coma.3'15 Une syncope6 peut traduire une defaillance circulatoire aigue.
La tachycardie (29%) est un signe non
specifique. Habituellement sinusale, elle
peut faire place a des troubles du rythme
exteriorisant la souffrance myocardique:
flutter auriculaire, fibrillation auriculaire,
et tachycardie supra-ventriculaire ont ete
observes (9%).2'3'14'15'17'21 La tachycardie
supra-ventriculaire en represente la forme
la plus grave; la levee de la tamponnade
permet de sauver le malade.3
Une paleur avec chute concomitante de
I’hematocrite (20%) est suggestive d ’une
spoliation sanguine chez les patients sous
anticoagulants. A I’examen clinique,
l’assourdissement des bruits cardiaques et
un frottement pericardique ne sont
retrouves que de fafon irreguliere. Un
pouls paradoxal est decele dans pres du
tiers des cas. Ce signe n’est cependant pas
specifique et peut se retrouver dans l’insuffisance myocardique congestive.2 Le
micro-voltage electrocardiographique
avec trouble de la repolarisation, evoquant un epanchement pericardique, est
mentionne trop peu souvent pour etre
fiable. Le bilan radiographique avec
analyse chronologique des differents
cliches postoperatoires m ontre un
elargissement progressif de l’ombre cardiaque avec augmentation du rapport
cardio-thoracique dans 75% des cas.
Dans un tiers des cas, Pepanchement
pleural est associe a une pleuropericardite.
Au terme de cette analyse on constate
que le polymorphisme de la tamponnade
tardive et la non specificite des signes expliquent le caractere aleatoire du
diagnostic. Toutefois, le fait d ’y penser
systematiquement permettra de la reconnaitre a coup sur ou de l’exclure.
Au plan paraclinique, le catheterisme
droit avec angiopneumographie est venu
etayer le diagnostic dans 18% des

L’echographie mono et bi-dimensionnelle s’est averee utile dans 14% des
cas.1317'22 L’echographie bidimensionnelle permet le diagnostic differentiel des
epanchements cloisonnes posterieurs ou
periventriculaires,20 et des epanchements
posterieurs retro-cardiaques.22 Hardesty
et collaborateurs19 ainsi que Fraser et
Ullyot12 ont eu recours a l’angiocardiographie isotopique.
Quand l’etat du malade le permet et si
1’on peut l’obtenir en urgence, la
tomographie axiale transverse avec ordinateur est un examen de choix permet tant d ’apprecier topographiquement et
quantitativem ent un epanchem ent
pericardique. Ce fut le cas dans notre
troisieme observation (fig. 5). Nous
n’avons pas retrouve de publication mentionnant [’utilisation de cet examen non
invasif et fiable dans le cadre des tampon
nades tardives.
La ponction pericardique a ete pratiquee a des fins diagnostiques et
therapeutiques dans environ un tiers des
cas. Cependant, celle-ci s’est revelee
negative dans 12% des cas lors d ’epanchements cloisonnes. Une pericardocentese negative procure done une
fausse securite.
Au terme de cette revue, on constate
que les diagnostics differentiels qui sont
plus frequents que la tamponnade tardive
doivent d ’abord etre exclus: celui de l’embolie pulmonaire pour lequel la mise en
route, a tort, d ’un traitement an
ticoagulant peut aggraver la tamponnade
tardive,3’12"17’19'20 voire etre cause de
deces;14 celui de l’insuffisance myocardi
que dont le traitement par un agent inotrope peut s’averer fatal;4'8’10 une fonction cardiaque postoperatoire acceptable
avec tableau de defaillance inexpliquee
doit faire penser a une tamponnade
tardive;3-6’7'10’12'14' 17'19'20 enfin, celui du
choc septique car son traitement par un
vasopresseur s’avere nocif.3
Sur le plan etiologique, la tamponnade
tardive est, dans tous les cas, I’apanage
de la chirurgie du coeur1'5-7'20 ou des gros
vaisseaux intrapericardiques6’14 avec
pericardiotomie. Sur les 99 cas rapportes,
on compte 89 (89.9%) chirurgies a coeur

c a s 3,12,15,19-22

Un equilibre des pressions dans les
cavites droites, une pression telediastolique ventriculaire droite superieure ou
egale au tiers du pic systolique et la
disparition du retour de la pression ven
triculaire droite a la ligne de base indiquent une alteration du remplissage
diastolique ventriculaire d ro it.19 Un
pseudo-gradient entre le ventricule droit
et 1’artere pulmonaire a ete mis en
evidence signant une compression
localisee.3
L’angiopneumographie permet d ’exclure le diagnostic d ’embolie pulmonaire.

FIG. 6—Sur 55 patients|-3-610 l7 '5 -'8 .2i).2i (>
compris nos trois cas) recenses, le delai d'apparition entre ('intervention et la tamponnade
postoperatoire tardive.
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ouvert. 7 (7.1%) operations a coeur
ferme, 1 operation de W aterston,8 1
comissurotomie a coeur ferme et 1 opera
tion de Blalock.16
Sur les 75 cas oil le type de chirurgie
est precise, les remplacements valvulaires
semblent surtout impliques (59 patients,
soit 78.7%), le remplacement valvulaire
aortique etant le plus frequemment cite.
On note ensuite les pontages aortocoronariens (14 cas, soit 18.7%) et autres
gestes de chirurgie a coeur ouvert (2.6%).
Si les remplacements valvulaires sont
frequemment associes a la tamponnade
tardive, on congoit que le role des an
ticoagulants soit important: sur 87 pa
tients pour lesquels le traitement est
precise, 67 (77%) etaient anticoagules.
Parmi ceux-ci, 82% recevaient des antivitamines K. Sur 63 patients chez qui
l’activite anticoagulante a ete mesuree, on
note 22 surdosages, soit 34.9% des
cas.M'6'9’lu2'15' 19'21 La prise de salicylates
qui augmentent le temps de prothrombine
est parfois mentionnee.1'4
La nature de l’epanchement permet de
preciser le type de reaction pericardique:
un epanchement sero-hematique signe
une pleuro-pericardite inflammatoire
(59.8% des cas) alors qu’un epanchement
sanglant pur identifie un hemopericarde
(40.2%). Le chylopericarde observe par
MacGoon5 fait figure de curiosite.
Dans l’hemopericarde, l’hematocrite
est celui du sang. Dans les epanchements
sero-hematiques, la composante hemorragique est reduite, Phematocrite etant de
l’ordre de 15% a 18% parfois,2'3'6 et le
liquide est alors citrin.4 Ce liquide est un
exsudat inflammatoire dont le taux de
proteine est eleve.8' 10' 16,17 Une lymphocytose a 100% a pu etre retrouvee.10
Les cultures sont habituellement
negatives.7'12'13,21 Exceptionnellement elle
est positive (1 cas sur 99).17
L ’histologie verifie des signes de
pericardite non specifique qualifiee de
fibrino-exsudative.12'16,21 Dans [’observa
tion de Fraser et Ullyot12 de meme que
dans notre 3e observation, la pericardite
etait chronique.
II nous semble que deux mecanismes
puissent etre a l’origine de la tamponnade
tardive: soit par hemorragie pericardique
a la faveur d ’une reaction inflammatoire
et d ’un surdosage medicamenteux, soit
par une forme exacerbee du syndrome
post-pericardotomie oil la composante in
flammatoire domine le tableau.
La conduite a tenir devant la tampon
nade tardive est toujours urgente.
L’analyse des modalites therapeutiques
auxquelles on eut recours se resume de la
fagon suivante: 55 fois sur 99 (55.6%) le
traitement fut chirurgical; dans ce groupe,
on constate trois deces (5.4%); 1 fois en
rapport avec une blessure ventriculaire
droite lors d ’un abo rd
sousxyphoidien,18 et 2 de fagon tardive,10-19
indirectement reliees a 1’acte operatoire.

Dans 33 cas (33.3%), la pericardiocentese
fut suffisante; on compte deux deces (6%)
en rapport avec cette technique, les deux
fois
apres
recurrence
de
la
tam ponnade.16 Enfin, 11 patients ne
regurent aucun traitement, la tamponnade
tardive etant restee meconnue; tous sont
decedes.1’3'6'8'10,14’16 L’analyse de ces
deces rend compte de diagnostics non
faits3-7'8 dans cinq cas ou de diagnostics
errones, soit d’embolie pulmonaire (deux
cas),14'16 soit d’insuffisance cardiaque
(deux cas)6'10 ou de septicemie (un cas).16
Un retard de traitement apres diagnostic
fut la cause d ’un deces.6
Sur le plan therapeutique, les opinions
sont partagees entre la chirurgie formel[ e 2 ,3 .io ,i 1,13,16,20 et [a p0nction pericardi
que simple.1’8'9’13’22 Cependant, les in
dications de ces deux methodes doivent
etre
nuancees
car
elles
sont
complementaires.
Si la pericardiocentese est apparue suf
fisante a Prewitt et collaborateurs,1
Radley-Smith et collaborateurs,8 Berger
et collaborateurs9 et B orkon et
collaborateurs,22 ces auteurs jugent
neanmoins que la voie sous-xyphoidienne
est utilisable en seconde intention.
Engelman et collaborateurs6 reservent
la pericardiocentese pour les syndromes
inflammatoires a liquide pericardique
fluide. Les partisans de la chirurgie considerent que la pericardiocentese donne
une fausse securite3,10'11,20 dans les cas
d ’evacuation incomplete ou d ’epanchement soit trop epais ou cloisonne. L’attitude raisonnable nous paraTt etre de considerer les deux methodes comme comple
mentaires, ne laissant a la ponction pericardiqde qu’un role diagnostique si elle
est positive, tout en etant un geste pretherapeutique permettant d’ameliorer
l’etat hemodynamique du malade avant
de le soumettre a une chirurgie de drai
nage sous anesthesie generate.14'1S'17' 19,21
La voie sous-xyphoidienne nous paraTt
etre un abord convenable et peu agressif
bien que nous soyons conscients de son
caractere limite. Seule une voie d ’abord
large, par sternotomie ou par thoracotomie, permet l’effondrement des adherences et des cloisonnements de l’epanchement, ainsi que l’evacuation d ’eventuels
caillots.
A l’analyse, on retrouve 11 recidives de tam ponnade tard iv e
(11.1%),113'6'9'10'13'18'21 si l’on excepte
l’observation de MacGoon5 ou le chyle
ne se tarissait pas au niveau du drain. De
ces 11 cas, 8 avaient ete traites initialement par ponction pericardique. La recidive semble done plus volontiers l’apanage de ce traitement peut-etre moins
complet. Survenant dans un delai varia
ble de 3 jours a plusieurs semaines apres
le traitement initial, la recidive peut etre
unique ou multiple.10'13 Meconnue, une
recidive tardive peut causer le deces du
patient.6

Conclusions
Traltresse et redoutable, la tam pon
nade tardive paraTt etre une complication
rare, fort heureusement, mais de diagnos
tic difficile. Son traitement, en urgence,
repose essentiellement sur le drainage chi
rurgical large de l’epanchem ent
pericardique.
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Aortocolic Fistula: a Rare Cause of Profuse Rectal Bleeding
A 62-year-old man with multiple
myeloma survived for 19 months follow
ing massive hemorrhage from an aorto
colic fistula secondary to an aortoiliac
aneurysm that was adherent to the
sigmoid colon. The literature indicates
that early death from multisystem failure
is to be expected and that sepsis is an
inevitable consequence of aortocolic
fistula. However, in this case the patient
did not die despite multisystem com
plications and his eventual death was
unrelated to sepsis or graft complica
tions. Reasons for the unexpected out
come are suggested. No survivors have
been reported in the literature.
Un homme, age de 62 ans, souffrant de
myelome multiple a survecu 19 mois
apres une hemorragie massive causee
par une fistule aortocolique secondaire a
un anevrisme aorto-iliaque adherent au
colon sigmoide. Une etude subsequente
a confirme que, dans un cas de ce
genre. Ton pouvait s'attendre a une mort
prematuree par suite de multiples deficiences organiques, et qu'une infection
septicemique etait la consequence inevi
table d'une fistule aortocolique. Cependant, et malgre les complications dues
aux deficiences organiques multiples, le
malade a survecu et ce n'est pas la septicemie ou les complications de greffes
qui ont finalement cause sa mort. Nous
tentons de donner les raisons de ce
resultat imprevu. Selon les recherches
effectuees, aucun autre cas semblable
n'a rechappe a cette maladie.

primary aortocolic fistula who survived
for 19 months despite an underlying
blood dyscrasia, and who did not die of
graft complications or sepsis.

Case Report
A 62-year-old Caucasian man was admitted
for investigation of back pain and fatigue in
January 1980. Anemia and thrombocyto
penia were found and a bone-marrow aspirate
showed an increased number of plasma cells
consistent with multiple myeloma. The
diagnosis was confirmed by quantitative im
munoglobulin and protein electrophoresis,
which showed a raised level of IgG. Before
treatment of this disorder, he had sudden pro
fuse bright red rectal bleeding with severe
hypotension requiring immediate operation.
An infrarenal abdominal aortic aneurysm was
identified, extending into both iliac arteries.
The left common iliac extension was firmly
adherent to the mesenteric aspect o f the
sigmoid colon and had ruptured into it. The
aorta was controlled proximally and the
aneurysmal wall laid open. A 22-mm Dacron
bifurcated graft was anastomosed end to end
to the infrarenal aorta. One 11-mm limb was
anastomosed end to end to the right common
iliac artery, 5 mm proximal to its division into
internal and external iliac arteries. On the left
side the sigmoid colon was dissected free from
the left common iliac artery without fecal
spillage. The left ureter was involved in the in
flammatory reaction around the left common
iliac artery and was inadvertently transected
during the procedure. It was repaired over a
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operation, w k

Primary aortoenteric fistula is a rare com
plication of aortic aneurysm. Most rup
tures occur into the duodenum.1'2 Aor
tocolic fistulas are exceedingly rare and
have been described as uniformly fatal.3
We report the case o f a patient with

stent. The 11-mm bifurcation graft was
anastomosed end to end to the common iliac
artery at its division into internal and external
branches. The remains of the aneurysm wall
were then used to overlay the graft. Segmen
tal sigmoid resection was performed and an end
colostomy and mucous fistula were formed.
There was no gross evidence of a sigmoid le
sion and subsequent examination of the
specimen identified a single transmural defect
lined by acute and chronic inflammatory cells
and blood clots. This defect was 9 mm in
diameter and opened into a hemorrhagic sec
tion of mesocolon.
Postoperatively, the patient had adult
respiratory distress syndrome, myocardial
dysfunction and acute renal failure, each of
which resolved over an 18-day period while he
was in the intensive care unit. Approximately
2 weeks postoperatively, he had recurrent
bowel obstruction caused by a volvulus of the
cecum with the mesentery twisted around a
dense fibrotic adhesive band. Lysis of the adhe
sions, cecopexy and appendectomy were car
ried out. Subsequent procedures performed in
cluded secondary closure of the wound for in
complete wound dehiscence and cystourethroscopy for removal of the ureteric stent.
During the first operation the patient receiv
ed gentamicin (100 mg intravenously then 80
mg q8h) and clindamycin (300 mg intravenous
ly then q6h,) and large doses (2 megaunits in
travenously q4h) of penicillin were given in the
immediate postoperative period. Following this
operation, multiple organisms were cultured
from the blood, sputum, urine and wound
(Table 1). Cefoxitin (500 mg intravenously q6h)

None

Haemophilus
influenzae
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was added approximately 4 days after opera
tion. At the time of the operation for bowel
obstruction he was receiving tobramycin (40
mg intravenously ql6h), ticarcillin (2 g in
travenously q4h) and metronidazole (500 mg
intravenously q8h). Approximately 6 weeks
after resection of his aneurysm antibiotic
therapy was discontinued. Blood, wound and
urine cultures at this time showed no growths.
Just before discharge a urinary tract infection
with group D streptococci developed. It was
treated with trimethoprim-sulfamethoxazole (2
tablets orally bid). Eight weeks after resection
the patient was fit enough to be given a 4-day
course of prednisone (100 mg orally once a day)
and melphalan (10 mg orally once a day) for
his multiple myeloma. One week later he was
discharged.
One week after discharge (April 1980) he was
readmitted with pain associated with a mass
in the right lower quadrant. The mass was an
intra-abdominal abscess; it was incised and
drained. Bacteroides fragilis was grown from
the pus. During the postoperative period he was
given appropriate antibiotics and was dis
charged in May 1980. In June he was readmit
ted for 2 weeks with a diagnosis of deep vein
thrombosis of his left leg. The condition was
treated with anticoagulants. In November he
was admitted for 10 days with bilateral bron
chopneumonia; the causative organism was
Haemophilus influenzae. In March 1981 he was
admitted for 4 weeks with respiratory dysfunc
tion and hypoxemia, but no evidence of a septic
focus or pulmonary embolus was found. In
June he was hospitalized for 2 weeks with in
creasing shortness of breath but no notable sep
sis. In August 1981 he was admitted for the
last tim e and died 3 weeks later of

coagulopathy secondary to the multiple
myeloma, congestive cardiac failure and
respiratory insufficiency. No important septic
focus was identified during this admission.
From March 1980 to July 1981 he received 10,
5-day courses of melphalan (4 mg orally qid,
a total of 1 mg/kg) and prednisone (50 mg oral
ly qid) for his multiple myeloma, with
mithramycin (2.4 mg intravenously, once a day
for 4 days) being added in July 1981 for hyper
calcemia. During the 19 months following
resection of his aorta, there was no evidence
of graft dysfunction or prolonged bacteremia
suggestive of graft infection. We made no at
tempt to restore bowel continuity.

Discussion
Aortoenteric fistulas were first de
scribed as a source o f intestinal hemor
rhage in 1829 by Sir Astley Cooper.4
Such communications occur most com
monly between an aortic aneurysm and
the duodenum.I>2 The first report o f an
aortocolic fistula was made by Jackman
and associates in 19485 and since then
nine cases have been recorded (Table

113,6-1°) ^11 were fata|. the iongest sur_

vivor was a patient who died after 5
m onths, o f graft in fection and
peritonitis.8 Our patient defied our ex
pectations, surviving for 19 months and
eventually dying o f complications secon
dary to multiple myeloma. There were no
signs of graft sepsis before he died.
In retrospect, there were a number of
features that probably contributed to the

success of our case. There was no obvious
fecal contamination o f the peritoneal
cavity. This was probably due to the in
direct nature of the fistulous connection
through the mesocolon rather than direct
ly into the sigmoid colon. There were no
signs of diverticular disease or neoplasm,
indicating that the inflammatory process
resulting in transmural penetration had
occurred secondary to the aneurysm
itself. These features inclined the vascular
surgeon towards aorto-bi-iliac grafting
rather than resection, closure o f the main
vessels and extra-anatomic axillofemoral
bypass grafting. Following its placement,
the graft was covered entirely by remnants
of the aneurysmal wall, thus protecting
the graft from intra-abdominal complica
tions. The single intra-abdominal abscess
was probably secondary to repair of the
cecal volvulus and appendectomy, as it
did not apparently involve the grafts.
Although chronic sepsis around the graft
is a possibility, there were no recurrent
intra-abdominal problems suggesting this.
Another feature that may have con
tributed to our patient’s survival was the
prolonged antibiotic therapy with careful
attention to the identification o f patho
genic organisms, including anaerobes,
and adjustment o f antibiotic therapy ac
cording to the sensitivity o f the
organisms. Anaerobes are o f particular
concern in intra-abdominal sepsis and
were controlled with clindamycin, cefoxi-

T a b le II-- A o r t o c o l i c F i s t u la s
D u r a t io n o f

Age,
A u th o rs

yr

Sex

J a c k m a n and

85

M

a s s o c ia t e s , 1 9 4 8 5

F i s t u la s it e
R ig h t in f r a r e n a l
ilia c a n e u r y s m

b le e d in g
A c u te

T h e ra p y
None

h e m o rrh a g e

( a n e u r y s m d ia g n o s e d
6 d b e fo r e )

to re c tu m
G a rzo n and

52

M

a s s o c ia t e s , 1 9 5 8 6

A o r t ic a n e u ry s m

R e s u lt s
D ie d im m e d ia t e ly

1 d

A n e u ry s m s u tu re d and
p acked

t o s ig m o id c o lo n

D ie d

1 d

p o s t o p e r a t iv e ly

(a n d d u o d e n u m )
A t in , 1 9 5 8 7

61

M

L e f t c o m m o n ilia c

5 d

R e s e c t io n o f a n e u r y s m ,

a n e u r y s m to

r e p a ir o f s ig m o id

s ig m o id c o lo n

p e r f o r a t io n , t r a n s v e r s e

D ie d 4 6

d

p o s t o p e r a t iv e ly

c o lo s t o m y
F o s t e r a n d V e tto ,

76

M

19628

A o r t ic a n e u ry s m

S e v e ra l d a ys

t o s ig m o id c o lo n

R e s e c t io n o f a n e u r y s m ,
r e p a ir o f s ig m o id

D ie d 5 m o
p o s t o p e r a t iv e ly

p e r f o r a t io n , t r a n s v e r s e
c o lo s t o m y
M a c b e th , 1 9 6 2 9

70

M

L e f t in t e r n a l ilia c

18 d

None

a n e u r y s m to

D ie d o n

1 2 th

h o s p it a l d a y

s ig m o id c o lo n
W ils o n a n d O w e n s ,

79

M

1 9 7 6 10

L e f t c o m m o n ilia c

7 wk

None

a n e u ry s m to

D ie d o n 8 t h
h o s p it a l d a y

s ig m o id c o lo n
69

F

A o r t ic a n e u ry s m to

8 wk

a p p e n d ix a n d

R e s e c t io n o f a o r t ic
a n e u ry sm , a p p e n d e c to m y

D ie d 1 d
p o s t o p e r a t iv e ly

cecu m
68

M

A o r t ic a n e u ry s m to

2 wk

s ig m o id c o lo n
Y o u n g s o n and

71

M

A o r t ic a n e u r y s m t o

62

M

L e f t c o m m o n ilia c

a s s o c ia t e s , 1 9 8 2 3
P re s e n t case

s ig m o id c o lo n
a n e u ry s m to
s ig m o id c o lo n

R e s e c t io n o f a n e u r y s m ,
a x illo b if e m o r a l g r a f t in g

A c u te
h e m o rrh a g e
A c u te
h e m o rrh a g e

E x c lu s io n o f a n e u r y s m ,
a x illo b if e m o r a l g r a f t in g
R e s e c t io n o f a n e u r y s m ,

D ie d 2 d
p o s t o p e r a t iv e ly
D ie d e a r ly
p o s t o p e r a t iv e ly
1 9 m o s u r v iv a l,

a o r t o - b i- ilia c g r a f t in g ,

d ie d o f u n re la t e d

s ig m o id r e s e c t io n ,

cau ses

c o lo s t o m y , m u c o u s f i s t u l a
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tin and metronidazole in series and in
combination. The last contributing
feature was the prolonged stay in an in
tensive care unit with appropriate atten
tion being paid to metabolic function and
nutritional status. The patient was given
supportive total parenteral nutrition for
3 weeks during his first stay in hospital.
Nevertheless, we find it extraordinary that
despite the presence of Escherichia coli
and subsequently B. fragilis in the blood,
the prosthetic graft did not apparently
become chronically infected.
The literature suggests that early
diagnosis is a sine qua non for survival
as exsanguinating hemorrhage is the
ultimate outcome in all patients.9'10 In
our case, the diagnosis was totally unex
pected and the presentation was that of
profuse rectal bleeding. Obviously,
diagnosing the lesion before major
hemorrhage occurred would have al
lowed us time to cleanse the bowel,
stabilize the patient hemodynamically and
initiate antibiotic therapy. The expecta
tion that graft sepsis inevitably occurs
following resection for aortocolic fistula
is negated by this report. Our case,
however, may be the exception that
proves the rule and in future we would
try to resect as much of the aneurysm as
technically feasible, close the aorta and
iliac arteries and perform axillobifemoral
bypass grafting rather than place an intra
abdominal prosthesis, whether or not
there was fecal contamination. We
recommend exteriorization of the colonic
opening or resection with proximal end
colostomy and distal mucous fistula for
mation. This avoids the possibility of a
recurrent leak from a patched defect and
also avoids an anastomosis in unprepared
bowel in a possibly contaminated area.
Appropriate attention to detail
postoperatively, preferably in an intensive
care unit, with precise antibiotic therapy
and maintenance of nutrition are essen
tial to a successful outcome. The manage
ment of these patients is improving, so
that, although this lethal condition is ex
tremely rare, we look forward to further
reports of unexpected survival from pro
fuse rectal bleeding due to an aortocolic
fistula.

iac artery; report of a case. Proc S ta ff Meet Mayo Clin
1948; 23: 305-8
6. G arzon FL, W ilson JS, G unter JU: Aneurysms with
double rupture into the digestive tract; report of two
cases. Gastroenterology 1958; 34: 509-14
7. ATIN HL: Rupture of an iliac-artery aneurysm into the
sigmoid colon; report of a case. N Engl J Med 1958; 258:
366-9

B O O K R E V IE W S

continued fro m page 279
The book contains a thorough review of
myocardial protection by Gerald Buckberg
who presents well-documented experimental
evidence that blood cardioplegia is the most ef
fective technique. Six subsequent chapters deal
with various aspects o f c o ro n ary
arteriosclerosis. Of particular interest is the
chapter detailing the Spokane experience in the
surgical management of acute myocardial in
farction. Of 260 consecutive patients operated
on the mortality was 2.3%. All patients were
operated upon within 6 hours of the onset of
angina; patients with cardiogenic shock were
also admitted into the series.
Two chapters deal with valvular heart disease
and one chapter reviews the current manage
ment of each congenital anomaly, focusing on
recent advances. C urrent concepts in
pathophysiology, and pharmacologic and
surgical treatment are outlined in a section on
acute aortic dissection. The final two chapters

8. FOSTER JH , Vetto RM: Aortic intra-aneurysmal abscess
caused by sigmoid-aortic fistula. A m J Surg 1962; 104:
850-4
9. MACBETH RA: Rupture of abdominal aneurysms into the
gastrointestinal tract. Can J Swrg 1962; 5: 372-8
10.

WILSON SE, OWENS ML: Aortocolic fistula, a lethal
cause of lower gastrointestinal bleeding: report o f a case.
Dis Colon Rectum 1976; 19: 614-7

concentrate on terminal myocardial failure;
one reviews the state of cardiac transplanta
tion and the other describes experience with
mechanical assist devices.
This is a gem of a book and will appeal not
only to residents but to practising surgeons and
cardiologists. It has succeeded admirably in
providing an up-to-date review o f cardiac
surgery. Moreover, the physical aspects of the
book — paper, type and illustrative material
— are all first class.
A

nthony

R.C.

D

o b e l l , m d , f a c s , f r c s io

Department of cardiovascular surgery,
Montreal Children’s Hospital,
Montreal, PQ
MICROBIOLOGY FOR CLINICIANS. R.N.
Griineberg. 179 pp. University Park Press,
Baltimore,
1981.
$19.95.
ISBN
0-8391-1682-9.
The author of this book states that it “ is not
continued on next page
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ADVERTISERS’ INDEX a comprehensive textbook, but is intended to

be a guide and adviser on Microbiologic mat
ters” . There is no question — this is not a text
book and, unfortunately, it will offer little
guidance.
Why it was ever written is a mystery. It is
a 179-page rambling of anecdotes; the sections
on treatment of infections are top-heavy with
misinformation (“ sets of blood cultures [in in
fective endocarditis] should be taken at three
separate times when the patient’s temperature
is raised” ) and with no information (“ skin le
sions should be examined microbiologically on
ly if they show signs of infection” ). We are
treated to historical fantasies such as the spread
of infections among wandering tribes many
thousands of years ago, with analogies being
made to wolf packs. At the beginning of each
chapter, we are exposed to irrelevant words of
wisdom quoted from such diverse sources as
the “ Bible” , Jonathan Swift and the unknown
author of the song “ Cockles and Mussels” .
The ultimate words of wisdom, however,
belong to the author who, on page 85, informs
us that “ Hospital patients are often more
unwell than their counterparts being manag
ed at home. This is partly because patients who
are more ill are sent to hospital for that
reason” !
If you can borrow this book and therefore
not have to pay for it, then by all means read
it. It’s 2 hours of entertainment and you’ll not
have to waste a minute of your time learning
anything.
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□ Chem otherapy □ Radiation therapy
Stemetil rapidly controls nausea in
most hospitalized patients
A single dose of Stemetil usually stops
nausea in just 30-45 minutes,1and keeps
working for up to four hours.

Stemetil helps keep surgical
patients com fortable and alert
Stemetil does not cause excessive sedation,2
so vital signs can be taken without delay. The
mild anxiolytic effect helps keep patients
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side effects.34
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